



Australian Government  
Department of Health  
Therapeutic Goods Administration

## AusPAR Attachment 2

# Extract from the Clinical Evaluation Report for Ivacaftor

Proprietary Product Name: kalydeco

Sponsor: Vertex Pharmaceuticals Australia Pty  
Ltd

**First round evaluation: 5 August 2015**

**Second round evaluation: 12 November 2015**

## About the Therapeutic Goods Administration (TGA)

- The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices.
- The TGA administers the *Therapeutic Goods Act 1989* (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary.
- The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices.
- The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action.
- To report a problem with a medicine or medical device, please see the information on the TGA website <<https://www.tga.gov.au>>.

## About the Extract from the Clinical Evaluation Report

- This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities.
- The words [Information redacted], where they appear in this document, indicate that confidential information has been deleted.
- For the most recent Product Information (PI), please refer to the TGA website <<https://www.tga.gov.au/product-information-pi>>.

### Copyright

© Commonwealth of Australia 2016

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[tga.copyright@tga.gov.au](mailto:tga.copyright@tga.gov.au)>.

# Contents

<b>1. Common abbreviations</b>	<b>5</b>
<b>1. Introduction</b>	<b>10</b>
<b>2. Clinical rationale</b>	<b>10</b>
<b>3. Contents of the clinical dossier</b>	<b>13</b>
3.1. Scope of the clinical dossier	13
3.2. Paediatric data	14
3.3. Good clinical practice	14
<b>4. Pharmacokinetics (PKs)</b>	<b>14</b>
4.1. Studies providing pharmacokinetic data	14
4.2. Summary of pharmacokinetics	15
4.3. Evaluator's overall conclusions on pharmacokinetics	18
<b>5. Pharmacodynamics</b>	<b>19</b>
<b>6. Dosage selection for the pivotal studies</b>	<b>19</b>
<b>7. Clinical efficacy</b>	<b>19</b>
7.1. 7.1. Indication 1	19
<b>8. Clinical Safety</b>	<b>67</b>
8.1. Studies providing evaluable safety data	67
8.2. Patient exposure	68
8.3. Adverse events	69
8.4. Laboratory tests	75
8.5. Post-marketing experience	77
8.6. Safety issues with the potential for major regulatory impact	77
8.7. Other safety issues	78
8.8. Evaluator's overall conclusions on clinical safety	83
<b>9. First round benefit-risk assessment</b>	<b>84</b>
9.1. First round assessment of benefits	84
9.2. First round assessment of risks	84
9.3. First round assessment of benefit-risk balance	85
<b>10. First round recommendation regarding authorisation</b>	<b>86</b>
<b>11. Clinical questions</b>	<b>87</b>
11.1. Pharmacokinetics	87
11.2. Pharmacodynamics	87
11.3. Efficacy	87
11.4. Safety	87

---

11.5. PI and CMI_____	87
<b>12. Second round evaluation of clinical data submitted in response to questions_____</b>	<b>88</b>
12.1. Pharmacokinetics_____	88
12.2. Efficacy _____	89
<b>13. Second round benefit-risk assessment _____</b>	<b>90</b>
13.1. Second round assessment of benefits_____	90
13.2. Second round assessment of risks_____	90
13.3. Second round assessment of benefit-risk balance _____	90
<b>14. Second round recommendation regarding authorisation____</b>	<b>90</b>
<b>15. References _____</b>	<b>90</b>

## 1. Common abbreviations

Abbreviation	Meaning
ADR	adverse drug reaction
AE	adverse event
AIC	Akaike information criterion
ALT	alanine aminotransferase
API	active pharmaceutical ingredient
AST	aspartate aminotransferase
ATP	adenosine triphosphate
AUC	area under the concentration-time curve
AUC $\tau$	area under the concentration versus time curve for the dosing interval
AusPAR	Australian Public Assessment Reports
bid	twice daily
BMI	body mass index
CCS	complete case set
CF	cystic fibrosis
CFF	Cystic Fibrosis Foundation (US)
CFQ-R	Cystic Fibrosis Questionnaire-Revised
CFTR	Cystic fibrosis transmembrane conductance regulator
CHMP	Committee for Medicinal Products for Human Use (EMA)
CI	confidence interval
CL/F	apparent (oral) clearance
CMI	Consumer Medicines Information
C <sub>min</sub>	minimum observed concentration
CV%	coefficient of variation percentage
D	Day

Abbreviation	Meaning
D1	zero order dose duration
DIOS	distal ileal obstruction syndrome
DMC	Data Monitoring Committee
ECG	electrocardiogram
ECL	extracellular loop
EMA	European Medicines Agency
EU	European Union
F508del or F508del-CFTR	CFTR gene mutation with an in-frame deletion of a phenylalanine codon corresponding to position 508 of the wild-type protein
FAS	full analysis set
FDA	Food and Drug Administration (US)
FEV <sub>1</sub>	forced expiratory volume in 1 second
G1244E CFTR	missense gene mutation that results in the replacement of a glycine residue at position 1244 of CFTR with a glutamic acid residue
G1349D CFTR	missense gene mutation that results in the replacement of a glycine residue at position 1349 of CFTR with an aspartic acid residue
G178R CFTR	missense gene mutation that results in the replacement of a glycine residue at position 178 of CFTR with an arginine residue
G551D or G551D CFTR	CFTR missense gene mutation that results in the replacement of a glycine residue at position 551 of CFTR with an aspartic acid residue
G551S CFTR	missense gene mutation that results in the replacement of a glycine residue at position 551 of CFTR with a serine residue
G970R CFTR	missense gene mutation that results in the replacement of a glycine residue at position 970 of CFTR with an arginine residue
h	hour/s

Abbreviation	Meaning
HBE	human bronchial epithelial
ICL	intracellular loop
IL-8	interleukin-8
IRT	Immunoreactive trypsinogen
Ivacaftor	Kalydeco/ VX-770/VRT-813077
K <sub>a</sub>	first-order absorption rate
LC	MS/MS - liquid chromatography with tandem mass spectrometric detection
M1	hydroxymethyl-ivacaftor
M6	ivacaftor carboxylate
MCID	minimal clinically important difference
MedDRA	Medical Dictionary for Regulatory Activities
MHRA	Medicines and Health Care Products Regulatory Agency (UK)
MMRM	mixed-effects model for repeated measures
MSD	membrane-spanning domain
NA	not available
NONMEM	nonlinear mixed-effects modelling
NR	not reported
P aeruginosa	Pseudomonas aeruginosa
PCR	polymerase chain reaction
PD	pharmacodynamic(s)
PI	Product Information
PK	pharmacokinetic(s)
PopPK	population pharmacokinetics
ppFEV <sub>1</sub>	percent predicted forced expiratory volume in 1 second

Abbreviation	Meaning
PPS	per protocol set
PSUR	Periodic Safety Update Report
PT	preferred term
Q/F	inter-compartmental clearance
q12h	every 12 hours
qd	once daily
QTc	QT interval corrected for heart rate according to Fridericia's formula
QTcB	QT interval corrected for heart rate according to Fridericia's formula
QTcF	QT interval corrected for heart rate according to Fridericia's formula
R	regulatory domain
R117C or R117C CFTR	a missense mutation that results in the replacement of an arginine residue at position 117 of CFTR with a cysteine residue
R117H or R117H CFTR	a missense mutation that results in the replacement of an arginine residue at position 117 of CFTR with a histidine residue
R117H-5T CFTR	allele with both an <i>R117H</i> mutation and a <i>5T</i> poly-T variant
R117H-7T CFTR	allele with both an <i>R117H</i> mutation and a <i>7T</i> poly-T variant
R117H-9T CFTR	allele with both an <i>R117H</i> mutation and a <i>9T</i> poly-T variant
S1251N CFTR	missense gene mutation that results in the replacement of a serine residue at position 1251 of CFTR with an asparagine residue
S1255P CFTR	missense gene mutation that results in the replacement of a serine residue at position 1255 of CFTR with a proline residue
S549N CFTR	missense gene mutation that results in the replacement of a serine residue at position 549 of CFTR with an asparagine residue
S549R CFTR	missense gene mutation that results in the replacement of a



Abbreviation	Meaning
	serine residue at position 549 of CFTR with an arginine residue
SAE	serious adverse event
SD	standard deviation
SDD	spray-dried dispersion
SEM	standard error of the mean
SOC	system organ class
UK	United Kingdom
ULN	upper limit of normal
URTI	upper respiratory tract infection
US	United States
USPI	US Prescribing Information
V <sub>c</sub> /F	central volume of distribution
Vertex	Vertex Pharmaceuticals Incorporated
V <sub>p</sub> /F	peripheral volume of distribution
W	week

## 1. Introduction

This is a submission to:

Extend indications for ivacaftor for an additional subset of cystic fibrosis (CF) patients.

The following dosage forms and strengths are currently registered:

Ivacaftor (kalydeco) film-coated tablets are supplied as light blue, capsule-shaped tablets (16.5 mm x 8.4 mm in modified caplet shape) containing 150 mg of ivacaftor. Each tablet is printed with "V 150" in black ink on one side only. KALYDECO tablets are packaged in a blister pack or a child-resistant bottle with desiccant. The following pack sizes are available: blister pack containing 56 film-coated tablets, bottle containing 56 film-coated tablets.

The approved indication is:

*'KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have a G551D or other gating (class III) mutation in the CFTR gene.'*

The proposed indication is:

*kalydeco is indicated for the treatment of cystic fibrosis (CF) in patients:*

- *Age 6 years and older who have a G551D or other gating (class III) mutation in the CFTR gene.*
- *Age 6 years and older who have an R117H mutation in the CFTR gene.*

## 2. Clinical rationale

Cystic fibrosis (CF) is an autosomal recessive disease with serious, chronically debilitating morbidities and high premature mortality and no cure available at present. CF affects approximately 70,000 individuals worldwide and is more common in the Caucasian populations of North America and Europe<sup>1</sup> than in Asian and African populations. Approximately, 3,100 individuals in Australia have CF.

CF is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that result in absent or deficient function of the CFTR protein at the cell surface. The CFTR protein is an epithelial chloride channel responsible for aiding in the regulation of salt and water absorption and secretion. CFTR protein is located in the apical membrane of epithelial cells in multiple organs, including lungs, pancreas, intestinal tract, biliary tract, sweat glands and vas deferens. The failure to regulate chloride transport in these organs results in the multisystem pathology associated with CF. Elevated sweat chloride concentrations are a hallmark of CF and is used for diagnostic purposes; sweat chloride concentrations  $\geq 60$  mmol/L is considered indicative of CF, whereas a sweat chloride concentration  $< 39$  mmol/L is considered normal; intermediate sweat chloride values in the range of 40 to 59 mmol/L are also observed in patients with CF.

More than 1900 mutations in the CFTR gene have been identified which result in reduced quantity of CFTR at the cell surface or reduced CFTR function leading to a decrease in epithelial chloride transport. Reduced CFTR function can be due to defects in channel gating (opening and closing of CFTR channel) or channel conductance (rate of chloride travel through the open channel). As for other ion channels, gating of the CFTR channel is measured by open probability, and conductance of the CFTR channel is measured by current amplitude. By definition, a CFTR

---

<sup>1</sup> CF affects approximately 30,000 individuals in the US, 36,000 individuals in the EU, 3,900 individuals in Canada

form that has lower open probability than normal CFTR has a gating defect. By definition, a CFTR form that has lower current amplitude than normal CFTR has a conductance defect. Some CFTR mutations cause more than 1 type of functional defect (for example, R117H) or reduce both the quantity and function of CFTR (for example, F508del). The amount of chloride transported by CFTR is a function of the quantity of CFTR on the cell surface, the open probability of the CFTR, and the current amplitude of the CFTR. Regardless of the type of defect(s) caused by the CFTR mutation, CF disease severity generally correlates with the severity of the loss of chloride transport.

The R117H-CFTR mutation is present in approximately 2 to 3% of patients with CF. In Europe, North America, and Australia, approximately 1,600 people with CF aged 6 years and older have at least 1 copy of an R117H-CFTR mutation. In the EU, approximately 744 people have the R117H-CFTR mutation, of whom more than half (n = 360) are aged > 18 years (Vertex data on file). In the US, approximately 729 people have the R117H-CFTR mutation, of whom approximately 300 are aged > 18 years (Vertex data on file). The prevalence of the R117H-CFTR mutation in patients with CF in individual countries is presented in Table 1; in Australia only 91 of the 3156 total patients with CF (2.8%) had the R117H-CFTR mutation which is the subject of this submission.


**Table 1: Prevalence of the R117H-CFTR mutation in patients with cystic fibrosis**

Geographic Region	Total Number of Patients With CF	Number of Patients With R117H Mutation
European Community		
Austria	800 <sup>a</sup>	0 <sup>b</sup>
Belgium	1138 <sup>39</sup>	25 <sup>39</sup>
Bulgaria	189 <sup>a</sup>	0 <sup>b</sup>
Croatia	108 <sup>a</sup>	4 <sup>b</sup>
Cyprus	26 <sup>4</sup>	NR
Czech Republic	507 <sup>14</sup>	2 <sup>b</sup>
Denmark	451 <sup>14</sup>	8 <sup>b</sup>
Estonia	40 <sup>17</sup>	n/a
Finland	64 <sup>4,17</sup>	2 <sup>40</sup>
France	5993 <sup>38</sup>	87 <sup>38</sup>
Germany	8115 <sup>41</sup>	64 <sup>41</sup>
Greece	555 <sup>17</sup>	1 <sup>b</sup>
Hungary	555 <sup>14</sup>	0 <sup>b</sup>
Ireland	1040 <sup>37</sup>	43 <sup>37</sup>
Italy	5064 <sup>4,17</sup>	50 <sup>b</sup>
Latvia	29 <sup>14</sup>	NR
Lithuania	47 <sup>4,17</sup>	NR
Luxembourg	40 <sup>17</sup>	NR
Malta	23 <sup>4,17</sup>	NR
Netherlands	1452 <sup>42</sup>	46 <sup>b</sup>
Poland	1150 <sup>a</sup>	0 <sup>b</sup>
Portugal	285 <sup>4,17</sup>	0 <sup>b</sup>
Romania	238 <sup>4,17</sup>	2 <sup>b</sup>
Slovakia	416 <sup>17</sup>	NR
Slovenia	66 <sup>4,14,17</sup>	NR
Spain	2900 <sup>a</sup>	43 <sup>b</sup>
Sweden	622 <sup>a</sup>	6 <sup>b</sup>
United Kingdom	10,078 <sup>15</sup>	361 <sup>15</sup>
North America		
United States	27,804 <sup>3</sup>	729 <sup>3</sup>
Canada	3913 <sup>3</sup>	43 <sup>b</sup>
Australia	3156 <sup>6</sup>	91
<b>TOTAL</b>	<b>76864</b>	<b>1607</b>
Percentage of total	Not applicable	2.09%


According to data from the US Cystic Fibrosis Foundation (CFF) Registry, there is an evident progression in lung function decline (as measured by percent predicted FEV<sub>1</sub>) with age. Among CF patients with an R117H-CFTR mutation who are 19 to 30 years of age, 34% of patients have

a percent predicted FEV<sub>1</sub> < 80%, and that number increases to 55% for patients aged more than 30 years (Figure 1). A decrease in lung function is also observed over time in these patients, with 90% of patients aged > 18 years having respiratory disease compared with 48% of patients aged 6 to 11 years. Additional Cystic Fibrosis Foundation (CFF) registry data also show a clear progression of CF-related symptoms as patients with an R117H-CFTR mutation age; CF-related symptoms were observed in 54% and 93% of patients aged 6 to 11 years and > 18 years, respectively (Figure 2). Although the R117H-CFTR mutation results in CF disease, the severity of CF per age group is generally less than that caused by the G551D-CFTR mutation or other CFTR mutations<sup>2</sup> associated with a severe phenotype (Mcloskey M, 2000; McKone EF, 2006; Comer, 2009, see References). Many patients with an R117H-CFTR mutation have clinical evidence of preserved pancreatic exocrine function (potentially associated with a better body mass index [BMI]) and sweat chloride in the range of 60 to 80 mmol/L (compared with 90 to 120 mmol/L in patients with the G551D-CFTR mutation or who are homozygous for the F508del-CFTR mutation).

**Figure 1: Percent predicted FEV<sub>1</sub> by age cohorts for CF patients with an R117H-CFTR mutation**



<sup>2</sup> The clinical and functional translation of CFTR (CFTR2). Available at: <http://cftr2.org> (Accessed 28 May 2014). Nat Genet 2013;45 (10); 1160-7.

**Figure 2: CF-related symptoms by age cohort for patients with R117H-CFTR mutation**

Despite advances in CF treatment, the predicted median age of survival of individuals born today with CF is 41.1 to 48.5 years. Most pharmacologic treatments for CF (including *R117H* patients) such as dornase alfa, inhaled tobramycin, inhaled aztreonam and exocrine pancreatic enzyme supplementation are focused on managing the downstream consequences of diminished CFTR function: controlling airway infection and inflammation, mobilizing secretions to reduce airway obstruction and correcting nutritional deficits caused by pancreatic insufficiency. The increasing availability of therapies to treat CF lung disease, while improving the patients' survival, has resulted in a high therapeutic burden.

Many individuals with an *R117H-CFTR* mutation were not diagnosed with CF until the late childhood or adult years, when the disease had progressed and symptoms became much more evident although this has changed recently due to advances in newborn screening for CFTR mutations. Given the unmet medical need of the population of CF patients with an *R117H-CFTR* mutation, and considering that there is no drug currently approved to treat the underlying cause of CF in this population, there is a substantial need to improve the treatment and outlook for CF patients with this CFTR mutation. These patients demonstrate progression of disease with advancing age and have a decreased life expectancy.

Ivacaftor (KALYDECO) is currently the only approved therapy that targets the molecular defect that underlies the pathophysiology of CF. Ivacaftor is also the only approved therapy for CF that has evaluated safety and efficacy in small subsets of CF patients based on their genetic profile. Ivacaftor is an orally bioavailable small molecule that targets the underlying defect in CF and represents the first in a new class of drugs, known as CFTR modulators, that provide a new therapeutic approach to the treatment of CF by restoring the function of the CFTR protein. As a type of CFTR modulator, ivacaftor restores the function of the CFTR protein. Ivacaftor is highly selective for CFTR protein in vitro and acts on the CFTR protein to enhance chloride transport by increasing the channel open probability.

### 3. Contents of the clinical dossier

#### 3.1. Scope of the clinical dossier

The submission contained the following clinical information:

- One clinical pharmacology study (VX11-770-110), which provided pharmacokinetic data.

- One population pharmacokinetic analyses (J178).
- Efficacy, safety and PK results from a pivotal, Phase III, placebo controlled, parallel-group, study (Study VX11-770- 110 or Study 110) to evaluate ivacaftor treatment in subjects with CF who have an *R117H-CFTR* mutation.
- Efficacy and safety results of an interim analysis of an ongoing, open-label, rollover study (Study VX12-770-112 [Study112]) enrolling subjects from Study 110.
- Periodic Safety Update Reports (PSURs).
- There were no pooled analysis, meta-analysis, and integrated summary of efficacy or safety.

### 3.2. Paediatric data

The submission included paediatric pharmacokinetic/pharmacodynamics/efficacy/safety data. The paediatric ages groups evaluated were adolescents (12 to 17years) and children aged 6 to 11 years.

### 3.3. Good clinical practice

All clinical studies were performed in compliance with Good Clinical Practices.

## 4. Pharmacokinetics (PKs)

### 4.1. Studies providing pharmacokinetic data

Table 2 shows the studies providing pharmacokinetic data.

**Table 2: Submitted pharmacokinetic studies**

PK topic	Subtopic	Study ID	Primary aim of the study
PK in Target populations*	Multi-dose PK	VX11-770-110	Efficacy, safety and PK in subjects with CF who have the <i>R117H-CFTR</i> mutation
Population PK analyses	Target population*	J178 <sup>3</sup>	Characterise the population pharmacokinetics (popPK) of ivacaftor in subjects with CF and the <i>R117H-CFTR</i> mutation.

\* Subjects who would be eligible to receive the drug if approved for the proposed indication.

None of the pharmacokinetic studies had deficiencies that excluded their results from consideration.

<sup>3</sup> Study J178: PopPK data, including ivacaftor plasma concentrations, dosing histories, event times, and covariate factors were included from Phase1, 2 and 3 studies (007, 010, 101, 102, 103, 104, 110 and 111). In total 369 subjects were included who contributed 4806 ivacaftor concentration readings.

## 4.2. Summary of pharmacokinetics


The information in the following summary is derived from conventional pharmacokinetic studies unless otherwise stated.

### 4.2.1. Physicochemical characteristics of the active substance

The following information is derived from the Sponsor's summaries in Module 2.

- Chemical name: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide.
- Empirical formula:  $C_{24}H_{28}N_2O_3$
- Molecular weight: 392.49.
- Structural formula is in Figure 2.
- Description: ivacaftor is a white to off-white powder that is practically insoluble in water (< 0.05 microgram/mL). The pKa<sup>4</sup> values of ivacaftor are 9.40 and 11.60. The log D value<sup>5</sup> of ivacaftor is 5.68 at pH = 7.4 and 25°C.

**Figure 2: The structural formula of ivacaftor**



### 4.2.2. Pharmacokinetics in healthy subjects

**Comment:** No new studies examined the PKs of ivacaftor in healthy subjects; therefore, the following discussion will in most cases relate to the PKs in the target population. In addition, although Study VX11-770-110 examined the plasma PKs of ivacaftor and its metabolites in subjects with CF who have the R117H-CFTR mutation, the results of the PK analysis was presented as part of the population pharmacokinetics (PopPK) Study J178. Only new information (that is not previously presented to the TGA) will be reported in the following discussion.

#### 4.2.2.1. Absorption

##### *Sites and mechanisms of absorption*

Ivacaftor is administered orally and PopPK analyses indicate that ivacaftor PKs are best fit using a two-compartment model with zero-order delivery to the absorption compartment and subsequent first order absorption. For a reference subject (70 kg, male, 18 years, CF subject with non-R117H mutation), the zero-order dose duration (90% CI) was estimated to be 2.96 h (2.88, 3.17) and the first-order absorption rate constant ( $k_a$ ) was 0.721 h<sup>-1</sup> (0.530, 0.765) (Table 3).

<sup>4</sup> pKa: logarithmic form of the acid dissociation constant

<sup>5</sup> Log D value: a distribution constant to describe the lipophilicity of a molecule

**Table 3: Study J178- parameter estimates from the ivacaftor final population pharmacokinetic model (Run 1010)**

Description	Model	Estimate	%RSE
apparent oral clearance	$CL/F \sim \theta_1 \cdot (WT/70)^{0.75} \cdot \theta_8^{FEMALE} \cdot (AGE/18)^{\theta_9} \cdot \theta_{10}^{HEALTHY} \cdot e^{\eta}$	18.2 L/h	3.87
central volume of distribution	$V_c/F \sim \theta_2 \cdot (WT/70)^{1.0} \cdot e^{\eta}$	246 L	4.25
peripheral volume of distribution	$V_p/F \sim \theta_3 \cdot (WT/70)^{1.0}$	150 L	20.9
intercompartmental clearance	$Q/F \sim \theta_4 \cdot (WT/70)^{0.75}$	3.09 L/h	13.1
first-order absorption rate constant	$K_a \sim \theta_5 \cdot e^{\eta}$	0.721 h <sup>-1</sup>	11.0
zero-order absorption rate constant	$D1 \sim \theta_6$	2.96 h	2.59
female effect on clearance	$FEMALE_{CL/F} \sim \theta_7$	1.09	5.03
age effect on clearance	$AGE_{CL/F} \sim \theta_8$	-0.121	38.8
disease status (healthy) on clearance	$HEALTHY_{CL/F} \sim \theta_9$	1.19	10.5
CL/F for R117H subjects (study 110)	$R117H_{CL/F} \sim \theta_{10}$	14.3	10.8
interindividual variability of clearance	$IV_{CL/F} \sim \Omega_{1,1}$	0.197	10.4
interindividual CL-Vc covariance	$COV_{CL,Vc} \sim \Omega_{2,1}$	0.0773	26.0
interindividual variability of central volume	$IV_{Vc/F} \sim \Omega_{2,2}$	0.143	20.9
interindividual variability of Ka	$IV_{Ka} \sim \Omega_{3,3}$	1.11	12.5
interoccasion variability in bioavailability	$IOV_{F1} \sim \Omega_{4,4}$	0.250	4.79
proportional error	$err_{prop} \sim \Sigma_{1,1}$	0.0303	2.66
additive error	$err_{add} \sim \Sigma_{2,2}$	19300	3.64

#### 4.2.2.2. Bioavailability

The bioavailability of ivacaftor has been previously discussed in TGA submission No. PM-2012-01491-3-5; however, a sub-analysis presented as part of the PopPK study provided estimates of ivacaftor minimum observed concentration ( $C_{min}$ ) and area under the concentration-time curve (AUC), stratified by age and study number in patients with CF. In the studies included in the PopPK analysis (which examined subjects with CF with non-R117H mutation), mean ivacaftor  $C_{min}$  ranged from 545 ng/mL to 1190 ng/mL (Table 4) and mean AUC ranged from 8550 ng.h/mL to 18400 ng.h/mL (Table 5). In Study 110, which examined the plasma PKs of ivacaftor at steady state in subjects with CF who have an R117H-CFTR mutation, the mean ivacaftor  $C_{min}$  was 810 ng/mL and AUC was 12100 ng.h/mL (Tables 4 and 5).

**Table 4: Study J178- summary statistics for ivacaftor  $C_{min}$  (ng/mL) for 150 mg every 12 hours (q12h) subjects by study**

Study	N	Min	Max	Median	Mean	SD	Q1	Q3
All	308	130	3020	612	724	409	454	882
Study 101	16	145	1120	622	684	252	537	879
Study 102	82	130	1960	658	714	326	498	873
Study 103	26	367	3020	1050	1190	631	668	1530
Study 104	112	138	1560	482	545	279	350	645
Study 110	34	283	2240	740	810	342	596	948
Study 111	38	303	2640	814	891	488	549	1140



**Table 5: Study J178- summary statistics for ivacaftor AUC (ng/mL.h) for 150 subjects by study**

Study	N	Min	Max	Median	Mean	SD	Q1	Q3
All	308	3230	39200	9630	11100	5620	7340	13300
Study 101	16	3700	15700	11400	10700	3140	8690	12900
Study 102	82	3230	26100	10100	10700	4150	7620	13000
Study 103	26	6920	39200	15700	18400	8430	11600	23700
Study 104	112	3400	21700	7800	8550	3580	6140	9930
Study 110	34	5400	29500	11400	12100	4660	9380	13800
Study 111	38	5190	38000	12200	13500	7080	8640	15600

Safety: Not applicable. Evaluator`s comments: The study design, conduct and analysis were satisfactory.

**Comment:** Can the sponsor please provide the estimates of ivacaftor  $C_{min}$  and AUC for Studies 007 and 010, which were undertaken in healthy subjects, as they have done for the studies in patients with CF in Tables 4 and 5?

#### 4.2.2.3. Distribution

##### *Volume of distribution*

PopPK analysis indicated that the typical central volume of distribution (90% CI) in a reference subject was 246 L (196 to 254) and the typical peripheral volume of distribution was 150 L (48.1 to 362) (Table 3).

#### 4.2.2.4. Metabolism

Ivacaftor metabolism has been previously discussed as part of TGA Submission No. PM-2012-01491-3-5. No further information was provided in this submission.

#### 4.2.2.5. Excretion

For a reference subject, the apparent oral clearance (CL/F) was estimated to be 18.2 L/h (16.9 to 19.3) and inter-compartmental clearance was 3.09 L/h (1.98 to 14.0) (Table 3). Ivacaftor CL/F was reduced 21% for subjects with the R117H mutation, relative to CF subjects with a gating mutation or homozygous for F508del, with an estimate of 14.3 L/h (12.7 to 16.0).

#### 4.2.2.6. Intra- and inter-individual variability of pharmacokinetics

Based on the PopPK analysis, the inter-individual variabilities on CL/F, central volume and first-order absorption rate ( $k_a$ ) were 0.197, 0.143 and 1.11, respectively (Table 3). Unexplained random variability for CL/F was 46.7 CV%.

#### 4.2.3. Pharmacokinetics in the target population

Based on the reported  $C_{min}$  and AUC values (Tables 4 and 5) it is difficult to determine whether ivacaftor PKs in subjects with CF who have the R117H mutation are consistent with the PKs in CF subjects with a gating mutation or homozygous for F508del, as the values given for Study 110 (R117H mutation) fall within the range of  $C_{min}$  and AUC values identified for CF subjects without R117H mutations. However, the PopPK results indicating that CL/F is reduced by 21% in subjects with the R117H mutation, relative to the reference CF subject would suggest that AUC may be increased and  $t_{1/2}$  lengthened in subjects with R117H mutations.

**Comment:** As it is difficult to judge whether ivacaftor PKs are consistent across both CF populations (that is reference CF subjects and subjects with the R117H mutation) a full non-compartmental PK analysis of the results of Study 110, which includes typical PK parameters such  $T_{max}$ ,  $C_{max}$ , AUC,  $t_{1/2}$  and so on may help answer this question. Therefore, can the sponsor please provide a full non-compartmental analysis of the ivacaftor PK parameters for Study 110?

#### **4.2.3.1. Pharmacokinetics (in other special population / according to other population characteristic)**

The PopPK analysis estimated that body weight was the most important predictor of the PKs of ivacaftor, with a change in ivacaftor CL/F of 39% and 131% for typical 20 kg and 100 kg subjects, respectively, when compared to the reference subject (70 kg). Gender and patient status (that is healthy versus CF) did not account for variability in ivacaftor PKs and age was also not a clinically important covariate, after accounting for body size.

#### **4.2.4. Pharmacokinetic interactions**

No new information was provided regarding drug-drug interactions between ivacaftor and other drugs.

### **4.3. Evaluator's overall conclusions on pharmacokinetics**

The following conclusions relate to the results of the PopPK study J178.

- Ivacaftor is administered orally and its PKs are best fit using a two-compartment model with zero-order delivery to the absorption compartment and subsequent first order absorption.
- For a reference subject (70 kg, male, 18 years, CF subject with non-R117H mutation), the zero-order dose duration (90% CI) was estimated to be 2.96 h (2.88 to 3.17) and the first-order absorption rate constant ( $k_a$ ) was  $0.721 \text{ h}^{-1}$  (0.530 to 0.765)
- In subjects with CF with non-R117H mutation, mean ivacaftor  $C_{min}$  ranged from 545 ng/mL to 1190 ng/mL and mean AUC ranged from 8550 ng.h/mL to 18400 ng.h/mL. In subjects with CF who have an R117H-CFTR mutation, the mean ivacaftor  $C_{min}$  was 810 ng/mL and AUC was 12100 ng.h/mL.
- The typical central volume of distribution (90% CI) in a reference subject was 246 L (196 to 254) and the typical peripheral volume of distribution was 150 L (48.1 to 362).
- For a reference subject the CL/F was 18.2 L/h (16.9 to 19.3) and inter-compartmental clearance was 3.09 L/h (1.98 to 14.0). Ivacaftor CL/F was reduced 21% for subjects with the R117H mutation, relative to CF subjects with a gating mutation or homozygous for F508del, with an estimate of 14.3 L/h (12.7 to 16.0).
- It is difficult to judge whether ivacaftor PKs are consistent across both CF populations (that is reference CF subjects and subjects with the R117H mutation) as the reported  $C_{min}$  and AUC values from Study 110 fall within the range of values identified in reference CF patients. Based on the decrease in oral clearance identified in subjects with the R117H mutation however, it is possible that AUC and  $t_{1/2}$  would be increased in this CF population.
- Inter-individual variabilities on CL/F, central volume and  $k_a$  were 0.197, 0.143 and 1.11, respectively. Unexplained random variability for CL/F was 46.7 CV%.
- Body weight was the most important predictor of ivacaftor PKs, with a change in ivacaftor CL/F of 39% and 131% for the typical 20 kg and 100 kg subject, when compared to the reference subject.

- Gender and patient status (that is healthy versus CF) did not account for variability in ivacaftor PKs and age was also not a clinically important covariate, after accounting for body size.

#### 4.3.1. Limitations of the PK studies

Lack of a full non-compartmental PK analysis of the results of Study 110 which examined ivacaftor PKs in CF subjects with the R117H mutation.

#### 4.3.2. Questions related to the PK studies

1. Can the sponsor please provide the estimates of ivacaftor  $C_{min}$  and AUC for Studies 007 and 010, which were undertaken in healthy subjects, as they have done for the studies in patients with CF in Tables 4 and 5?
2. As it is difficult to judge whether ivacaftor PKs are consistent across both CF populations (that is reference CF subjects and subjects with the R117H mutation) a full non-compartmental PK analysis of the results of Study 110, which includes typical PK parameters such  $T_{max}$ ,  $C_{max}$ , AUC,  $t_{1/2}$  etc may help answer this question. Therefore, can the sponsor please provide a full non-compartmental analysis of the ivacaftor PK parameters for Study 110?

## 5. Pharmacodynamics

No new studies specifically examined ivacaftor PDs in the current submission.

## 6. Dosage selection for the pivotal studies

Studies 102, 103, and 111 evaluated ivacaftor 150 mg q12h which is the recommended ivacaftor (kalydeco) dosage for CF patients 6 years of age and older.

Similar PK parameter estimates between healthy subjects and subjects with CF suggested that exposure to ivacaftor in subjects with the R117H-CFTR mutation would be similar to the exposure in subjects with other CFTR mutations. The in vitro potency of ivacaftor towards the R117H mutation relative to other mutations that cause gating defects, as well as the efficacy and safety results obtained in Studies 102, 103, and 111 supported evaluation of 150 mg q12h in study 110. Hence, the dose of 150 mg q12h, which was well tolerated and resulted in robust treatment effects in subjects with other CFTR mutations that cause gating defects, was chosen for pivotal study 110 in CF patients with R117H-CFTR mutation.

## 7. Clinical efficacy

### 7.1. Indication 1

Ivacaftor (kalydeco) is indicated for the treatment of cystic fibrosis (CF) in patients: aged 6 years and older who have an R117H mutation in the CFTR gene.

Two clinical studies evaluated the efficacy of ivacaftor in subjects with an R117H-CFTR mutation. Study 110 was a placebo-controlled study and Study 112 is an ongoing open-label rollover study in which subjects from Study 110 could enrol. Results of the final analysis of Study 110 and interim analysis of Study 112 are included in this submission.

### 7.1.1. Pivotal study 110


#### 7.1.1.1. Study design, objectives, locations and dates

##### *Study design, objectives, locations and dates*

This was a Phase III, randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy (primary objective) and safety (secondary objective) of ivacaftor in subjects with CF who have the R117H-CFTR mutation. The tertiary objective was to characterize the plasma pharmacokinetics (PK) of ivacaftor and metabolites [hydroxymethyl-ivacaftor (M1) and ivacaftor carboxylate (M6)] at steady state in subjects with CF who have an R117H-CFTR mutation.

Subjects were randomized to receive either placebo or ivacaftor 150 mg q12h for 24 weeks. The study included a Screening Period (Day -35 to Day -15), a Run-In Period (Day -14 to Day -1 relative to the first dose of study drug), a Treatment Period (Day 1 [first dose of study drug] to Week 24), and a Follow-up Period. Study visits during the Treatment Period occurred on Day 1, Weeks 2, 4, 8, 16, and 24 (Figure 3). Subjects who prematurely discontinued study drug treatment had an Early Termination Visit. These subjects were not required to complete the Follow-up Visit if the Early Termination Visit occurred 3 weeks or later after the last dose of study drug.

**Figure 3: Study 110- schematic of study design VX11-770-110**



D: day; q12h: every 12 hours, W:week. Since the study was terminated early by the sponsor, study drug was administered for periods of up to 24 weeks.

Subjects who completed study drug treatment were offered the opportunity to enrol in the open-label treatment arm of Study 112; subjects who choose not to enrol in the open-label treatment arm were offered enrolment in the observational arm of Study 112.

In the event of early study termination, subjects who had not had their Week 24 Visit were considered to have completed their assigned study drug treatment duration and were to have completed the Follow-up Visit. These subjects were offered enrolment in the open-label treatment arm of Study 112; subjects who chose not to enrol in the open-label treatment arm were offered enrolment in the observational arm of Study 112.

An independent Data Monitoring Committee (DMC) was formed using the CF Foundation Data Safety Monitoring Board. As part of its responsibilities, the DMC conducted planned reviews of the study data. The DMC reviewed the unblinded interim analysis results for safety and efficacy after 40 subjects had completed Week 8 Visit and based on the results and rules pre-specified by Vertex provided guidance on whether further enrolment could have been stopped due to strong efficacy results. The DMC did not recommend any changes to study conduct as a result of their review.

The study was conducted from July 2012 to October 2013 at 27 sites in the United States and the European Union.

### 7.1.1.2. Inclusion and exclusion criteria

The main inclusion criteria were: male and female subjects with CF aged > 6 years who have the *R117H-CFTR* mutation on at least 1 allele and a confirmed diagnosis of CF, defined as chronic sinopulmonary disease and a sweat chloride value  $\geq 60$  mmol/L by quantitative pilocarpine iontophoresis or two CF-causing mutations. Subjects must have had percent predicted forced expiratory volume in 1 second (FEV<sub>1</sub>) of 40% to < 90% for subjects aged > 12 years or 40% to < 105% for subjects aged 6 to 11 years. Patients with other CFTR mutations and acute respiratory infections in past 4 weeks were excluded from the study. Other exclusion criteria are listed in Table 6.

**Table 6: Exclusion criteria for study 110**

Exclusion criteria	
1.	CFTR gene mutation leading to CFTR channel with gating defect (that is any 1 of the following mutations: <i>G551D</i> , <i>G178R</i> , <i>G551S</i> , <i>S549N</i> , <i>G970R</i> , <i>G1244E</i> , <i>S1251N</i> , <i>S1255P</i> , or <i>G1349D</i> )
2.	History of any illness or condition that, in the opinion of the investigator, might have confounded the results of the study or posed an additional risk in administering study drug to the subject
3.	An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before Day 1 (first dose of study drug)
4.	Pregnant, planning a pregnancy, breastfeeding, or not willing to follow contraception requirements
5.	Hemoglobin < 10 g/dL at screening
6.	Abnormal liver function at screening, defined as $\geq 3$ X upper limit of normal (ULN), of any 3 or more of the following: serum aspartate transaminase (AST), serum alanine transaminase (ALT), gamma-glutamyl transpeptidase (GGT)
7.	Abnormal renal function at screening, defined as glomerular filtration rate (GFR) $\leq 30$ mL/min/1.73 m <sup>2</sup> (calculated by the Modification of Diet in Renal Disease [MDRD] Study Equation) for subjects $\geq 18$ years of age; $\leq 45$ mL/min/1.73 m <sup>2</sup> (calculated by the Counahan-Barratt equation) for subjects aged 6 to 17 years (inclusive)
8.	History of solid organ or haematological transplantation
9.	History of alcohol, medication, or illicit drug abuse within 1 years before Day 1 (first dose of study drug)
10.	Colonization with organisms associated with a more rapid decline in pulmonary status (for example <i>Burkholderia cenocepacia</i> , <i>Burkholderia dolosa</i> , and <i>Mycobacterium abscessus</i> ) at screening
11.	Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days before screening. A washout period of $\geq 5$ terminal half-lives of the previous investigational study drug, or 30 days,

Exclusion criteria	
	whichever is longer, must have elapsed before Screening.
12.	Any 'non-CF-related' illness within 2 weeks before Day 1 (first dose of study drug). 'Illness' was defined as an acute (serious or non-serious) condition (for example gastroenteritis).
13.	Use of any inhibitors or inducers of cytochrome P450 (CYP) 3A, including consumption of certain herbal medications (for example St. John's Word) and grapefruit/grapefruit juice. Subjects must have stopped consuming these items from 14 days before Day 1 (first dose of study drug).
14.	Evidence of cataract or lens opacity at Screening.

#### 7.1.1.3. Study treatments

Ivacaftor 150-mg tablets or matching placebo tablets were administered orally at a dosage of 150 mg q12h. It was recommended to take ivacaftor with fat containing food such as a standard 'CF' high-fat, high calorie meal or snack. The planned duration of study drug administration was 24 weeks. Excluding the Screening and Run-in Periods, each subject was planned to participate in the study for approximately 28 weeks (Day 1 through the Follow up Visit).

**Comments:** As with Studies 102, 103, and 111 (evaluated in initial submission PM-2012-01491-3-5), treatment in Studies 110 and 112 was in addition to the subject's usual prescribed CF therapy (which had to remain stable during the study). Subjects were encouraged to remain on their prescribed CF therapies, such as high-dose ibuprofen, dornase alfa, azithromycin, and inhaled antibiotics. Specific guidelines were provided for inhaled antibiotics to minimize confounding effects of concomitant use on the results of the study. For Study 110, subjects who were taking inhaled hypertonic saline at the time of study entry should have remained on hypertonic saline through the Follow-up Visit; subjects who were not taking inhaled hypertonic saline at the time of study entry should have remained off hypertonic saline through the Follow-up Visit.

#### 7.1.1.4. Efficacy variables and outcomes

The main efficacy variables were: Spirometry, BMI, sweat chloride test, Cystic Fibrosis Questionnaire-Revised (CFQ-R), pulmonary exacerbations, weight, height, CF-related complications (for example pancreatitis, distal ileal obstruction syndrome [DIOS]), inflammatory mediators, microbiological cultures, immunoreactive trypsinogen (IRT) and faecal elastase-1.

The primary efficacy endpoint was the absolute change from baseline in FEV<sub>1</sub> through Week 24 in the Full Analysis Set (FAS). Additional supportive analyses of the primary endpoint were conducted by repeating the primary analysis on the Per Protocol Set (PPS) and the Complete Case Set (CCS). A responder analysis was also conducted by categorizing the absolute change from baseline in percent predicted FEV<sub>1</sub> at Week 24 as  $\geq 3.5\%$  or  $< 3.5\%$ ,  $\geq 5\%$  or  $< 5\%$ ,  $\geq 7.5\%$  or  $< 7.5\%$ , and  $\geq 10\%$  or  $< 10\%$ .

Secondary efficacy variables were absolute change from baseline in sweat chloride, rate of change from baseline in BMI, time-to-first pulmonary exacerbation and absolute change from baseline in the respiratory domain of the CFQ-R.

Subgroup analyses of the primary and secondary endpoints were performed in the same manner as the primary analysis for the following subgroups: age at baseline ( $> 18$  years and  $6$  to  $< 11$  years); percent predicted FEV<sub>1</sub> at baseline ( $< 70\%$ ,  $70\%$  to  $< 90\%$ , and  $> 90\%$  of the

predicted value); geographic region (North America and Europe); sex (female and male); *Pseudomonas aeruginosa* (*P aeruginosa*) infection status at baseline (yes and no); and R117H allele poly-T variant (5T, 7T, or 9T<sup>6</sup>). A subgroup analysis for subjects aged 12 to < 17 years was not conducted because there were only 2 subjects in that age group.

The tertiary efficacy variables included pulmonary exacerbations (count and duration), change from baseline in non-respiratory domains of the CFQ-R through 24 weeks of treatment, rate of change from baseline in weight, rate of change from baseline in height, CF-related complications (pancreatitis or DIOS), change from baseline in inflammatory mediators, change from baseline in qualitative microbiology cultures, change from baseline in IRT and change from baseline in faecal elastase-1.

The following additional spirometry endpoints (through Week 24) were analysed in a similar manner to that of the primary analysis of the primary efficacy endpoint (no sensitivity analyses were performed): relative change in percent predicted FEV<sub>1</sub> from baseline, absolute and relative change from baseline in FEV<sub>1</sub> (L), FVC (L), FEF<sub>25%-75%</sub> (L/sec), FEV<sub>1</sub>/FVC, percent predicted FVC, percent predicted FEF<sub>25%</sub> to 75% and percent predicted FEV<sub>1</sub>/FVC.

**Comments:** The primary and other efficacy endpoints complied with the EMEA guidelines on clinical development of medicinal products for the treatment of CF (2009). The primary endpoint evaluated lung function in terms of change in % predicted FEV<sub>1</sub>. Secondary and other endpoints evaluated effect of study drug on growth / nutrition and other markers of CF such as sweat chloride, inflammatory markers and pulmonary exacerbations. Spirometry was performed according to the American Thoracic Society Guidelines.

#### **7.1.1.5. Randomisation and blinding methods**

Subjects were randomized in a 1:1 ratio, stratifying for age ( $\geq 18$  years, 12 to < 17 years, and 6 to < 11 years) and FEV<sub>1</sub> severity (< 70%,  $\geq 70\%$  to  $\leq 90\%$ , and > 90%). The randomization codes were produced by Vertex or a designated vendor. To protect the study blind and maintain the scientific integrity of the data, 3 biostatisticians<sup>7</sup> were involved in the randomization process. A copy of the final randomization list (in sealed tamper evident envelopes) was archived at Vertex.

This was a double-blind study. The subjects, all site personnel including the investigator, the study monitor, and the Vertex study team remained blinded to treatment assignments until database lock and study unblinding with some exceptions (not included in this summary).

#### **7.1.1.6. Analysis populations**

The Full Analysis Set (FAS) and the Safety Set (both defined as all randomized subjects who received at least 1 dose of study drug) included 69 subjects. The Per Protocol Set (PPS) included the 63 FAS subjects without major protocol violations. The Complete Case Set (CCS) included the 61 FAS subjects who had the opportunity to complete 24 weeks of treatment. The FAS was used for all efficacy analyses. PPS analyses were performed for primary endpoint to provide supportive evidence for efficacy; CCS analyses were performed for primary and secondary endpoints to assess the impact of early termination of the study.

---

<sup>6</sup>This was pre-specified as per the Statistical Analysis Plan however, as the subjects recruited into study were either 5T or 7T (ie no 9T), poly T analyses and summaries based only on 5T and 7T were conducted.

<sup>7</sup>A study biostatistician who was blinded to the actual treatment code, an unblinded biostatistician not associated with the study, and an unblinded quality check (QC) biostatistician. The study biostatistician created the randomization specification and dummy randomization codes, which were reviewed and approved by the unblinded biostatistician. After approval, the unblinded biostatistician generated the final randomization list. The QC unblinded biostatistician reviewed and approved the final randomization list. The unblinded biostatistician provided the final randomization list to the interactive web response system (IWRS) vendor.

### 7.1.1.7. Sample size

Enrolment was planned for a minimum of 40 and a maximum of approximately 80 subjects in total who have the R117H-CFTR mutation on at least 1 allele. The estimated study power for detecting different treatment effect sizes between the ivacaftor and placebo groups in the absolute change in percent predicted FEV<sub>1</sub> from baseline through the Week 24 Visit, assuming 40, 60, or 80 randomized subjects was summarised in Table 7. The treatment effect sizes and standard deviation are based on the results of Studies 102 and 103 and a review of the clinical CF literature.

**Table 7: Study 110- power estimates (%) under possible scenarios of treatment effect and number of randomized and evaluable subjects**

Absolute Change in Percent Predicted FEV <sub>1</sub>	Total Number of Randomized and Evaluable Subjects		
	40	60	80
3.5%	27.1	38.5	48.9
4.0%	33.8	47.8	59.8
4.5%	41.1	57.2	70.0
5.0%	48.7	66.3	78.8
5.5%	56.3	74.5	85.9
6.0%	63.7	81.5	91.2
6.5%	70.7	87.2	94.8
7.0%	76.9	91.5	97.2
7.5%	82.4	94.6	98.5
8.0%	86.9	96.8	99.3

Notes: Treatment effect = absolute change from baseline in percent predicted FEV<sub>1</sub> for ivacaftor minus absolute change from baseline in percent predicted FEV<sub>1</sub> for placebo. Power estimates are based on 2-sided t-test with  $\alpha = 0.0448$ , assuming a common standard deviation of 8%.

**Comment:** The sample size of this study had an estimated 70% power to detect an improvement of at least 5% in percent predicted FEV<sub>1</sub> with ivacaftor treatment over placebo.

### 7.1.1.8. Statistical methods

The primary analysis for the primary efficacy variable was based on a mixed-effects model for repeated measures (MMRM). Data were assumed missing at random and no imputation of missing data was done for the primary analysis. The consistency of treatment effect over different visits was evaluated using the primary MMRM with treatment by visit interaction added to the model. To assess the robustness of the primary analysis, sensitivity analyses including pattern mixture model, dropout reason-based multiple imputation (using ANCOVA) and stratified Wilcoxon rank-sum test were implemented.

The analysis for rate of change from baseline in BMI was based on a linear mixed effects model (LMM). The primary analyses for change from baseline in sweat chloride value and change from baseline in the CFQ-R respiratory domain score were similar to that of the primary efficacy endpoint. Time to first pulmonary exacerbation was analysed using Cox regression; additionally, Kaplan-Meier methods were used to produce graphical presentations of the survival curves by treatment and to estimate cumulative survival rates by treatment. A sensitivity analysis of the rate of change from baseline in BMI was conducted by analysing the rate of change from baseline in BMI-for-age z-score as calculated using the Centers for Disease Control and Prevention (CDC) growth charts. Additional supportive analyses of the secondary endpoints were based on the CCS.

Responder analyses for BMI were conducted by categorizing the change from baseline in BMI (kg/m<sup>2</sup>) as either  $\geq 0.46$  kg/m<sup>2</sup> or  $< 0.46$  kg/m<sup>2</sup>; those for sweat chloride were conducted by categorizing absolute change from baseline in sweat chloride values at Week 24 as  $\geq 5$  or  $< 5$  mmol/L decrease,  $\geq 10$  or  $< 10$  mmol/L decrease,  $\geq 15$  or  $< 15$  mmol/L decrease,  $\geq 20$  or  $< 20$  mmol/L decrease; and those for CFQ-R respiratory domain score by categorizing the absolute change from baseline in the pooled CFQ-R respiratory domain score through Week 24 as either  $\geq 4$  points or  $< 4$  points.



The primary analysis for tertiary efficacy variables was performed for the FAS only. Pulmonary exacerbations were analysed using negative binomial regression (count) and Wilcoxon rank-Sum test (duration). CFQ-R non-respiratory domains were analysed in the same manner as the primary analysis of the secondary efficacy variable of CFQ-R respiratory domain score. Weight and height were analysed in the same manner as the primary analysis of the secondary efficacy variable of BMI. Analysis of inflammatory mediators was conducted on the raw change from baseline result and the log transformed change from baseline result in a similar manner as for the primary efficacy variable. CF-related complications were only summarized; qualitative levels of microbiological cultures were only summarized by shift tables. Change from baseline in IRT and faecal elastase-1 were analysed using ANCOVA with change from baseline as the dependent variable.

#### 7.1.1.9. Participant flow

A total of 69 subjects (35 in the placebo group and 34 in the ivacaftor group) were randomised and received at least one dose of study drug; 67 completed their full assigned duration of dosing; 59 of these subjects (28 in the ivacaftor group and 31 subjects in the placebo group) completed the 24-week treatment period. The remaining 8 subjects did not complete 24 weeks of treatment because the study was terminated early by the sponsor (Table 8). The overall treatment compliance was similar in the ivacaftor (98.97%) and placebo (98.43%) groups.

**Table 8: Subject disposition**

Disposition Category	Placebo n (%)	Ivacaftor n (%)	Overall n (%)
All Screened Subjects	NA	NA	108
All Randomized Subjects	36	34	70
Safety Set	35	34	69
Full Analysis Set (FAS)	35	34	69
Complete Case Set (CCS)	31	30	61
Per Protocol Set (PPS)	33	30	63
Never Dosed <sup>a</sup>	NA	NA	39
Last Scheduled Visit Completed:			
Day 1	0	0	0
Week 2	1 (2.9)	2 (5.9)	3 (4.3)
Week 4	1 (2.9)	0	1 (1.4)
Week 8	1 (2.9)	2 (5.9)	3 (4.3)
Week 16	1 (2.9)	2 (5.9)	3 (4.3)
Week 24	31 (88.6)	28 (82.4)	59 (85.5)
Completed Full Assigned Duration of Dosing	35 (100)	32 (94.1)	67 (97.1)
Failed to Complete Full Assigned Duration of Dosing	0	2 (5.9)	2 (2.9)
Reason for Discontinuation			
Adverse Event	0	0	0
Refused Further Dosing (Not Due to AE)	0	0	0
Lost to Follow-up	0	0	0
Death	0	0	0
Did Not Meet Eligibility Criteria	0	0	0
Non-Compliance with Study Drug	0	0	0
Other Non-Compliance	0	1 (2.9) <sup>b</sup>	1 (1.4)
Physician Decision	0	0	0
Required Prohibited Medication	0	0	0
Pregnancy (Self or Partner)	0	1 (2.9)	1 (1.4)
Study Terminated by Sponsor	0	0	0
Other	0	0	0

NA: not applicable; AE: adverse event. Percentages are calculated relative to the number of subjects in the FAS. FAS is defined as all randomised subjects who received at least 1 dose of study drug. Safety Set is defined as all subjects who received at least 1 dose of study drug. CCS is defined as all FAS subjects who had the opportunity to complete the full 24 week treatment period. PPS is defined as all FAS subjects without major protocol violations that could affect efficacy data. A: The 39 subjects counted as 'never dosed' were screen failures. In

addition, 1 subject [information redacted] was randomised to the placebo group but not dosed (reason: PI decision due to high percent predicted FEV<sub>1</sub> value on Day 1). b: Subject [information redacted] was discontinued from the study due to non-compliance in completing the required ophthalmologic examination at Screening.

#### **7.1.1.10. Major protocol violations/deviations**

Overall, 57 major protocol deviations were reported in 32 subjects (15 subjects on placebo and 17 subjects on ivacaftor) and the most common deviations included those that were related to use of a prohibited medication (ciprofloxacin, clarithromycin, fluconazole, prednisolone and prednisone), study drug compliance, eligibility and entry criteria not met. However, only 6 subjects who had major protocol violations (defined as major protocol deviations that may have had a substantial impact on efficacy assessment) were excluded from the PPS: 4 subjects in the ivacaftor group (3 subjects for prohibited medications- prednisone; 1 subject for missing 2 or more primary endpoint visits) and 2 subjects in the placebo group (1 subject discontinued inhaled antibiotic treatment during treatment period and 1 subject with treatment compliance < 80%).

#### **7.1.1.11. Baseline data**

All subjects in both treatment groups were White, and the majority of subjects in both treatment groups were of non-Hispanic or Latino ethnicity (placebo: 100%; ivacaftor: 97.1%). The mean age was 32.7 years (range: 6 to 68 years) for the placebo group and 29.2 years (range: 6 to 55 years) for the ivacaftor group. There were 19 subjects overall in the < 18 years subgroup (2 of whom were 12 to 17 years of age) and 50 subjects overall in the ≥ 18 years subgroup. Baseline percent predicted FEV<sub>1</sub> and BMI were slightly higher in the ivacaftor group than in the placebo group, and baseline sweat chloride and *P. aeruginosa* infection rate were slightly lower for the ivacaftor group than the placebo group. In data from subjects for whom the R117H allele poly-T variant was confirmed or derived<sup>8</sup>, the R117H-5T variant was more prevalent in the placebo group (placebo: 27 of 34 subjects; ivacaftor: 21 of 33 subjects). Overall, 53 (76.8%) of subjects had F508del mutation in the second allele. The mean sweat chloride value of about 70 mmol/L for the FAS is consistent with the residual function phenotype generally associated with the R117H-CFTR mutation. Overall, there were no significant differences between the ivacaftor and placebo groups (Table 9).

**Comment:** Overall, the baseline characteristics seem to indicate that patients in the ivacaftor group had a slightly better profile with less severe disease manifestations at baseline (higher percent predicted FEV<sub>1</sub>, BMI, lower sweat chloride and *P. aeruginosa* infection and lower prevalence of the more severe R117H-5T variant) (Table 9). The effect of this slight imbalance on interpretation of efficacy of ivacaftor was not discussed. Clarification regarding this has been sought from sponsors (see efficacy questions in Section 12).

---

<sup>8</sup> For subjects who either had DNA samples that could not be analysed or did not consent to the optional DNA samples, the poly-T variant for the R117H allele was derived if the subject had either a R117H/F508DEL or R117H/R117H genotype. All subjects who had the R117H/F508DEL genotype had one 9T variant; it was assumed that the 9T was on the F508DEL allele, and therefore the other variant (5T or 7T) was on the R117H allele. This assumption was considered valid because: (1) if a subject had R117H-9T they would have had a very mild disease phenotype (for example sweat chloride <60 mmol/L) and would not have qualified for entry into the study, and (2) a survey of the scientific literature indicates that the F508DEL allele has always been reported with the 9T variant except in some Lebanese Maronites, 1 North Iranian individual and 1 Hispanic individual. For subjects who did not have either a R117H/F508DEL or R117H/R117H genotype, the 5T/7T status for the R117H allele could not be derived.

**Table 9: Demographics and baseline characteristics, full analysis set**

Variable	Placebo N = 35	Ivacaftor N = 34	Overall N = 69
<b>Sex, n (%)</b>			
Male	15 (42.9)	15 (44.1)	30 (43.5)
Female	20 (57.1)	19 (55.9)	39 (56.5)
<b>Race, n (%)</b>			
White	35 (100.0)	34 (100.0)	69 (100.0)
Black or African American	--	--	--
Asian	--	--	--
American Indian or Alaska Native	--	--	--
Native Hawaiian or Other Pacific Islander	--	--	--
Other	--	--	--
Not Collected Per Local Regulations	--	--	--
<b>Ethnicity, n (%)</b>			
Hispanic or Latino	--	1 (2.9)	1 (1.4)
Not Hispanic or Latino	35 (100.0)	33 (97.1)	68 (98.6)
Not Collected Per Local Regulations	--	--	--
<b>Age (years)</b>			
N	35	34	69
Mean	32.7	29.2	31.0
SD	17.43	16.57	16.98
Median	37.0	30.0	32.0
Minimum	6	6	6
Maximum	68	55	68
<b>Age Group (years), n (%)</b>			
6 to 11 (inclusive)	8 (22.9)	9 (26.5)	17 (24.6)
12 to 17 (inclusive)	1 (2.9)	1 (2.9)	2 (2.9)
≥18	26 (74.3)	24 (70.6)	50 (72.5)
<b>CFTR Genotype, n (%)</b>			
<i>R117H/2184INSA</i>	1 (2.9)	--	1 (1.4)
<i>R117H/3659DELC</i>	1 (2.9)	--	1 (1.4)
<i>R117H/621+1G&gt;T</i>	--	1 (2.9)	1 (1.4)
<i>R117H/F508DEL</i>	25 (71.4)	28 (82.4)	53 (76.8)
<i>R117H/DELTA I507</i>	--	1 (2.9)	1 (1.4)
<i>R117H/E60X</i>	1 (2.9)	--	1 (1.4)
<i>R117H/G103X</i>	1 (2.9)	--	1 (1.4)
<i>R117H/G542X</i>	--	1 (2.9)	1 (1.4)
<i>R117H/R117H</i>	1 (2.9)	1 (2.9)	2 (2.9)
<i>R117H/R553X</i>	1 (2.9)	--	1 (1.4)
<i>R117H/R560T</i>	--	1 (2.9)	1 (1.4)
<i>R117H/S341P</i>	1 (2.9)	--	1 (1.4)
<i>R117H/S489X</i>	--	1 (2.9)	1 (1.4)
<i>R117H/UNKNOWN</i>	1 (2.9)	--	1 (1.4)
<i>R117H/W1282X</i>	2 (5.7)	--	2 (2.9)
<b>CFTR Poly-T Variant<sup>a</sup>, n</b>			
<b>5T on <i>R117H</i> allele</b>			
<i>5T/5T</i>	--	--	--
<i>5T/7T</i>	6	1	7
<i>5T/9T</i>	21	20	41
<b>7T on <i>R117H</i> allele</b>			
<i>7T/5T</i>	1	--	1
<i>7T/7T</i>	2	2	4
<i>7T/9T</i>	4	10	14

Table 9: continued

Variable	Placebo N = 35	Ivacaftor N = 34	Overall N = 69
<b>Sweat Chloride (mmol/L)</b>			
N	35	32	67
Mean	73.436	67.258	70.485
SD	19.7417	23.4544	21.6524
Median	77.500	70.500	74.750
Minimum	22.50	23.25	22.50
Maximum	108.75	120.00	120.00
<b>Percent Predicted FEV<sub>1</sub></b>			
N	35	34	69
Mean	70.2315	75.6968	72.9245
SD	18.94347	19.26241	19.15899
Median	71.9440	76.2470	73.2040
Minimum	37.392	32.542	32.542
Maximum	102.849	105.503	105.503
<b>Percent Predicted FEV<sub>1</sub>, n (%)</b>			
<70%	15 (42.9)	13 (38.2)	28 (40.6)
≥70% to ≤90%	14 (40.0)	14 (41.2)	28 (40.6)
>90%	6 (17.1)	7 (20.6)	13 (18.8)
<b>Height (cm)</b>			
N	35	34	69
Mean	161.8	160.6	161.2
SD	15.34	20.32	17.84
Median	163.0	163.0	163.0
Minimum	127	115	115
Maximum	198	188	198
<b>Weight (kg)</b>			
N	35	34	69
Mean	62.83	66.10	64.44
SD	25.412	25.469	25.306
Median	61.00	65.85	64.90
Minimum	22.0	19.0	19.0
Maximum	148.3	111.0	148.3

Table 9: continued

<b>BMI (kg/m<sup>2</sup>)</b>			
N	35	34	69
Mean	23.066	24.480	23.762
SD	6.0204	6.2497	6.1306
Median	21.500	24.030	22.760
Minimum	13.64	14.37	13.64
Maximum	37.83	42.87	42.87
<b>Height-for-age z-score (points)</b>			
N	10	12	22
Mean	0.5605	-0.0691	0.2171
SD	0.55857	0.89620	0.81079
Median	0.6355	-0.3580	0.0640
Minimum	-0.435	-1.166	-1.166
Maximum	1.303	1.912	1.912
<b>Weight-for-age z-score (points)</b>			
N	10	12	22
Mean	0.1679	0.2105	0.1911
SD	0.81852	1.04420	0.92669
Median	0.4180	0.1490	0.2690
Minimum	-1.397	-1.239	-1.397
Maximum	1.457	2.233	2.233
<b>BMI-for-age z-score (points)</b>			
N	10	12	22
Mean	-0.1310	0.3483	0.1305
SD	0.99173	0.89548	0.94933
Median	0.1945	0.3340	0.2600
Minimum	-1.739	-0.780	-1.739
Maximum	1.305	1.831	1.831
<b><i>P. aeruginosa</i> Infection Status, n (%)</b>			
Yes	19 (54.3)	15 (44.1)	34 (49.3)
No	16 (45.7)	19 (55.9)	35 (50.7)
<b>Fecal Elastase-1, n (%)</b>			
<200 µg/g	5 (14.3)	2 (5.9)	7 (10.1)
≥200 µg/g	28 (80.0)	32 (94.1)	60 (87.0)
Missing	2 (5.7)	--	2 (2.9)
<b>Geographic Region, n (%)</b>			
North America	30 (85.7)	24 (70.6)	54 (78.3)
Europe	5 (14.3)	10 (29.4)	15 (21.7)

All results displayed are Baseline results. Baseline was defined as the most recent measurement before intake of the first dose of study drug. Baseline sweat chloride was the average of Day-14 and Day 1. Weight for age z-score and BMI for age z-score were calculated by using National Center for Health Statistics (NCHS) growth charts. Z-scores were defined as missing if the subject is over 240 months old at the time of assessment. a: The poly-T variant for the R117H allele was derived for subjects where this information was missing and the subject had either R117H/F508DEL or R117H/R117H.

For subjects > 18 years of age, all subjects were White with mean age of 40.6 and 37.5 years for the placebo and ivacaftor groups, respectively. The mean overall baseline percent predicted FEV<sub>1</sub> was 64.53%, and mean overall baseline sweat chloride value was 71.29 mmol/L. Baseline percent predicted FEV<sub>1</sub> was slightly higher and baseline sweat chloride slightly lower for the ivacaftor group than the placebo group (Table 10A). For subjects aged 6 to 11 years, the mean age was 9.0 and 8.8 years for the placebo and ivacaftor groups, respectively. The mean overall baseline percent predicted FEV<sub>1</sub> was 95.84%, and mean overall baseline sweat chloride value was 69.41 mmol/L. Baseline percent predicted FEV<sub>1</sub> was slightly higher and baseline sweat chloride slightly lower for the ivacaftor group than the placebo Group (Table 10B).

**Table 10A: Demographics and baseline characteristics; full analysis set, subjects  $\geq 18$  years of age**

Variable	Placebo N = 26	Ivacaftor N = 24	Overall N = 50
<b>CFTR Poly-T Variant*, n</b>			
<i>5T</i> on <i>R117H</i> allele			
<i>5T/5T</i>	--	--	--
<i>5T/7T</i>	4	1	5
<i>5T/9T</i>	17	16	33
<i>7T</i> on <i>R117H</i> allele			
<i>7T/5T</i>	1	--	1
<i>7T/7T</i>	1	1	2
<i>7T/9T</i>	2	5	7
<b>Percent Predicted FEV<sub>1</sub></b>			
N	26	24	50
Mean	62.2149	67.0287	64.5255
SD	14.40616	15.36930	14.92196
Median	64.8460	67.6535	66.4895
Minimum	37.392	32.542	32.542
Maximum	85.843	92.621	92.621
<b>Percent Predicted FEV<sub>1</sub>, n (%)</b>			
<70%	15 (57.7)	13 (54.2)	28 (56.0)
$\geq 70\%$ to $\leq 90\%$	11 (42.3)	10 (41.7)	21 (42.0)
>90%	--	1 (4.2)	1 (2.0)
<b>Sweat Chloride (mmol/L)</b>			
N	26	23	49
Mean	73.010	69.337	71.286
SD	17.3225	24.0967	20.6360
Median	78.375	74.000	75.500
Minimum	35.50	23.25	23.25
Maximum	102.25	120.00	120.00
<b>Height (cm)</b>			
N	26	24	50
Mean	168.3	170.1	169.2
SD	9.72	12.12	10.86
Median	167.0	166.5	167.0
Minimum	155	147	147
Maximum	198	188	198
<b>Weight (kg)</b>			
N	26	24	50
Mean	71.74	77.90	74.70
SD	22.515	16.734	19.993
Median	69.00	75.50	71.90
Minimum	42.0	56.0	42.0
Maximum	148.3	111.0	148.3
<b>BMI (kg/m<sup>3</sup>)</b>			
N	26	24	50
Mean	24.947	26.894	25.882
SD	5.7086	5.2291	5.5161
Median	24.610	25.695	25.135
Minimum	17.04	21.50	17.04
Maximum	37.83	42.87	42.87
<b><i>P. aeruginosa</i> Infection Status, n (%)</b>			
Yes	18 (69.2)	14 (58.3)	32 (64.0)
No	8 (30.8)	10 (41.7)	18 (36.0)
<b>Fecal Elastase-1, n (%)</b>			
<200 $\mu\text{g/g}$	5 (19.2)	2 (8.3)	7 (14.0)
$\geq 200 \mu\text{g/g}$	20 (76.9)	22 (91.7)	42 (84.0)
Missing	1 (3.8)	--	1 (2.0)
<b>Geographic Region, n (%)</b>			
North America	21 (80.8)	16 (66.7)	37 (74.0)
Europe	5 (19.2)	8 (33.3)	13 (26.0)

**Table 10B: Demographics and baseline characteristics; full analysis set, subjects 6 to 11 years of age (inclusive)**

Variable	Placebo N = 8	Ivacaftor N = 9	Overall N = 17
<b>Sex, n (%)</b>			
Male	5 (62.5)	4 (44.4)	9 (52.9)
Female	3 (37.5)	5 (55.6)	8 (47.1)
<b>Race, n (%)</b>			
White	8 (100.0)	9 (100.0)	17 (100.0)
Black or African American	--	--	--
Asian	--	--	--
American Indian or Alaska Native	--	--	--
Native Hawaiian or Other Pacific Islander	--	--	--
Other	--	--	--
Not Collected Per Local Regulations	--	--	--
<b>Ethnicity, n (%)</b>			
Hispanic or Latino	--	--	--
Not Hispanic or Latino	8 (100.0)	9 (100.0)	17 (100.0)
Not Collected Per Local Regulations	--	--	--
<b>Age (years)</b>			
N	8	9	17
Mean	9.0	8.8	8.9
SD	1.60	1.92	1.73
Median	9.5	9.0	9.0
Minimum	6	6	6
Maximum	11	11	11
<b>CFTR Genotype, n (%)</b>			
<i>R117H/2184INSA</i>	1 (12.5)	--	1 (5.9)
<i>R117H/F508DEL</i>	6 (75.0)	8 (88.9)	14 (82.4)
<i>R117H/R117H</i>	1 (12.5)	--	1 (5.9)
<i>R117H/S489X</i>	--	1 (11.1)	1 (5.9)
<b>CFTR Poly-T Variant<sup>a</sup>, n</b>			
<b>5T on <i>R117H</i> allele</b>			
<i>5T/5T</i>	--	--	--
<i>5T/7T</i>	1	--	1
<i>5T/9T</i>	4	4	8
<b>7T on <i>R117H</i> allele</b>			
<i>7T/5T</i>	--	--	--
<i>7T/7T</i>	1	1	2
<i>7T/9T</i>	2	4	6
<b>Percent Predicted FEV<sub>1</sub></b>			
N	8	9	17
Mean	93.9806	97.4854	95.8361
SD	8.36373	8.60900	8.42099
Median	96.8130	101.0610	98.1710
Minimum	79.956	84.077	79.956
Maximum	102.849	105.503	105.503
<b>Percent Predicted FEV<sub>1</sub>, n (%)</b>			
<70%	--	--	--
≥70% to ≤90%	2 (25.0)	3 (33.3)	5 (29.4)
>90%	6 (75.0)	6 (66.7)	12 (70.6)
<b>Sweat Chloride (mmol/L)</b>			
N	8	8	16
Mean	74.656	64.156	69.406
SD	28.6132	22.5938	25.4890
Median	81.000	65.750	70.500
Minimum	22.50	33.00	22.50
Maximum	108.75	100.50	108.75

Table 10B: Continued

Variable	Placebo N = 8	Ivacaftor N = 9	Overall N = 17
<b>BMI (kg/m<sup>3</sup>)</b>			
n	8	9	17
Mean	17.101	17.646	17.389
SD	2.3761	3.2998	2.8272
Median	17.255	16.740	16.840
Minimum	13.64	14.37	13.64
Maximum	21.50	24.69	24.69
<b>Height-for-age z-score (points)</b>			
n	8	9	17
Mean	0.6095	-0.2621	0.1481
SD	0.58427	0.74923	0.79443
Median	0.6530	-0.4420	0.1540
Minimum	-0.435	-1.166	-1.166
Maximum	1.303	1.381	1.381
<b>Weight-for-age z-score (points)</b>			
n	8	9	17
Mean	0.3120	-0.0194	0.1365
SD	0.68086	0.96162	0.83322
Median	0.4180	-0.2950	0.1840
Minimum	-0.669	-1.239	-1.239
Maximum	1.457	1.810	1.810
<b>BMI-for-age z-score (points)</b>			
n	8	9	17
Mean	0.0109	0.1868	0.1040
SD	0.95037	0.89346	0.89581
Median	0.2245	0.2030	0.2030
Minimum	-1.739	-0.780	-1.739
Maximum	1.305	1.577	1.577
<b><i>P. aeruginosa</i> Infection Status, n (%)</b>			
Yes	1 (12.5)	1 (11.1)	2 (11.8)
No	7 (87.5)	8 (88.9)	15 (88.2)
<b>Fecal Elastase-1, n (%)</b>			
<200 µg/g	--	--	--
≥200 µg/g	7 (87.5)	9 (100.0)	16 (94.1)
Missing	1 (12.5)	--	1 (5.9)
<b>Height (cm)</b>			
n	8	9	17
Mean	139.8	133.9	136.6
SD	9.25	13.86	11.94
Median	139.0	132.0	135.0
Minimum	127	115	115
Maximum	154	161	161
<b>Weight (kg)</b>			
n	8	9	17
Mean	34.03	32.86	33.41
SD	9.097	13.329	11.198
Median	32.60	32.70	32.70
Minimum	22.0	19.0	19.0
Maximum	51.0	64.0	64.0

The incidence of medical history conditions occurring in at least 15% of subjects was similar in the 2 treatment groups with the exception of asthma (placebo: 14.3%; ivacaftor: 35.3%), pancreatic insufficiency (placebo: 28.6%; ivacaftor: 8.8%), and drug hypersensitivity (placebo: 34.3%; ivacaftor: 17.6%). The rate of faecal elastase-1  $\geq$  200 µg/g was slightly higher in the ivacaftor group (placebo: 80.0%; ivacaftor: 94.1%) (Table 11). The mean number of hospitalizations (planned and unplanned) and clinic visits in the past year were similar for the 2 groups (Table 12). The most commonly reported concomitant medications were indicated for management of CF complications. The use of concomitant medications received by at least 15%



of subjects was similar in both treatment groups with the exceptions of paracetamol (placebo: 37.1%; ivacaftor: 11.8%) and pancreatin (placebo: 20.0%; ivacaftor: 2.9%) (Table 13).

**Table 11: medical history consistent with a diagnosis of CF with an incidence of at least 15% of subjects in any treatment group, full analysis set**

Condition	Placebo N = 35 n (%)	Ivacaftor N = 34 n (%)	Overall N = 69 n (%)
Cystic fibrosis lung disease	35 (100.0)	34 (100.0)	69 (100.0)
Gastroesophageal reflux disease	16 (45.7)	11 (32.4)	27 (39.1)
Chronic sinusitis	11 (31.4)	14 (41.2)	25 (36.2)
Drug hypersensitivity	12 (34.3)	6 (17.6)	18 (26.1)
Asthma	5 (14.3)	12 (35.3)	17 (24.6)
Constipation	9 (25.7)	7 (20.6)	16 (23.2)
Pancreatic insufficiency	10 (28.6)	3 (8.8)	13 (18.8)
Nasal polyps	7 (20.0)	5 (14.7)	12 (17.4)
Osteopenia	7 (20.0)	4 (11.8)	11 (15.9)
Sinusitis	6 (17.1)	3 (8.8)	9 (13.0)
Seasonal allergy	7 (20.0)	2 (5.9)	9 (13.0)
Anxiety	6 (17.1)	2 (5.9)	8 (11.6)

**Table 12: hospitalisations (planned and unplanned) and clinic visits in the past year full analysis set**

Event Category	Statistic	Placebo (N=35)	Ivacaftor (N=34)	Overall (N=69)
<b>Planned Hospitalizations for Antibiotics</b>				
	n	35	34	69
	Mean	0.2	0.1	0.1
	SD	0.47	0.29	0.39
	Median	0.0	0.0	0.0
	Min	0	0	0
	Max	2	1	2
<b>Unplanned Hospitalizations for CP-Related Disease</b>				
<b>for Pancreatitis</b>				
	n	35	34	69
	Mean	0.0	0.0	0.0
	SD	0.17	0.00	0.12
	Median	0.0	0.0	0.0
	Min	0	0	0
	Max	1	0	1
<b>for Distal Intestinal Obstructive Syndrome (DIOS)</b>				
	n	35	34	69
	Mean	0.0	0.0	0.0
	SD	0.00	0.00	0.00
	Median	0.0	0.0	0.0
	Min	0	0	0
	Max	0	0	0
<b>for Other Reasons</b>				
	n	35	34	69
	Mean	0.1	0.3	0.2
	SD	0.40	0.94	0.72
	Median	0.0	0.0	0.0
	Min	0	0	0
	Max	2	5	5
-----				
Event Category	Statistic	Placebo (N=35)	Ivacaftor (N=34)	Overall (N=69)
<b>Outpatient Sick Visits for CF Complications</b>				
	n	35	34	69
	Mean	2.1	1.6	1.9
	SD	2.62	2.02	2.34
	Median	1.0	1.0	1.0
	Min	0	0	0
	Max	10	9	10
<b>Pulmonary Exacerbation Requiring Antibiotics, n (%)</b>				
	Yes	28 (80.0)	23 (67.6)	51 (73.9)
	No	7 (20.0)	11 (32.4)	18 (26.1)
<b>Pulmonary Exacerbation Requiring Antibiotics</b>				
	n	28	23	51
	Mean	2.4	2.6	2.5
	SD	1.87	1.67	1.77
	Median	2.0	2.0	2.0
	Min	1	1	1
	Max	9	7	9
<b>Requiring Hospitalisation</b>				
	n	28	22	50
	Mean	0.6	0.6	0.6
	SD	0.78	1.14	0.95
	Median	0.5	0.0	0.0
	Min	0	0	0
	Max	3	5	5
<b>Requiring IV Antibiotics</b>				
	n	28	22	50
	Mean	0.7	0.7	0.7
	SD	0.76	1.17	0.95
	Median	1.0	0.0	0.5
	Min	0	0	0
	Max	3	5	5

**Table 13: concomitant medications received by at least 15% of subjects in any treatment group, full analysis set**

WHO Drug Dictionary Classification	Placebo N = 35 n (%)	Ivacaftor N = 34 n (%)	Overall N = 69 n (%)
Subjects with Any Concomitant Medication	35 (100.0)	34 (100.0)	69 (100.0)
Salbutamol	28 (80.0)	22 (64.7)	50 (72.5)
Dornase Alfa	23 (65.7)	21 (61.8)	44 (63.8)
Azithromycin	18 (51.4)	14 (41.2)	32 (46.4)
Multivitamins, Combinations	10 (28.6)	13 (38.2)	23 (33.3)
Fluticasone Propionate	10 (28.6)	9 (26.5)	19 (27.5)
Paracetamol	13 (37.1)	4 (11.8)	17 (24.6)
Tobramycin	9 (25.7)	7 (20.6)	16 (23.2)
Colecalciferol	7 (20.0)	7 (20.6)	14 (20.3)
Ibuprofen	5 (14.3)	9 (26.5)	14 (20.3)
Seretide	7 (20.0)	7 (20.6)	14 (20.3)
Omeprazole	9 (25.7)	4 (11.8)	13 (18.8)
Cetirizine Hydrochloride	9 (25.7)	3 (8.8)	12 (17.4)
Ciprofloxacin	5 (14.3)	7 (20.6)	12 (17.4)
Aztreonam Lysine	6 (17.1)	4 (11.8)	10 (14.5)
Budesonide w/Formoterol Fumarate	6 (17.1)	4 (11.8)	10 (14.5)
Colistin	6 (17.1)	1 (2.9)	7 (10.1)
Doxycycline	6 (17.1)	2 (5.9)	8 (11.6)
Levofloxacin	6 (17.1)	2 (5.9)	8 (11.6)
Pancreatin	7 (20.0)	1 (2.9)	8 (11.6)

Preferred Terms (PT) are sorted in descending order of frequency in the Overall column. A subject with multiple concomitant medications within Anatomical Therapeutic Chemical (ATC) level or PT is counted only once within the ATC level or PT. Concomitant medications were coded from the WHHO Drug Dictionary Enhanced, March 2012.

#### 7.1.1.12. Results for the primary efficacy outcome

Although the mean absolute change from baseline in percent predicted FEV<sub>1</sub> through Week 24 by MMRM for the FAS was greater for the ivacaftor group than the placebo group (2.57 versus 0.46 percentage points), the difference was not statistically significant (difference for ivacaftor versus placebo was 2.11 percentage points; (95% CI: -1.13, 5.35; p = 0.1979). Although not statistically significant, the differences favoured ivacaftor at all treatment period time points; the trend in treatment effect observed at Week 8 was consistent with that observed at Week 24 (Table 14-15). The gains seen in percent predicted FEV<sub>1</sub> for the ivacaftor group during the treatment period reversed in the follow-up period when the subjects were no longer receiving ivacaftor (Figure 3).

The results of the sensitivity analyses were consistent with the results of the primary analysis; the absolute change from baseline was greater for the ivacaftor group than the placebo group for all analyses, but was not statistically significant (Table 16).

A responder analysis was conducted by categorizing the absolute change from baseline in percent predicted FEV<sub>1</sub> through Week 24 as  $\geq 3.5\%$  or  $< 3.5\%$ ,  $\geq 5\%$  or  $< 5\%$ ,  $\geq 7.5\%$  or  $< 7.5\%$ ,  $\geq 10\%$  or  $< 10\%$ . The number of responders favoured ivacaftor at all thresholds, with approximately twice as many responders in the ivacaftor group as the placebo group; however, these differences were not statistically significant (Table 17).


**Table 14: Absolute change from baseline in predicted FEV<sub>1</sub> by MMRM, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	N	LS Mean	Difference (95% CI)	P value
Baseline	Placebo	35	70.2315	--	--	--	--
	Ivacaftor	34	75.6968	--	--	--	--
Overall Post-baseline	Placebo	35	71.1264	35	0.4611	2.1114	0.1979
	Ivacaftor	34	78.0432	34	2.5724	(-1.1305, 5.3532)	

**Table 15: Absolute change from baseline in percent predicted FEV<sub>1</sub> by MMRM, consistency of treatment effect over visits, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	N	LS Mean	Difference (95% CI)	P value <sup>b</sup>
Baseline	Placebo	35	70.2315	--	--	--	--
	Ivacaftor	34	75.6968	--	--	--	--
Week 2	Placebo	35	70.1335	35	-0.1634	2.0371	0.2695
	Ivacaftor	34	77.4862	34	1.8738	(-1.6020, 5.6763)	
Week 4	Placebo	34	71.7526	34	1.2675	1.4811	0.4262
	Ivacaftor	32	77.8576	32	2.7487	(-2.1948, 5.1571)	
Week 8	Placebo	33	69.9406	33	-0.0903	2.9372	0.1173
	Ivacaftor	32	77.9558	32	2.8469	(-0.7505, 6.6249)	
Week 16	Placebo	32	71.4261	32	0.1691	1.6087	0.3933
	Ivacaftor	30	77.6327	30	1.7778	(-2.1111, 5.3286)	
Week 24	Placebo	31	72.5135	31	1.1224	2.4926	0.1911
	Ivacaftor	28	79.4713	28	3.6151	(-1.2619, 6.2471)	

Sample statistics are unadjusted results. Difference is ivacaftor- placebo. A positive difference favors ivacaftor. A: Estimates were obtained from MMRM with absolute change from baseline as the dependent variable; with treatment, categorical visit (Weeks 2,4,8 and 16) and treatment by visit interaction as fixed effects; with subject as a random effect; and with adjustment for the continuous baseline value of age and percent predicted FEV<sub>1</sub> using compound symmetry covariance matrix. b: P value for overall post-baseline is from the main treatment effect; p values at individual visits are from linear contrasts between the 2 treatments at the given visit.

**Figure 3: modelled absolute change from baseline in percent predicted FEV<sub>1</sub> by treatment up to follow-up visit, full analysis set**

**Table 16: Absolute change from baseline in percent predicted FEV<sub>1</sub>, sensitivity analysis, full analysis set**

Sensitivity Analysis	Treatment Group	Absolute Change From Baseline		Treatment Effect (Ivacaftor vs Placebo)	
		n	LS Mean	Difference (95% CI)	P value
Stratified Wilcoxon <sup>a</sup>	Placebo	35	-0.0000	--	0.1115
	Ivacaftor	34	0.5128		
Dropout Reason-based Multiple Imputation (using ANCOVA) <sup>b</sup>	Placebo	--	--	1.898 (-1.8908, 5.6871)	0.3235
	Ivacaftor	--	--		
Pattern Mixture Model <sup>c</sup> : Overall	Placebo	35	-0.0949	2.487 (-0.4683, 5.4428)	0.0991
	Ivacaftor	34	2.3923		

a: Stratified (by age group and percent predicted FEV<sub>1</sub> at baseline) Wilcoxon rank-sum test of the mean change from baseline. Medians are displayed in the LS Mean column. b: ANCOVA model with drop-out reason based method. c: Estimates from MMRM with the dependent variable absolute change from baseline; with fixed effects for visit, treatment, dropout pattern, interaction between dropout pattern and treatment, and interaction between dropout pattern and visit; and adjustment for continuous baseline value of percent predicted FEV<sub>1</sub> using compound symmetry covariance matrix. The overall treatment effect adjusting for dropout patterns was obtained from pattern-specific estimates by a weighted average.

**Table 17: Responder analysis of absolute change through Week 24 in percent predicted FEV<sub>1</sub>, full analysis set**

Category	Placebo N = 35 n (%)	Ivacaftor N = 34 n (%)	P value
≥3.5%	8 (22.9)	13 (38.2)	0.1975
<3.5%	27 (77.1)	21 (61.8)	
≥5%	7 (20.0)	13 (38.2)	0.1165
<5%	28 (80.0)	21 (61.8)	
≥7.5%	4 (11.4)	8 (23.5)	0.2182
<7.5%	31 (88.6)	26 (76.5)	
≥10%	2 (5.7)	5 (14.7)	0.2595
<10%	33 (94.3)	29 (85.3)	

Absolute change through Week 24 is the average change from baseline over 24 weeks for percent predicted FEV<sub>1</sub>.

**Comment:** The sponsors state that the magnitude of change observed in pulmonary function (that is percent predicted FEV<sub>1</sub>) in subjects ≥ 18 years of age is within a clinically relevant range observed in established treatments approved to treat CF. However, the treatment difference (ivacaftor-placebo) of around 4 to 5% was much lesser than the 10 to 12% treatment difference observed in the pivotal studies 103 and 104 in that observed in 213 subjects with CF who had a G551D mutation in the CFTR gene (PM-2012-01491-3-5).

#### 7.1.1.13. Results for other efficacy outcomes

##### Secondary efficacy results

The mean absolute change from baseline in sweat chloride showed statistically significantly greater reduction with ivacaftor compared to placebo (-26.28 versus -2.31 mmol/L; treatment difference for ivacaftor versus placebo was -23.97 mmol/L; 95% CI: -28.01, -19.93; p < 0.0001). The treatment effect was highly consistent from Week 2 through Week 24. Furthermore, the decrease seen in sweat chloride for the ivacaftor group during the Treatment Period reversed in the Follow-up Period when the subjects were no longer receiving ivacaftor (Figure 4).

The majority of subjects in the ivacaftor group who had ≥ 5 mmol/L decrease in sweat chloride at Week 24 also had ≥ 15 mmol/L decrease at Week 24. Only 1 subject (2.9%) in the placebo

group achieved a  $\geq 15$  mmol/L decrease in sweat chloride compared to 21 subjects (61.8%) in the ivacaftor group. None of the subjects in the placebo group achieved a  $\geq 20$  mmol/L decrease in sweat chloride compared to 9 subjects (26.5%) in the ivacaftor group (Table 18).


The rate of increase in BMI from baseline was greater in the ivacaftor groups compared with placebo although the treatment difference was not statistically significant (diff = 0.26 kg/m<sup>2</sup>; 95% CI: -1.57, 2.09; p = 0.7780). BMI-for-age z-scores were calculated using the CDC growth chart for the 22 subjects who were 20 years of age or younger and showed similar results (Table 19-20).

The calculated hazard ratio of 0.928 for time to first pulmonary exacerbation favoured ivacaftor, but was not statistically significant (p = 0.8556). Survival curves by treatment group for time-to-first pulmonary exacerbation, pulmonary exacerbation requiring hospitalization, and pulmonary exacerbation requiring IV antibiotics showed no significant difference between ivacaftor and placebo groups (Figure 5-6-7).

The mean absolute change from baseline in the pooled CFQh-R respiratory domain score through Week 24 was greater for the ivacaftor group (7.56 points) than the placebo group (-0.83 points). The treatment difference for ivacaftor versus placebo was 8.39 points (95% CI: 2.17 to 14.61), which is approximately double the defined minimal clinically important difference (MCID) of 4 points and was statistically significant (p = 0.0091). Ivacaftor showed better scores at all treatment period time points. Furthermore, the gains seen in the CFQ-R respiratory domain score for the ivacaftor group during the Treatment Period reversed in the Follow-up Period when subjects were no longer on ivacaftor (Figure 8). The percentage of subjects with the clinically important  $\geq 4$  point increase from baseline in the CFQ-R respiratory domain score through Week 24 was greater for the ivacaftor group (41.2%) than the placebo group (28.6%).

The mean absolute change from baseline in the CFQ-R respiratory domain score through Week 24 was lower for the ivacaftor group than the placebo group in the Children Ages 6 to 11 Years version and in the Parent/Caregiver version but the treatment difference was not statistically significant (Table 21). The Children Ages 12 to 13 Years version was not analysed with MMRM due to sample size constraints. The mean absolute change from baseline in the CFQ-R respiratory domain score through Week 24 in the Adolescents and Adults version was greater for the ivacaftor group (12.10 points) than the placebo group (-0.26 points). The treatment difference of 12.36 points (95% CI: 5.03, 19.69) was statistically significant (P = 0.0014) and larger than that seen in the pooled analysis. The mean absolute change from baseline for the CFQ-R respiratory domain score through Week 24 was lower for the ivacaftor group (-3.72 points) than the placebo group (-2.10 points), but the treatment difference of -1.62 points (95% CI: -13.65, 10.41) was not statistically significant (p= 0.7766).

**Figure 4: Mean absolute change from baseline in sweat chloride (mmol/L) by treatment up to follow-up visit, full analysis set**



**Table 18: responder analysis of absolute change through week 24 of sweat chloride (mmol/L), full analysis set**

Category	Placebo (N = 35) n (%)	Ivacaftor (N = 34) n (%)
≥5 mmol/L decrease	13 (37.1)	31 (91.2)
<5 mmol/L decrease	22 (62.9)	1 (2.9)
≥10 mmol/L decrease	9 (25.7)	29 (85.3)
<10 mmol/L decrease	26 (74.3)	3 (8.8)
≥15 mmol/L decrease	1 (2.9)	21 (61.8)
<15 mmol/L decrease	34 (97.1)	11 (32.4)
≥20 mmol/L decrease	--	9 (26.5)
<20 mmol/L decrease	35 (100.0)	23 (67.6)

Absolute change through Week 24 is the average change from baseline over 24 weeks for sweat chloride.

**Table 19: rate of change from baseline in BMI (kg/m<sup>2</sup>) by LMM, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Rate of Change in Treatment Period <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	n	LS Mean	Difference (95% CI)	P value <sup>b</sup>
Baseline	Placebo	35	23.066	--	--	--	--
	Ivacaftor	34	24.480	--	--	--	--
Week 24	Placebo	31	23.735	35	0.2284	0.2626	0.7780
	Ivacaftor	28	24.542	34	0.4910	(-1.5698, 2.0950)	


Sample statistics are unadjusted results. a: Estimated change from baseline per 168 days was obtained from a linear mixed model, with BMI as the dependent variable; with treatment as a fixed effect; with intercept and visit (days on study, including all visits through Week 24) as random effects; and with adjustment for baseline percent predicted FEV<sub>1</sub>, age, and visit by treatment interaction included as covariates in the model. b: p value for the treatment effect is from the slope of BMI (kg/m<sup>2</sup>) versus time (days).

**Table 20: Rate of change from baseline in BMI-for-age Z-score by LMM, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Rate of Change in Treatment Period <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	n	LS Mean	Difference (95% CI)	P value <sup>b</sup>
Baseline	Placebo	10	-0.1310	--	--	--	--
	Ivacaftor	12	0.3483	--	--	--	--
Week 24	Placebo	8	0.2886	10	0.0301	0.0988	0.7692
	Ivacaftor	9	0.4838	12	0.1288	(-0.5692, 0.7668)	


Sample statistics are unadjusted results. BMI-for-age z-scores were calculated using National Center for Health Statistics (NCHS) growth chart. Z-scores are defined as missing if the subject was over 240 months old at the time of assessment. a: Estimated change from baseline per 168 days was obtained from a linear mixed model, with BMI-for-age z-score as the dependent variable; with treatment as a fixed effect; with intercept and visit (days on study, including all visits through Week 24) as random effects; and with adjustment for baseline percent predicted FEV<sub>1</sub>, age, and visit by treatment interaction included as covariates in the model. b: p value for the treatment effect is from the slope of BMI-for-age z-score versus time (days).

**Figure 5: time-to-first pulmonary exacerbation, full analysis set**




The open circles on the plot denote censored objects.

**Figure 6: time-to-first pulmonary exacerbation requiring hospitalisation, full analysis set**




The open circles on the plot denote censored objects.

**Figure 7: time-to-first pulmonary exacerbation requiring IV antibiotics, full analysis set**



The open circles on the plot denote censored objects.



**Figure 8: mean absolute change from baseline in pooled CFQ-R respiratory domain score by treatment up to follow-up visit, full analysis set****Table 21: absolute change from baseline in CFQ-R respiratory domain score by MMRM, full analysis set**

Questionnaire Version	Visit or Time Period	Treatment Group	Sample Statistics		Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
			n	Mean	n	LS Mean	Difference (95% CI)	P value
Children Ages 6 to 11 Years <sup>b</sup>	Baseline	Placebo	7	91.6667	--	--	--	--
		Ivacaftor	8	92.7084	--	--	--	--
	Overall Post-baseline	Placebo	7	89.0625	7	-1.6694	-5.8563 (-16.2820, 4.5693)	0.2410
		Ivacaftor	8	83.8095	8	-7.5257		
Children Ages 12 to 13 Years <sup>b</sup>	Baseline	Placebo	0	--	--	--	--	--
		Ivacaftor	1	100.00	--	--	--	--
	Overall Post-baseline	Placebo	0	--	0	--	--	--
		Ivacaftor	1	100.00	1	--	--	--
Adolescents and Adults	Baseline	Placebo	27	59.8766	--	--	--	--
		Ivacaftor	24	68.4259	--	--	--	--
	Overall Post-baseline	Placebo	27	62.1528	27	-0.2599	12.3621 (5.0323, 19.6918)	0.0014
		Ivacaftor	24	79.7101	24	12.1022		
Parent/Caregiver	Baseline	Placebo	8	98.6111	--	--	--	--
		Ivacaftor	10	89.9999	--	--	--	--
	Overall Post-baseline	Placebo	8	92.1922	8	-2.1026	-1.6207 (-13.6511, 10.4097)	0.7766
		Ivacaftor	10	86.6666	10	-3.7233		
Pooled <sup>c</sup>	Baseline	Placebo	34	66.4216	--	--	--	--
		Ivacaftor	33	75.2693	--	--	--	--
	Overall Post-baseline	Placebo	34	67.5347	34	-0.8289	8.3874 (2.1658, 14.6090)	0.0091
		Ivacaftor	33	80.7946	33	7.5585		

Sample statistics are unadjusted results. Analysis was conducted only when the number of subjects with results in each treatment group  $\geq 5$ . Difference is ivacaftor- placebo. A positive difference favours ivacaftor. a: Estimates were obtained from MMRM, with absolute change from baseline as the dependent variable; with treatment group, categorical visit (Weeks 2, 4, 8, 16 and 24), and treatment by visit interaction as fixed effects; with subject as a random effect, and with adjustment for the continuous baseline values of age, percent predicted FEV1, and CFQ-R respiratory domain score using a compound symmetry covariance matrix. b: The Children Ages 6 to 11 Years (interviewer format) CFQ-R instrument response option cards may not have been used. c: Pooled was defined as all questionnaire versions except for the Parent/Caregiver version.

*Tertiary efficacy results:*

The event rate of pulmonary exacerbations was slightly lower in the ivacaftor group compared to placebo, but the difference was not statistically significant (0.249 versus 0.295; rate ratio = 0.843, 95% CI: 0.409, 1.737;  $p = 0.6432$ ). Rates for subcategories of pulmonary exacerbations (that is requiring hospitalization and requiring IV antibiotics) were not calculated due to low event incidence, however, the number of events requiring hospitalization or IV antibiotics was notably lower for the ivacaftor group (Table 22). The mean (SD) duration of pulmonary exacerbations was non-significantly ( $p = 0.8472$ ) lower for the ivacaftor group (5.92 [11.006] days) than the placebo group (8.20 [14.371] days).

The treatment differences favoured ivacaftor in the pooled analysis for the CFQ-R non-respiratory domains (physical, emotional, social, eating and digestion), but were statistically significantly better in ivacaftor group for the emotional, social and eating domains (Table 23).

Although patients treated with ivacaftor showed greater increase in weight compared to placebo through week 24, the difference was not statistically significant (1.85 versus 0.92kg; treatment difference = 0.93 kg; 95% CI: -5.97, 7.82,  $p = 0.7912$ ). For subjects 20 years of age or younger, weight-for-age z-scores were calculated using the CDC growth chart and it showed similar results (Table 24-25). Rate of change from baseline in height was slightly lower for the ivacaftor group with no statistically significant difference from placebo and similar results for height for age-z-scores calculated using CDC growth charts for subjects < 20years old (Table 26-27).

No analysis of CF-related complications was performed because no episodes of pancreatitis or distal ileal obstruction syndrome (DIOS) occurred during the study.

Generally, subjects had a greater decrease in inflammatory mediator (leukocytes, CRP, IgG, and IL-8) concentrations for the ivacaftor group than the placebo group; the treatment difference for the log-transformed data was statistically significant for each of the inflammatory mediators except for log-transformed CRP which was near statistical significance (Table 28).

Shift from baseline in qualitative microbiology cultures<sup>9</sup> from throat swabs and sputum samples for the following common or important microbiological organisms<sup>10</sup> that affect patients with CF in general, shifts to higher or lower amounts of each microbe were sporadic and did not show any patterns across the treatment groups; however, this analysis is limited by the small number of subjects and a high incidence of unknown results for sputum samples.

Change from baseline in immunoreactive trypsinogen (IRT) through Week 24 showed a decrease for the ivacaftor group (-9.2588 ng/mL) and an increase for the placebo group (3.9988 ng/mL), but the treatment difference of -13.2576 ng/mL (95% CI: -27.5323 to 1.0171) was not statistically significant ( $p = 0.0679$ ). A decrease from baseline in faecal elastase-1 through Week 24 was seen for the placebo group (-15.2619  $\mu\text{g/g}$ ) while there was a slight increase for the ivacaftor group (0.1587  $\mu\text{g/g}$ ). However, the treatment difference of 15.4206  $\mu\text{g/g}$  (95% CI: -29.4148, 60.2560) was not statistically significant ( $P = 0.4922$ ).

<sup>9</sup> Culture outcomes were qualified as negative, light, moderate, heavy, or unknown.

<sup>10</sup> *Achromobacter xylosoxidans*; *Haemophilus influenzae*; *P aeruginosa*, small colony variant; *P aeruginosa*, mucoid; *P aeruginosa*, non-mucoid; *Staphylococcus aureus*; and *Stenotrophomonas maltophilia*.

**Table 22: number of pulmonary exacerbations, full analysis set**

Event Type	Statistics	Placebo	Ivacaftor	Rate Ratio	P value <sup>a</sup>
		N = 35	N = 34	(95% CI)	
	Total Number of Days on Study	5485	5182	--	--
All Pulmonary Exacerbations <sup>b</sup>	Number of Subjects with Events	13	11	--	--
	Number of Events (Event Rate)	17 (0.295)	13 (0.249)	0.843 (0.409, 1.737)	0.6432
Requiring Hospitalization	Number of Subjects with Events	6	2	--	--
	Number of Events	7	2	--	0.2595
Requiring IV antibiotic therapy	Number of Subjects with Events	6	2	--	--
	Number of Events	8	2	--	0.2595

Estimates were obtained from negative binomial regression with the number of events as the dependent variable, treatment as a fixed effects, and adjustment for baseline percent predicted FEV<sub>1</sub> and age, with log (time on study) as an offset. Negative binomial regression was conducted only when the number of subjects with events in each treatment group was  $\geq$  and the models converged. a: When estimates are presented, p values are from the treatment effect in negative binomial regression; otherwise, p values are from Fisher's Exact test. b: Pulmonary exacerbation includes events that met the protocol definition of pulmonary exacerbations (that is treatment with new or changed antibiotic therapy for  $\geq$  4 sinopulmonary signs/symptoms).

**Table 23: absolute change from baseline in pooled CFQ-R non-respiratory domain scores by MMRM, full analysis set**

Domain	Treatment Group	Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		N	LS Mean	Difference (95% CI)	P value
Physical	Placebo	34	-1.1448	6.7224	0.0885
	Ivacaftor	33	5.5776	(-1.0433, 14.4881)	
Emotion	Placebo	34	-1.3006	5.4440	0.0048
	Ivacaftor	33	4.1434	(1.7232, 9.1649)	
Social	Placebo	34	-0.7188	7.1716	0.0063
	Ivacaftor	33	6.4529	(2.1042, 12.2390)	
Body Image	Placebo	34	0.1265	-0.4051	0.8615
	Ivacaftor	33	-0.2787	(-5.0262, 4.2159)	
Eating	Placebo	34	-1.0431	4.6528	0.0411
	Ivacaftor	33	3.6097	(0.1939, 9.1117)	
Treatment Burden	Placebo	34	5.8691	-2.8084	0.3289
	Ivacaftor	33	3.0607	(-8.5178, 2.9010)	
Digestion	Placebo	34	-2.4274	2.5616	0.2431
	Ivacaftor	32	0.1342	(-1.7858, 6.9089)	

Analysis was conducted only when the number of subjects with results in each treatment group was  $\geq$  5. Pooled is defined as all questionnaire versions except for the Parent/Caregiver version. The Children Ages 6 to 11 Years (interviewer format) CFQ-R instrument response option cards may not have been used. A: Estimates were obtained from MMRM with absolute change from baseline as the dependent variable; with treatment group, categorical visit (Weeks 2, 4, 8, 16 and 24) and treatment by visit interaction as fixed effects; with subject as a random effect; and with adjustment for the continuous baseline value of age, percent predicted FEV<sub>1</sub>, and domain score, using compound symmetry covariance matrix.

**Table 24: rate of change from baseline in weight (kg) by LMM, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	N	LS Mean	Difference (95% CI)	P value <sup>b</sup>
Baseline	Placebo	35	62.83	--	--	--	--
	Ivacaftor	34	66.10	--	--		
Week 24	Placebo	31	65.47	35	0.9214	0.9275	0.7912
	Ivacaftor	28	67.58	34	1.8490	(-5.9659, 7.8210)	

Sample statistics are unadjusted results. a: Estimated change from baseline per 168 days were obtained from a linear mixed model with the dependent variables weight and treatment as a fixed effect; with adjustment for baseline percent predicted FEV<sub>1</sub>, age and visit by treatment interaction as covariates in the model; and with intercept, visit (days on study, including all visits through Week 24) as random effects. b: p value for the treatment effect is from the slope of weight (kg) versus time (days).

**Table 25: rate of change from baseline in weight-for-age z-score by LMM, part 1, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	N	LS Mean	Difference (95% CI)	P value <sup>b</sup>
Baseline	Placebo	10	0.1679	--	--	--	--
	Ivacaftor	12	0.2105	--	--	--	--
Week 24	Placebo	8	0.4090	10	-0.0256	0.2085	0.5305
	Ivacaftor	9	0.2897	12	0.1829	(-0.4505, 0.8675)	

Sample statistics are unadjusted results. Weight-for-age z-scores were calculated using NCHS growth charts. Z-scores are defined as missing if the subject is over 240 months old at the time of assessment. a: Estimated change from baseline per 168 days were obtained from a linear mixed model with the dependent variable weight-for-age z-score and treatment as a fixed effect; with adjustment for baseline percent predicted FEV<sub>1</sub>, age, and visit by treatment interaction as covariates in the model, and with intercept, visit (days on study, including all visits through Week 24) as random effects. b: p value for the treatment effect is from the slope of weight-for-age z-score versus time (days).

**Table 26: rate of change from baseline in height (cm) by LMM, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	N	LS Mean	Difference (95% CI)	P value <sup>b</sup>
Baseline	Placebo	35	161.8	--	--	--	--
	Ivacaftor	34	160.6	--	--	--	--
Week 24	Placebo	8	147.4	35	1.7551	-1.3851	0.7709
	Ivacaftor	10	147.0	34	0.3699	(-10.8213, 8.0510)	

**Table 27: rate of change from baseline in height-for-age Z-score by LMM, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	N	LS Mean	Difference (95% CI)	P value <sup>b</sup>
Baseline	Placebo	10	0.5605	--	--	--	--
	Ivacaftor	12	-0.0691	--	--	--	--
Week 24	Placebo	8	0.5515	10	0.0194	0.0794	0.7783
	Ivacaftor	9	-0.1073	12	0.0988	(-0.4803, 0.6391)	

**Table 28: absolute change from baseline in inflammatory mediator and log-transformed inflammatory mediator concentrations by MMRM, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistic		Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	N	LS Mean	Difference (95% CI)	P value <sup>b</sup>
<b>Leukocytes (10<sup>9</sup>/L)</b>							
Period Baseline	Placebo	35	7.8180	--	--	--	--
	Ivacaftor	34	7.4159	--	--	--	--
Overall Postbaseline	Placebo	35	8.1885	35	0.3455	-0.7183	0.0254
	Ivacaftor	34	7.2906	34	-0.3729	(-1.3453, -0.0914)	
<b>Leukocytes (10<sup>9</sup>/L), Log-Transformed Data</b>							
Period Baseline	Placebo	35	0.9276	--	--	--	--
	Ivacaftor	34	0.9133	--	--	--	--
Overall Postbaseline	Placebo	35	0.9438	35	0.0153	-0.0363	0.0140
	Ivacaftor	34	0.9033	34	-0.0211	(-0.0650, -0.0076)	
<b>C-reactive Protein (umol/L)</b>							
Period Baseline	Placebo	32	71.5297	--	--	--	--
	Ivacaftor	33	73.5513	--	--	--	--
Overall Postbaseline	Placebo	32	68.2838	32	-9.8400	-15.9667	0.1575
	Ivacaftor	33	49.4290	33	-25.8067	(-38.2823, 6.3488)	
<b>C-reactive Protein (umol/L), Log-Transformed Data</b>							
Period Baseline	Placebo	32	1.4469	--	--	--	--
	Ivacaftor	33	1.3166	--	--	--	--
Overall Postbaseline	Placebo	32	1.4504	32	0.0483	-0.1331	0.0455
	Ivacaftor	33	1.2788	33	-0.0848	(-0.2633, -0.0028)	
<b>Immunoglobulin G (g/L)</b>							
Period Baseline	Placebo	33	12.1324	--	--	--	--
	Ivacaftor	33	12.4567	--	--	--	--
Overall Postbaseline	Placebo	33	12.2238	33	-0.0327	-0.7161	0.0050
	Ivacaftor	33	11.8728	33	-0.7488	(-1.2079, -0.2243)	
<b>Immunoglobulin G (g/L), Log-Transformed Data</b>							
Period Baseline	Placebo	33	1.0995	--	--	--	--
	Ivacaftor	33	1.1110	--	--	--	--
Overall Postbaseline	Placebo	33	1.1028	33	-0.0008	-0.0197	0.0142
	Ivacaftor	33	1.0964	33	-0.0205	(-0.0353, -0.0041)	
<b>Interleukin-8 (pg/mL)</b>							
Period Baseline	Placebo	33	10.0000	--	--	--	--
	Ivacaftor	33	9.0909	--	--	--	--
Overall Postbaseline	Placebo	33	11.8333	33	1.9416	-2.6662	0.0229
	Ivacaftor	33	8.5522	33	-0.7246	(-4.9474, -0.3849)	
<b>Interleukin-8 (pg/mL), Log-Transformed Data</b>							
Period Baseline	Placebo	33	1.0109	--	--	--	--
	Ivacaftor	33	0.9890	--	--	--	--
Overall Postbaseline	Placebo	33	1.0461	33	0.0446	-0.1013	0.0001
	Ivacaftor	33	0.9405	33	-0.0568	(-0.1513, -0.0513)	

Sample statistics are unadjusted results. a: Estimates were obtained from MMRM with absolute change from baseline as the dependent variable; with treatment group, categorical visit (Weeks 2, 4, 8, 16 and 24) and treatment by visit interaction as fixed effects; with subject as random effect; and with adjustment for the continuous baseline value of age, percent predicted FEV<sub>1</sub>, and baseline inflammatory mediator as covariates using compound symmetry covariance matrix. b: P value is the from the main treatment effect.

#### *Additional efficacy results:*

The mean relative change from baseline in percent predicted FEV<sub>1</sub> through Week 24 was greater for the ivacaftor group than the placebo group (4.83 versus -0.21 percentage points), but the treatment difference did not reach statistical significance (difference = 5.04 percentage points; 95% CI: -0.24, 10.31; p = 0.0611). Treatment differences favoured ivacaftor at all

Treatment Period time points, and achieved statistical significance at the Week 8 Visit ( $p = 0.0396$ ). Furthermore, difference from week 24 to follow-up visit showed significantly greater reduction in % predicted FEV<sub>1</sub> in the ivacaftor group compared with placebo (Table 29-31). There was a statistically significant difference ( $p = 0.0118$ ) in the responder<sup>k</sup> rate between placebo and ivacaftor at the 10% threshold; the number of responders also favoured ivacaftor at the lower thresholds, with approximately twice as many responders in the ivacaftor group as the placebo group (Table 32).

**Table 29: relative change from baseline through Week 24 in percent predicted FEV<sub>1</sub> by MMRM, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Relative Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	N	LS Mean	Difference (95% CI)	P value
Baseline	Placebo	35	70.2315				
	Ivacaftor	34	75.6968				
Overall Post-baseline	Placebo	35	71.1264	35	-0.2092	5.0364	0.0611
	Ivacaftor	34	78.0432	34	4.8272	(-0.2404, 10.3133)	

**Table 30: relative change from baseline in percent predicted FEV<sub>1</sub> by MMRM, consistency of treatment effect over visits, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Relative Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	N	LS Mean	Difference (95% CI)	P value <sup>b</sup>
Baseline	Placebo	35	70.2315	--	--	--	--
	Ivacaftor	34	75.6968	--	--	--	--
Week 2	Placebo	35	70.1335	35	-1.0704	4.9629	0.0917
	Ivacaftor	34	77.4862	34	3.8925	(-0.8194, 10.7452)	
Week 4	Placebo	34	71.7526	34	1.2529	4.0919	0.1669
	Ivacaftor	32	77.8576	32	5.3449	(-1.7390, 9.9228)	
Week 8	Placebo	33	69.9406	33	-1.2340	6.1436	0.0396
	Ivacaftor	32	77.9558	32	4.9096	(0.2973, 11.9899)	
Week 16	Placebo	32	71.4261	32	-0.5675	4.1567	0.1645
	Ivacaftor	30	77.6327	30	3.5892	(-1.7314, 10.0448)	
Week 24	Placebo	31	72.5135	31	0.5729	5.8270	0.0542
	Ivacaftor	28	79.4713	28	6.3999	(-0.1060, 11.7601)	

Sample statistics are unadjusted results. Difference is ivacaftor- placebo. A positive difference favours ivacaftor. a: Estimates were obtained from MMRM with relative change from baseline as the dependent variable; with treatment, categorical visit (Weeks 2, 4, 8, 16 and 24), and treatment by visit interaction as fixed effects; with subject as a random effect; and with adjustment for the continuous baseline value of age and percent predicted FEV<sub>1</sub> using compound symmetry covariance matrix. b: P values at individual visits are from linear contrasts between the 2 treatments at the given visit.

**Table 31: Relative change from Week 24 through the Follow-Up Visit in percent predicted FEV<sub>1</sub> by mixed model, full analysis set**

Visit or Time Period	Treatment Group	Sample Statistics		Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	n	LS Mean	Difference (95% CI)	P value
Week 24	Placebo	31	72.5135	--	--	--	--
	Ivacaftor	28	79.4713	--	--	--	--
Follow-up Visit	Placebo	31	72.2239	31	0.0178	-3.5954	0.0416
	Ivacaftor	28	76.7292	28	-3.5776	(-7.0496, -0.1412)	

Sample statistics are unadjusted results. Difference is ivacaftor- placebo. a: Estimates were obtained from mixed model with dependent variable relative change in percent predicted FEV<sub>1</sub>, with treatment group as fixed effect, subject as random effect, and with adjustment for the continuous baseline value of age and percent predicted FEV<sub>1</sub>.

**Table 32: responder analysis of relative change through Week 24 in percent predicted FEV<sub>1</sub>, full analysis set**

Category	Placebo N = 35 n (%)	Ivacaftor N = 34 n (%)	P value
≥3.5%	8 (22.9)	13 (38.2)	0.1975
<3.5%	27 (77.1)	21 (61.8)	
≥5%	8 (22.9)	13 (38.2)	0.1975
<5%	27 (77.1)	21 (61.8)	
≥7.5%	6 (17.1)	11 (32.4)	0.1706
<7.5%	29 (82.9)	23 (67.6)	
≥10%	2 (5.7)	10 (29.4)	0.0118
<10%	33 (94.3)	24 (70.6)	

Relative change through Week 24 is relative change from baseline over 24 weeks for percent predicted FEV<sub>1</sub>. Percentages are calculated using the category totals as the denominator.

#### 7.1.1.14. Subgroup analysis of efficacy:


In addition to a pre-planned subgroup analysis of efficacy by age, subgroup analyses for other baseline and disease characteristics were pre-planned for the primary and secondary endpoints. The selection of the other subgroups was based on standard demographic factors (geographic region and sex) and those likely to affect disease severity/ response (baseline lung function, P aeruginosa infection, R117H allele poly-T variant).

#### 7.1.1.15. Effect of age on efficacy:

*Efficacy in subjects > 18 years of age:*

The mean absolute change from baseline in percent predicted FEV<sub>1</sub> through Week 24 for the 50 subjects ≥ 18 years of age was statistically and clinically significantly greater for the ivacaftor group than the placebo group (4.51% versus 0.46%; treatment difference = 4.96% ; 95% CI: 1.15, 8.78; p = 0.0119). Statistically significant treatment differences were observed by Week 2 (first post-baseline time point assessed and were sustained through Week 24. During the Follow-up Period, a greater decline in percent predicted FEV<sub>1</sub> occurred in the ivacaftor group (-3.15%) than the placebo group (-1.13%) (Figure 9).

**Figure 9: modelled absolute change from baseline in percent predicted FEV<sub>1</sub> by treatment, subject ≥ 18 years of age, full analysis set**



**Comments:** During the design and execution of Study 110, it was anticipated that children and adolescents could show different efficacy profiles in response to ivacaftor treatment primarily because of the differences in the manifestation of disease at different ages.

Specifically, CF patients with the R117H-CFTR mutation have less advanced disease in childhood and adolescence compared to older subjects (McCloskey M, et al, 2000; McKone EF, et al 2006- see references). Therefore, it was anticipated that a positive effect of ivacaftor would more likely be observed in adult patients (that is subjects > 18 years). Thus, in addition to the primary analysis using the full dataset (that is the FAS), a pre-planned subgroup analysis by subject age was included for the primary and secondary endpoints.

Among this subgroup of patients aged > 18 years, those with a baseline percent predicted FEV<sub>1</sub> of ≥ 70% to ≤ 90% showed a statistically significant response to ivacaftor treatment in percent predicted FEV<sub>1</sub> (p = 0.0090). Female subjects had a larger treatment difference in favour of ivacaftor than male subjects (females: 6.96%; males: 2.10%). The treatment differences were similar in North America and Europe (North America 4.81%; Europe: 4.51%). Subjects without *P aeruginosa* infection at baseline had a slightly larger treatment difference in favour of ivacaftor than subjects with *P aeruginosa* infection at baseline (infected: 4.32%; not infected: 5.73%) (Table 33).

**Table 33: absolute change from baseline through Week 24 in percent predicted FEV<sub>1</sub> by MMRM: presented by percent predicted FEV<sub>1</sub> at baseline, sex, geographic region, and *P aeruginosa* infection status at baseline, subjects ≥ 18 years of age, full analysis set**

Subgroup	Subgroup Category	Treatment Group	Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
			n	LS Mean	Difference (95% CI)	P value
Percent Predicted FEV <sub>1</sub> at Baseline	<70%	Placebo	15	0.4484	4.0126	0.1878
		Ivacaftor	13	4.4609	(-2.0920, 10.1171)	
	≥70% to ≤90%	Placebo	11	-1.3463	6.4370	0.0090
		Ivacaftor	10	5.0907	(1.8173, 11.0567)	
	>90%	Placebo	0	--	--	--
		Ivacaftor	1	--	--	
Sex	Male	Placebo	10	0.9135	2.1001	0.5043
		Ivacaftor	11	3.0136	(-4.4149, 8.6152)	
	Female	Placebo	16	-1.2026	6.9625	0.0136
		Ivacaftor	13	5.7599	(1.5593, 12.3657)	
Geographic Region	North America	Placebo	21	-0.5740	4.8108	0.0532
		Ivacaftor	16	4.2368	(-0.0707, 9.6922)	
	Europe	Placebo	5	0.4532	4.5108	0.2438
		Ivacaftor	8	4.9640	(-3.6710, 12.6926)	
<i>P aeruginosa</i> Infection Status at Baseline	Yes	Placebo	18	-0.5470	4.3181	0.1231
		Ivacaftor	14	3.7711	(-1.2470, 9.8832)	
	No	Placebo	8	-0.1709	5.7348	0.0410
		Ivacaftor	10	5.5639	(0.2702, 11.1994)	

Sample statistics are unadjusted results. Analysis conducted only when the number of subjects with results in each treatment group ≥ 5. Difference is ivacaftor- placebo. A positive difference favours ivacaftor. a: Estimates were obtained from MMRM with absolute change from baseline as the dependent variable; with treatment group, categorical visit (Weeks 2, 4, 8, 16 and 24), and treatment by visit interaction as fixed effects; and with adjustment for the continuous baseline value of age and percent predicted FEV<sub>1</sub> using compound symmetry covariance matrix. For the subgroup percent predicted FEV<sub>1</sub>, severity, no adjustment was made for baseline percent predicted FEV<sub>1</sub>.

**Comments:** The above subgroup analysis should be interpreted with caution due to small sample sizes.


The mean absolute change from baseline in sweat chloride was statistically significantly greater for ivacaftor compared to placebo group (25.89 versus 4.03 mmol/L; treatment difference = 21.87 mmol/L; 95% CI: -26.46, -17.28, p < 0.0001). Statistically significant treatment differences were detected by Week 2 (first post-baseline time point assessed) and



were sustained through Week 24. The mean rate of change from baseline in BMI and BMI for age z-scores did not show any statistically significant improvement with ivacaftor. The pattern of the survival curve was consistent with the time-to-first pulmonary exacerbation survival curves in FAS.

The improvement with ivacaftor in the mean absolute change from baseline in CFQ-R respiratory domain score through Week 24 for subjects  $\geq 18$  years of age was much greater than that observed in the FAS. In subjects aged  $> 18$  years, treatment difference for ivacaftor versus placebo was 12.64 points (95% CI: 5.02, 20.25), which is more than triple the defined MCID of 4 points and was statistically significant ( $p = 0.0017$ ). Statistically significant treatment differences were detected at Week 2 (first post-baseline time point assessed), Week 16 and Week 24. Furthermore, ivacaftor group shows a greater decline in CFQ-R respiratory domain score in the Follow-up Period than the placebo group providing further evidence of the ivacaftor treatment effect on CFQ-R score (Figure 10).


**Figure 10: Mean absolute change from baseline in pooled CFQ-R respiratory domain score by treatment; full analysis set, subjects  $\geq 18$  years of age**



The mean relative change from baseline in percent predicted FEV<sub>1</sub> through Week 24 was clinically and statistically significantly greater in the ivacaftor group compared with placebo (7.68 versus -1.46 percentage points; difference = 9.13 percentage points; 95% CI: 2.46, 15.80;  $p = 0.0083$ ). The significant difference was observed from week 2 and maintained till week 24 (Figure 11). The responder<sup>11</sup> analysis categorizing the relative change from baseline in percent predicted FEV<sub>1</sub> through Week 24 shows that there is a statistically significant difference in the responder rate between placebo and ivacaftor at all thresholds ( $p \leq 0.02$ ). Only a single subject on placebo had a  $\geq 10\%$  response compared to 41.7% of the ivacaftor subjects (Table 34).

<sup>11</sup> A responder analysis was conducted by categorizing the relative change from baseline in percent predicted FEV<sub>1</sub> through Week 24 for subjects  $\geq 18$  years of age as  $\geq 3.5\%$  or  $< 3.5\%$ ,  $\geq 5\%$  or  $< 5\%$ ,  $\geq 7.5\%$  or  $< 7.5\%$ , and  $\geq 10\%$  or  $< 10\%$ .

**Figure 11: Mean relative change from baseline in percent predicted FEV<sub>1</sub> by treatment; full analysis set, subjects ≥ 18 years of age**



**Table 34: Responder analysis of relative change through Week 24 in percent predicted FEV<sub>1</sub>; full analysis set, subjects ≥ 18 years of age**

Category	Placebo N = 26 n (%)	Ivacaftor N = 24 n (%)	P value
≥3.5%	5 (19.2)	13 (54.2)	0.0176
<3.5%	21 (80.8)	11 (45.8)	
≥5%	5 (19.2)	13 (54.2)	0.0176
<5%	21 (80.8)	11 (45.8)	
≥7.5%	3 (11.5)	11 (45.8)	0.0110
<7.5%	23 (88.5)	13 (54.2)	
≥10%	1 (3.8)	10 (41.7)	0.0016
<10%	25 (96.2)	14 (58.3)	


Relative change through Week 24 is relative change from baseline over 24 weeks for percent predicted FEV<sub>1</sub>. Percentages are calculated using the category totals as the denominator.

*Efficacy in subjects in other age groups <18 years:*


There were only 2 subjects (1 in each treatment group) aged 12 to 17 years enrolled in the study and so no statistical analysis was done for this age group.

There were 17 subjects aged 6 to 11 years in the study. The primary efficacy endpoint of change from baseline to week 24 in mean % predicted FEV<sub>1</sub> showed a statistically significant greater increase in the placebo group compared with ivacaftor; however, the treatment difference between the ivacaftor and placebo groups was statistically significant only at Week 2 and Week 4. Analysis of individual subject response to ivacaftor and placebo, up to Week 24 (Figure 12-13) suggested a stable pattern in the ivacaftor group with no overall negative effect and a notable increase in the placebo group during the first few weeks of treatment that was sustained through the 24 weeks of treatment. The mean absolute change from baseline in sweat chloride through Week 24 for subjects 6 to 11 years of age showed statistically significant greater reductions in ivacaftor group compared with placebo which were similar to those observed for subjects aged > 18 years. The mean absolute change from baseline in BMI and the CFQ-R respiratory domain score through Week 24 favoured placebo but difference was not statistically significant. No protocol-defined pulmonary exacerbations occurred in subjects 6 to 11 years of age. The mean relative change from baseline in percent predicted FEV<sub>1</sub> through Week 24 significantly favoured placebo (Table 35).

**Figure 12: Percent predicted FEV<sub>1</sub> up to Week 24, placebo group; full analysis set, subjects 6 to 11 years of age (inclusive)**



**Figure 13: Percent predicted FEV<sub>1</sub> up to Week 24, ivacaftor group; full analysis set, subjects 6 to 11 years of age (inclusive)**



**Table 35: Absolute change from baseline in sweat chloride (mmol/L) by MMRM; full analysis set, subjects 6 to 11 years of age (inclusive)**

Visit or Time Period	Treatment Group	Sample Statistics		Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
		n	Mean	n	LS Mean	Difference (95% CI)	P value
Baseline	Placebo	8	74.6563	--	--	--	--
	Ivacaftor	8	64.1563	--	--	--	--
Overall	Placebo	8	77.8857	8	1.0376	-27.6322	<0.0001
Post-baseline	Ivacaftor	8	37.1667	8	-26.5946	(-37.1640, -18.1005)	

Sample statistics are unadjusted results. Difference is ivacaftor- placebo. A negative difference favors ivacaftor. a: Estimates were obtained from MMRM with absolute change from baseline as the dependent variable; with treatment group, categorical visit (Weeks 2, 4, 8, 16 and 24) and treatment by visit interaction as fixed effects; with subject as a random effect; and with adjustment for the continuous baseline value of percent predicted FEV<sub>1</sub>, and sweat chloride, using a compound symmetry covariance matrix.

**Comments:** Interpretation of results in this subgroup of subjects aged 6 to 11 years was limited by small number of patients in each treatment group. Overall, results from this pivotal study suggested that ivacaftor did not improve lung function, BMI or CFQ-R score in patients aged < 18 years and the only significant improvement group was observed in terms of reduction in sweat chloride.

### 7.1.1.16. Efficacy in subgroups by baseline percent predicted FEV<sub>1</sub>

Pre-planned analyses were conducted for subgroups of baseline percent predicted FEV<sub>1</sub> < 70%, ≥70% to ≤90%, >90%. The greatest treatment differences were seen in the < 70% subgroup, with treatment differences of 4.01 percentage points (95% CI: -2.09, 10.12) in absolute change in percent predicted FEV<sub>1</sub>, 9.87 percentage points (95% CI: -1.52, 21.25) in relative change in change in percent predicted FEV<sub>1</sub> and 11.38 points (95% CI: 1.17, 21.59) in absolute change in the CFQ-R respiratory domain. Smaller treatment differences that still favoured ivacaftor were seen in the ≥ 70% to ≤ 90% subgroup. In the percent predicted FEV<sub>1</sub> > 90% subgroup, 12 of 13 subjects were 6 to 11 years of age and this subgroup did not show evidence of efficacy in absolute change in percent predicted FEV<sub>1</sub> relative change in percent predicted FEV<sub>1</sub>, or absolute change in the CFQ-R respiratory domain. However, the treatment difference in sweat chloride response was similar to that seen in the percent predicted FEV<sub>1</sub> < 70% and ≥ 70% to ≤ 90% subgroups (Table 36-37).

**Table 36: subgroup analyses by percent predicted FEV<sub>1</sub> at baseline and geographical region- treatment difference versus placebo (95% CI) p value**

Baseline Percent Predicted FEV <sub>1</sub>			Geographical Region	
<70%	≥70% to ≤90%	>90%	North America	Europe
<b>Absolute Change From Baseline in Percent Predicted FEV<sub>1</sub> (percentage points)<sup>a</sup></b>				
N = 15:13	N = 14:14	N = 6:7	N = 30:24	N = 5:10
4.0126 (-2.0920, 10.1171)	2.6041 (-2.2729, 7.4810)	-4.3236 (-9.9347, 1.2875)	1.7840 (-2.0213, 5.5894)	4.1480 (-4.8195, 13.1156)
0.1878	0.2819	0.1155	0.3509	0.3300
<b>Absolute Change From Baseline in Sweat Chloride (mmol/L)<sup>a</sup></b>				
N = 15:12	N = 14:14	N = 6:6	N = 30:22	N = 5:10
-25.5260 (-31.7527, -19.2993)	-19.9469 (-26.8952, -12.9986)	-26.8350 (-39.5398, -14.1302)	-22.8512 (-27.6944, -18.0081)	-22.6457 (-31.4702, -13.8212)
<0.0001	<0.0001	0.0012	<0.0001	0.0002
<b>Absolute Change From Baseline in BMI (kg/m<sup>2</sup>)<sup>b,c</sup></b>				
N = 15:13	N = 14:14	N = 6:7	N = 30:24	N = 5:10
0.2672 (-2.4666, 3.0011)	0.3952 (-3.0131, 3.8036)	-0.1275 (-2.4942, 2.2391)	0.1868 (-2.0055, 2.3790)	0.4132 (-3.3294, 4.1558)
0.8467	0.8185	0.9142	0.8667	0.8259
<b>Absolute Change From Baseline in BMI-for-Age Z-score<sup>b,c,d</sup></b>				
N = 0:0	N = 4:6	N = 6:6	N = 10:8	N = 0:4
--	--	0.1283 (-0.6278, 0.8844)	-0.0143 (-0.8312, 0.8026)	--
		0.7341	0.9722	
<b>Absolute Change From Baseline in CFQ-R Respiratory Domain Score (points): Pooled Analysis<sup>a,e</sup></b>				
N = 15:13	N = 13:14	N = 6:6	N = 29:23	N = 5:10
11.3797 (1.1720, 21.5875)	8.8037 (-2.5765, 20.1840)	-0.6898 (-10.3636, 8.9841)	7.3652 (0.4976, 14.2328)	19.8972 (2.0186, 37.7759)
0.0305	0.1233	0.8732	0.0361	0.0326

**Table 37: subgroup analyses by percent predicted FEV<sub>1</sub> at baseline and geographical region- treatment difference versus placebo (95% CI) p value**

Subject Sex		<i>P. aeruginosa</i> Infection Status at Baseline	
Male	Female	Yes	No
<b>Relative Change From Baseline in Percent Predicted FEV<sub>1</sub> (percentage points)<sup>a</sup></b>			
N = 15:15	N = 20:19	N = 19:15	N = 16:19
1.2248 (-6.7964, 9.2461)	7.8019 (0.2648, 15.3389)	7.9137 (-1.8578, 17.6852)	2.3387 (-2.7391, 7.4165)
0.7560	0.0429	0.1085	0.3549

Number of subjects (n) is presented as placebo: ivacaftor. Analysis conducted only when the number of subjects with results in each treatment group was ≥ 5. a: Estimates were obtained from MMRM, with absolute or relative change from baseline as the dependent variable; with treatment, visit, and treatment by visit corresponding baseline value of the analysed variable, using a compound symmetry covariance matrix. For the subgroups of percent predicted FEV<sub>1</sub> severity, no adjustment was made for baseline percent predicted FEV<sub>1</sub>. b: Estimated change from baseline per 168 days were obtained from linear mixed models conducted by subgroup with dependent variable weight and treatment intercept, visit (days on study, including all visits through Week 24) included as random effects. With the baseline percent predicted FEV<sub>1</sub> subgroups models did not include adjustment for baseline percent predicted FEV<sub>1</sub>. c: p value for the treatment effect is from the slope of BMI (kg/m<sup>2</sup>) or BMI-for-age z-score versus time (days). d: BMI-for-age z-score is calculated using NCHS growth charts. e: Pooled is defined as all.

### 7.1.1.17. Geographical region

Larger treatment differences were seen in Europe than North America for the absolute change in percent predicted FEV<sub>1</sub> (Europe versus North America: 4.15 versus 1.78 percentage points), relative change in percent predicted FEV<sub>1</sub> (5.66 versus 5.17 percentage points) and absolute change in CFQ-R respiratory domain (19.90 versus 7.37 points). The treatment differences for change from baseline in sweat chloride (-22.65 versus -22.85 mmol/L) were similar for both geographic regions. In North America, 15 of 54 subjects were 6 to 11 years of age, while in Europe only 2 of 15 subjects were 6 to 11 years of age. When the geographical region subgroup analysis was limited to subjects ≥18 years of age, the absolute change in percent predicted FEV<sub>1</sub> was similar between the 2 subgroups (4.51 versus 4.81 percentage points) (Table 36-37).

### 7.1.1.18. Gender and *P. aeruginosa* infection status at baseline

Larger treatment differences were seen in females than males for absolute change in percent predicted FEV<sub>1</sub> (females versus males: 3.66 versus 0.087 percentage points), relative change in percent predicted FEV<sub>1</sub> (7.81 versus 1.22 percentage points) and CFQ-R respiratory domain score (13.87 versus 2.44 points); the reason for the difference is unclear but the sponsor states that is most likely driven by random factors in a small population. The treatment differences for absolute change from baseline in sweat chloride (females: -25.43 mmol/L; males: -24.05 mmol/L) were similar for both sexes. There were no substantial imbalances in age or R117H poly-T variant between the male and female subjects. The patterns of the survival curves for time-to-first pulmonary exacerbation do not reveal any clinically important signal (Table 38).

**Table 38: Subgroup analysis by subject sex and *P. aeruginosa* infection status at baseline-treatment difference versus placebo (95% CI) p value**

	Subject Sex		<i>P. aeruginosa</i> Infection Status at Baseline	
	Male	Female	Yes	No
<b>Absolute Change From Baseline in Percent Predicted FEV<sub>1</sub> (percentage points)<sup>a</sup></b>				
	N = 15:15	N = 20:19	N = 19:15	N = 16:19
	0.0869	3.6588	3.5333	0.8653
	(-5.0382, 5.2120)	(-0.9236, 8.2412)	(-1.9130, 8.9796)	(-3.0779, 4.8084)
	0.9724	0.1140	0.1951	0.6576
<b>Absolute Change From Baseline in Sweat Chloride (mmol/L)<sup>a</sup></b>				
	N = 15:14	N = 20:18	N = 19:14	N = 16:18
	-24.0510	-25.4342	-23.0423	-24.4189
	(-29.6278, -18.4741)	(-31.6688, -19.1996)	(-28.9551, -17.1295)	(-30.3551, -18.4826)
	<0.0001	<0.0001	<0.0001	<0.0001
<b>Absolute Change From Baseline in BMI (kg/m<sup>2</sup>)<sup>b,c</sup></b>				
	N = 15:15	N = 20:19	N = 19:15	N = 16:19
	0.6894	-0.0460	0.2098	0.4036
	(-1.7120, 3.0909)	(-2.6974, 2.6054)	(-2.0049, 2.4244)	(-2.5827, 3.3900)
	0.5704	0.9727	0.8516	0.7896
<b>Absolute Change From Baseline in BMI-for-Age Z-score<sup>b,c,d</sup></b>				
	N = 5:4	N = 5:8	N = 2:1	N = 8:11
	--	0.0248	--	0.1039
		(-0.8256, 0.8753)		(-0.5911, 0.7988)
		0.9534		0.7662
<b>Absolute Change From Baseline in CFQ-R Respiratory Domain Score (points): Pooled Analysis<sup>a*</sup></b>				
	N = 14:15	N = 20:18	N = 19:15	N = 15:18
	2.4393	13.8659	9.1800	7.3670
	(-8.5354, 13.4139)	(5.6943, 22.0375)	(0.0291, 18.3309)	(-2.0890, 16.8230)
	0.6503	0.0015	0.0493	0.1218
<b>Relative Change From Baseline in Percent Predicted FEV<sub>1</sub> (percentage points)<sup>a</sup></b>				
	N = 15:15	N = 20:19	N = 19:15	N = 16:19
	1.2248	7.8019	7.9137	2.3387
	(-6.7964, 9.2461)	(0.2648, 15.3389)	(-1.8578, 17.6852)	(-2.7391, 7.4165)
	0.7560	0.0429	0.1085	0.3549

Number of subjects (n) is presented as placebo: ivacaftor. Analysis conducted only when the number of subjects with results in each treatment group was ≥ 5. a: Estimates were obtained from MMRM, with absolute or relative change from baseline as the dependent variable; with treatment, visit and treatment by visit interaction as fixed effects; with subject as a random effect; and with adjustment for the continuous baseline values of age, percent predicted FEV<sub>1</sub> and corresponding baseline value of the analysed variable, using a compound symmetry covariance matrix. For the subgroup of percent predicted FEV<sub>1</sub> severity, no adjustment was made for baseline percent predicted FEV<sub>1</sub>. b: Estimated change from baseline per 168 days were obtained from linear mixed models conducted by subgroup with dependent variable weight and treatment as a fixed effect; with adjustment for baseline percent predicted FEV<sub>1</sub>, age, and visit treatment interaction included as covariates in the model; and with intercept, visit (days on study, including all visits through Week 24) included

as covariates in the model; and with intercept, visit (days on study, including all visits through Week 24) included as random effects. With the baseline percent predicted FEV<sub>1</sub> subgroups models did not include adjustment for baseline percent predicted FEV<sub>1</sub>. c: p value for the treatment effect is from the slope of BMI (kg/m<sup>2</sup>) or BMI-for-age z-score versus time (days). d: BMI-for-age z-score is calculated using NCHS growth charts. e: Pooled is defined as all questionnaire versions except for the Parent/Caregiver version. The Children's Ages 6 to 11 (interview format) CFQ-R instrument response option cards may not have been used.

Larger treatment differences were seen in subjects infected with *P. aeruginosa* at baseline than in subjects not infected with *P. aeruginosa* for absolute change in percent predicted FEV<sub>1</sub> (infected: 3.53 percentage points; not infected: 0.87 percentage points), relative change in percent predicted FEV<sub>1</sub> (infected: 7.91 percentage points; not infected: 2.34 percentage points), and CFQ-R respiratory domain score (infected: 9.18 points; not infected: 7.37 points). The treatment differences for absolute change from baseline in sweat chloride (infected: -23.04 mmol/L; not infected: -24.42 mmol/L) were similar for both subgroups. In the subgroup not infected with *P. aeruginosa* at baseline, 15 of 35 subjects were 6 to 11 years of age (inclusive), while in the subgroup infected with *P. aeruginosa* at baseline, only 2 of 34 subjects were 6 to 11 years of age. When the *P. aeruginosa* subgroup analysis was limited to subjects  $\geq 18$  years of age, a larger treatment difference in the absolute change in percent predicted FEV<sub>1</sub> was seen for the subjects not infected with *P. aeruginosa* than those infected (infected: 4.32 percentage points; not infected: 5.74 percentage points (Table 38)).

#### **7.1.1.19. R117H Poly-T Variant**

The poly-T variant affects splice efficiency during synthesis of CFTR protein, and for patients with the R117H allele, the poly-T variant on the R117H allele affects the severity of their CF disease (Chu C et al, 1993; Kieswetter S et al, 1993; Massie RJH et al, 2001, see references). R117H-5T results in a more severe disease phenotype than R117H-7T and R117H-9T is highly unlikely to cause disease. All subjects enrolled in this study would have had the R117H-5T or R117H-7T alleles because the study entry criteria required that subjects have CF, as evidenced by sinopulmonary disease and a sweat chloride  $\geq 60$  mmol/L or two CF-causing mutations.

In both the primary and supportive analysis, the treatment difference for absolute change from baseline in percent predicted FEV<sub>1</sub> was larger for subjects with the R117H-5T variant than for subjects with the R117H-7T variant. In the supportive analysis, a treatment effect favouring placebo was observed for subjects with R117H-7T. However, 8 of the 19 subjects with R117H-7T were 6 to 11 years of age (inclusive) and which may have influenced the finding (Table 39). The treatment differences for absolute change from baseline in sweat chloride were similar and statistically significant for subjects with either the R117H-5T or R117H-7T variants, indicating that both groups have a relevant pharmacodynamic response (Table 740). The treatment differences for change from baseline in BMI at week 24 favoured ivacaftor for subjects with either the R117H-5T or R117H-7T variants. None of the treatment differences were statistically significant. Similar results were seen in subjects  $\geq 18$  years of age with R117H-5T (Table 41). The treatment difference for mean absolute change from baseline in the pooled CFQ-R respiratory domain score through Week 24 was larger for subjects with the R117H-5T variant than for subjects with the R117H-7T variant. Eight of the 19 subjects with R117H-7T were 6 to 11 years of age (inclusive), and this may have influenced the finding (Table 42).

**Table 38: Absolute change from baseline in percent predicted FEV<sub>1</sub> by MMRM, R117H Poly-T variants; full analysis set**

<i>R117H</i> Poly-T Variant	Visit or Time Period	Treatment Group	Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
			N	LS Mean	Difference (95% CI)	P value
<b>Poly-T Variant (confirmed)<sup>b</sup></b>						
5T	Overall	Placebo	24	0.7287	5.2947	0.0115
	Post-baseline	Ivacaftor	14	6.0234	(1.2657, 9.3237)	
7T	Overall	Placebo	5	-0.9169	0.2000	0.9590
	Post-baseline	Ivacaftor	11	-0.7169	(-8.1353, 8.5354)	
<b>Poly-T Variant Supportive Analysis (confirmed + derived)<sup>b</sup></b>						
5T	Overall	Placebo	27	0.4979	3.1913	0.0871
	Post-baseline	Ivacaftor	21	3.6891	(-0.4844, 6.8669)	
7T	Overall	Placebo	7	0.6328	-1.4636	0.6719
	Post-baseline	Ivacaftor	12	-0.8308	(-8.6918, 5.7647)	

a: Estimates were obtained from MMRM with absolute change from baseline as the dependent variable; with treatment group, categorical visit (Weeks 2, 4, 8, 16 and 24) and treatment by visit interaction as fixed effects; with subject as a random effect; and with adjustment for the continuous baseline value of age and percent predicted FEV<sub>1</sub> using a compound symmetry covariance matrix. b: The poly-T variant for the R117H allele was derived for subjects where this information was missing and the subject had either R117H/F508DEL or R117H/R117H.

**Table 40: Absolute change from baseline in sweat chloride (mmol/L) by MMRM, R117H allele Poly-T variants, full analysis set**

<i>R117H</i> Poly-T Variant	Visit or Time Period	Treatment Group	Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
			N	LS Mean	Difference (95% CI)	P value
<b>Poly-T Variant (confirmed)<sup>b</sup></b>						
5T	Overall	Placebo	24	-4.5563	-24.1684	<0.0001
	Post-baseline	Ivacaftor	13	-28.7247	(-30.1611, -18.1757)	
7T	Overall	Placebo	5	3.8804	-24.0899	0.0003
	Post-baseline	Ivacaftor	10	-20.2095	(-33.8604, -14.3193)	
<b>Poly-T Variant Supportive Analysis (confirmed + derived)<sup>b</sup></b>						
5T	Overall	Placebo	27	-3.6886	-25.0549	<0.0001
	Post-baseline	Ivacaftor	20	-28.7435	(-30.1300, -19.9798)	
7T	Overall	Placebo	7	1.3718	-20.5561	<0.0001

a: Estimates were obtained from MMRM with absolute change from baseline as the dependent variable; with treatment group, categorical visit (Weeks 2, 4, 8, 16 and 24) and treatment by visit interaction as fixed effects; with subjects as a random effect; and with adjustment for the continuous baseline value of age, percent predicted FEV<sub>1</sub>, and sweat chloride, using a compound symmetry covariance matrix. b: The poly-T variant for the R117H allele was derived for subjects where this information was missing and the subject had either R117H/F508FRL or R117H/R117H.

**Table 41: Rate of change from baseline in BMI (kg/m<sup>2</sup>) by LMM, R117H Poly-T variants, full analysis set**

R117H Poly-T Variant	Visit or Time Period	Treatmen t Group	Rate of Change in Treatment Period <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
			N	LS Mean	Difference (95% CI)	P value <sup>b</sup>
<b>Poly-T Variant (confirmed)<sup>c</sup></b>						
5T	Overall	Placebo	24	0.2823	0.1861	0.8680
	Post-baseline	Ivacaftor	14	0.4685	(-2.0237, 2.3959)	
7T	Overall	Placebo	5	0.1691	0.3533	0.9076
	Post-baseline	Ivacaftor	11	0.5224	(-5.7122, 6.4188)	
<b>Poly-T Variant Supportive Analysis (confirmed + derived)<sup>c</sup></b>						
5T	Overall	Placebo	27	0.2629	0.2212	0.8236
	Post-baseline	Ivacaftor	21	0.4841	(-1.7340, 2.1763)	
7T	Overall	Placebo	7	-0.0422	0.3534	0.8877
	Post-baseline	Ivacaftor	12	0.3113	(-4.6246, 5.3315)	

Source table refers to the 'supportive analysis' as 'sensitivity analysis'. a: Estimated change from baseline per 168 days was obtained from a linear mixed model, with BMI as the dependent variable; with treatment as a fixed effect; with intercept and visit (days on study, including all visits through Week 24) as random effects; and with adjustment for baseline age, predicted FEV<sub>1</sub>, and visit by treatment interaction included as covariates in the model. B: p value for the treatment effect is from the slope of BMI (kg/m<sup>2</sup>) versus time (days). c: The poly-T variant for the R117H allele was derived for subjects where this information was missing and the subject had either R117H/F508DEL or R117H/R117H.

**Table 42: Absolute change from baseline in pooled CFQ-R respiratory domain score (points) by MMRM, R117H poly-T variants, full analysis set**

R117H Poly-T Variant	Visit or Time Period	Treatment Group	Absolute Change From Baseline <sup>a</sup>		Treatment Effect (Ivacaftor vs Placebo)	
			N	LS Mean	Difference (95% CI)	P value
<b>Poly-T Variant (confirmed)<sup>b</sup></b>						
5T	Overall	Placebo	24	-0.5947	15.3237	0.0003
	Post-baseline	Ivacaftor	14	14.7289	(7.6659, 22.9814)	
7T	Overall	Placebo	5	-5.9738	5.2328	0.5380
	Post-baseline	Ivacaftor	11	-0.7410	(-12.9426, 23.4083)	
<b>Poly-T Variant Supportive Analysis (confirmed + derived)<sup>b</sup></b>						
5T	Overall	Placebo	27	0.7181	9.6166	0.0086
	Post-baseline	Ivacaftor	20	10.3347	(2.5832, 16.6500)	
7T	Overall	Placebo	6	-4.7418	2.3370	0.7682
	Post-baseline	Ivacaftor	12	-2.4048	(-14.4129, 19.0870)	

Pooled is defined as all questionnaire versions except for the parent/caregiver version. The Children Ages 6 to 11 Years (interviewer format) CFQ-R instrument response option cards may not have been used. Difference is ivacaftor- placebo. A positive difference favours ivacaftor. Source table refers to the 'supportive analysis' as 'sensitivity analysis'. b: Estimates were obtained from MMRM with absolute change from baseline as the dependent variable; with treatment group, categorical visit (Weeks 2, 4, 8, 16 and 24) and treatment by visit interaction as fixed effects; with subjects as a random effect; and with adjustment for the continuous baseline value of age, percent predicted FEV<sub>1</sub>, and CFQ-R respiratory domain score, using compound symmetry covariance matrix. b: The poly-T variant for the R117H allele was derived for subjects where this information was missing and the subject had either R117H/F508DEL or R117H/R117H.

### 7.1.2. Other efficacy studies

Study 112 is an ongoing Phase III, two-arm, multicentre, open-label, rollover study conducted in subjects with CF who had previously been enrolled in Study VX11-770-110 (Study 110; subjects with an R117H-CFTR mutation), Study VX12-770-111 (Study 111; subjects with a non-G551D-CFTR gating mutation), or Study VX12-770-113 (Study 113; subjects who have



phenotypic or molecular evidence of residual CFTR function). The study was initiated on 13 Feb, 2013 and is still ongoing. End of week 12 interim analysis (25 April, 2014) was the last date of results included in analysis submitted in the current dossier. The primary objective of study 112 was to evaluate the safety of long-term ivacaftor treatment in subjects with cystic fibrosis (CF); the secondary objective was to evaluate the efficacy of long-term ivacaftor treatment in subjects with CF.

This study enrolled male and female subjects, aged > 6 years, with CF and a non-G551D CFTR mutation, who completed their assigned study drug treatment duration in earlier studies 110, 111 or 113 into one of the following arms:

**7.1.2.1. Ivacaftor arm:**

These subjects are being treated with ivacaftor 150 mg q12h (same dosage used in Study 110). The ivacaftor arm of Study 112 includes those subjects who:

- - completed their assigned study drug treatment duration in Study 110 or Study 111;
- - completed all study-related treatments through the Follow-up Visit in Study 113 and met at least 1 of the Study 113 responder criteria during the 8-week open-label period of that study.

**7.1.2.2. Observational arm:**

The observational arm only includes subjects from Studies 110 and 111 who:

- - prematurely discontinued study drug treatment and received at least 4 weeks of treatment in the previous ivacaftor study;
- - completed the previous study and enrolled in the observational arm; or
- - completed the previous study but did not meet the inclusion criteria of the ivacaftor arm.

The Follow-up Visit of Study 110 served as the baseline visit for Study 112.

Subjects received ivacaftor 150 mg tablets orally at a dosage of 150 mg q12h with fat-containing food such as a standard 'CF' high-fat, high-calorie meal or snack. The planned duration of study drug administration for subjects in the ivacaftor arm is the shorter of either approximately 108 weeks or Kalydeco (commercially available ivacaftor) being clinically indicated for the subject and reimbursed for that indication in the subject's country. Subjects in the observational arm will participate in the study for approximately 2 years.

Efficacy evaluations for interim analysis included spirometry, sweat chloride test, and the respiratory domain of the Cystic Fibrosis Questionnaire-Revised (CFQ-R). Subjects were analysed overall and according to the study drug (ivacaftor or placebo) to which they were randomised in Study 110. Efficacy analyses were conducted using the FAS consisting of subjects from Study 110 who received at least 1 dose of ivacaftor during Study 112. All summaries and figures were generated for all subjects in the FAS, as well as for 2 FAS subgroups: subjects 6 to 11 years of age (inclusive) at Study 110 baseline and subjects  $\geq 18$  years of age at Study 110 baseline. The following additional ad hoc analyses for evaluation of absolute change from baseline in percent predicted FEV<sub>1</sub> using the following methods for the overall population, subjects aged  $\geq 18$  years and subjects aged 6 to 11 years were conducted:

- - Change from the Study 112 baseline to Week 12 for the FAS using a one-sample t-test;
- - Change from Study 112 baseline to Week 12 for subjects who were treated with placebo in Study 110 (placebo/ivacaftor group) using a one-sample t-test; and
- - Change from Study 112 baseline to Week 12 for subjects who were treated with ivacaftor in Study 110 (ivacaftor/ivacaftor group) using a one-sample t-test.

Of the 69 subjects enrolled in Study 110, 65 subjects enrolled in the ivacaftor arm of Study 112 and were included in the Study 112 FAS, 2 subjects enrolled in the observational arm of Study 112, and 2 subjects did not enrol in Study 112 due to early discontinuation of treatment in Study 110. Of the 65 subjects in the ivacaftor arm of Study 112, 64 subjects completed at least 12 weeks of treatment in Study 112, and 1 subject (in the ivacaftor/ ivacaftor group) discontinued between Week 2 and 12 because she was moving from the UK to the US (discontinuation was not due to an AE. Three other subjects (1 subject in the placebo/ ivacaftor group and 2 subjects in the ivacaftor/ ivacaftor group) discontinued treatment in Study 112 after Week 12.

Demographic and baseline characteristics of the 65 subjects in study 112 is summarised in Table 43. For the FAS in Study 112, mean baseline percent predicted FEV<sub>1</sub> values were comparable for the placebo/ivacaftor and ivacaftor/ivacaftor groups; baseline sweat chloride levels were lower in the ivacaftor/ivacaftor group than in the placebo/ivacaftor group. In the 6 to 11 years subgroup, baseline percent predicted FEV<sub>1</sub> values were lower in the ivacaftor/ivacaftor group than in the placebo/ivacaftor group and baseline sweat chloride levels were comparable for the ivacaftor/ivacaftor and placebo/ivacaftor groups. In the ≥ 18 years subgroup, baseline percent predicted FEV<sub>1</sub> values were higher in the ivacaftor/ivacaftor group than in the placebo/ivacaftor group and baseline sweat chloride levels were lower in the ivacaftor/ivacaftor group than in the placebo/ivacaftor group. The 1 placebo/ivacaftor subject in the 12 to 17 years subgroup had a baseline percent predicted FEV<sub>1</sub> of 96.477% and a sweat chloride value of 71.0 mmol/L.

**Table 43: Study 112- demographics and baseline characteristics, full analysis set**

Variable	Placebo/Ivacaftor N = 35	Ivacaftor/Ivacaftor N = 30	Overall N = 65
<b>Sex, n (%)</b>			
Male	15 (42.9)	13 (43.3)	28 (43.1)
Female	20 (57.1)	17 (56.7)	37 (56.9)
<b>Race, n (%)</b>			
White	35 (100.0)	30 (100.0)	65 (100.0)
<b>Ethnicity, n (%)</b>			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	35 (100.0)	30 (100.0)	65 (100.0)
Not Collected Per Local Regulations	0	0	0
<b>Age (Years at Study 110 Baseline)</b>			
N	35	30	65
Mean (SD)	32.7 (17.43)	31.0 (16.52)	31.9 (16.91)
<b>Age Group (Years at Study 110 Baseline), n (%)</b>			
6 to 11	8 (22.9)	7 (23.3)	15 (23.1)
12 to 17	1 (2.9)	0	1 (1.5)
≥18	26 (74.3)	23 (76.7)	49 (75.4)
<b>Percent Predicted FEV<sub>1</sub></b>			
FAS			
Mean (SD)	70.9964 (21.47051)	72.6868 (19.45402)	71.7766 (20.42321)
6 to 11 Years			
N	8	7	15
Mean (SD)	97.5358 (11.84615)	85.8421 (22.07433)	92.0787 (17.76126)
≥18 Years			
N	26	23	49
Mean (SD)	61.8505 (15.78896)	68.6830 (17.15106)	65.0576 (16.62923)
<b>Sweat Chloride (mmol/L)</b>			
FAS			
N	33	26	59
Mean (SD)	65.38 (19.508)	55.31 (18.141)	60.94 (19.423)
6 to 11 Years			
N	8	6	14
Mean (SD)	62.81 (26.164)	60.42 (25.732)	61.79 (24.996)
≥18 Years			
N	24	20	44
Mean (SD)	66.00 (17.806)	53.78 (15.750)	60.44 (17.808)

FEV<sub>1</sub>: forced expiratory volume in 1 second; SD: standard deviation. All results displayed are baseline results in Study 112, except for subject age, which is the baseline age in Study 110. N is the number of subjects with non-missing assessment at baseline. Baseline is defined as the most recent measurement before the first dose of study drug.

### 7.1.2.3. Results:

For the FAS and for the ≥ 18 years subgroup, statistically significant increases in percent predicted FEV<sub>1</sub> occurred for the overall population, for the placebo/ ivacaftor group, and for the ivacaftor/ ivacaftor group (Table 44-46). Although an overall mean increase in percent predicted FEV<sub>1</sub> was observed for subjects 6 to 11 years of age, this was not statistically significant and was influenced by 1 subject in the ivacaftor/ ivacaftor group who had a substantial increase in percent predicted FEV<sub>1</sub> (absolute change: 49.72 percentage points) following resolution of a pulmonary exacerbation in Study 110. When spirometry summary statistics and figures were re-run with this subject excluded, the overall mean absolute change

from baseline to Week 12 for the 6 to 11 years subgroup was 3.38 percentage points. The results do not suggest any deleterious effect of ivacaftor treatment in this age subgroup.

**Table 44: Absolute change from Baseline to Week 2 and Week 12 in percent predicted FEV<sub>1</sub>, full analysis set**

Study Population	Study Visit	N	Mean Change from Baseline	P Value <sup>a</sup>
Overall	Week 2	65	3.8034	0.0003
	Week 12	62	5.4521	<0.0001
Placebo/Ivacaftor	Week 2	35	3.2399	0.0072
	Week 12	35	4.9976	0.0005
Ivacaftor/Ivacaftor	Week 2	30	4.4609	0.0142
	Week 12	27	6.0413	0.0057

Baseline is defined as the most recent measurement prior to intake of the first dose of study drug. Age is based on age at the Study 110 baseline. a: p values are based on the one-sample t-test.

**Table 45: Absolute change from Baseline to Week 2 and Week 12 in percent predicted FEV<sub>1</sub>, full analysis set, ≥ 18 years**

Study Population	Study Visit	N	Mean Change from Baseline	P Value <sup>a</sup>
Overall	Week 2	49	3.8850	<0.0001
	Week 12	46	5.1489	<0.0001
Placebo/Ivacaftor	Week 2	26	4.7083	0.0022
	Week 12	26	5.4685	0.0016
Ivacaftor/Ivacaftor	Week 2	23	2.9544	0.0051
	Week 12	20	4.7334	0.0036

Baseline is defined as the most recent measurement prior to intake of the first dose of study drug. Age is based on age at the Study 110 baseline. a: p values are based on the one-sample t-test.

**Table 46: Absolute change from Baseline to Week 2 and Week 12 in percent predicted FEV<sub>1</sub>; full analysis set, subjects 6 to 11 years**

Study Population	Study Visit	N	Mean Change from Baseline	P Value <sup>a</sup>
Overall	Week 2	15	3.4234	0.3246
	Week 12	15	6.4713	0.0806
Placebo/Ivacaftor	Week 2	8	-1.8155	0.0346
	Week 12	8	3.5778	0.2334
Ivacaftor/Ivacaftor	Week 2	7	9.4107	0.2074
	Week 12	7	9.7781	0.1978

Baseline is defined as the most recent measurement prior to intake of the first dose of study drug. Age is based on age at the Study 110 baseline. a: p values are based on the one-sample t-test.

**Comment:** The above results should be interpreted with caution as these are just interim results from an open label study with no control group. The 'statistical significance' was compared to baseline value of study 112 using single-side t-test. The proposed duration of treatment in this open label study is 104 weeks and this submission only has interim results up to 12 weeks.

Summary statistics for relative change in percent predicted FEV<sub>1</sub>, absolute change in sweat chloride, and absolute change in CFQ-R respiratory domain score for all FAS subjects (Table 47), the ≥ 18 years of age subgroup (Table 48) and the 6 to 11 years (Table 49) subgroup. The results observed in absolute change from baseline in percent predicted FEV<sub>1</sub> for the FAS and both age subgroups were also reflected in the relative change from baseline in percent predicted FEV<sub>1</sub>. Decreases in sweat chloride values from baseline were observed at Week 2 for the FAS and for subjects in both age subgroups. For the FAS and for the ≥ 18 years subgroup,

absolute decreases from baseline sweat chloride values were slightly greater in the placebo/ivacaftor group than in the ivacaftor/ivacaftor group. For the 6 to 11 years subgroup, comparable decreases from baseline sweat chloride values were observed for the placebo/ivacaftor and ivacaftor/ivacaftor groups. The overall CFQ-R respiratory domain scores increased from baseline at Weeks 2 and 12 for the FAS and for subjects in both age subgroups; these increases were all greater than the defined minimal clinically important difference (MCID) of 4 points. The overall increase in pooled CFQ-R respiratory domain scores for subjects 6 to 11 years of age was greater than the increase observed for the FAS and for the  $\geq 18$  years subgroup at the 2 study visits although this was driven by one subject. For all age subgroups, increases in CFQ-R respiratory domain scores were lower at Weeks 2 and 12 for subjects in the placebo/ivacaftor group than for those subjects in the ivacaftor/ ivacaftor group.

**Table 47: Results for efficacy endpoints- mean (SD) change from Study 112 baseline, full analysis set**

Endpoint	Study Visit	Placebo/Ivacaftor		Ivacaftor/Ivacaftor		Overall	
		N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Absolute Change from Baseline in Percent Predicted FEV <sub>1</sub> (Percentage Points)	Week 2	35	3.2399 (6.70765)	30	4.4609 (9.36423)	65	3.8034 (8.00078)
	Week 12	35	4.9976 (7.67196)	27	6.0413 (10.41802)	62	5.4521 (8.90728)
Relative Change from Baseline in Percent Predicted FEV <sub>1</sub> (Percentage Points)	Week 2	35	6.3835 (11.94264)	30	8.1420 (21.97405)	65	7.1951 (17.18564)
	Week 12	35	8.5669 (13.21388)	27	10.9232 (23.74457)	62	9.5930 (18.41247)
Absolute Change from Baseline in Sweat Chloride (mmol/L) <sup>a</sup>	Week 2	33	-20.94 (9.073)	26	-17.21 (12.286)	59	-19.30 (10.676)
Absolute Change from Baseline in Pooled CFQ-R Respiratory Domain Score (points) <sup>b</sup>	Week 2	35	2.14 (19.222)	30	9.35 (15.671)	65	5.47 (17.908)
	Week 12	35	8.17 (13.986)	29	15.71 (21.417)	64	11.59 (17.992)

CFQ-R: Cystic Fibrosis Questionnaire- Revised; FEV<sub>1</sub>: forced expiratory volume in 1 second. Baseline is defined as the most recent measurement before the first dose of study drug in Study 112. a: Sweat chloride was only collected at the Baseline and the Week 2 visit. b: Pooled was defined as all questionnaire version except for the parent/caregiver version.

**Table 48: Results for efficacy endpoints- mean (SD) changes from Study 112 Baseline, age  $\geq 18$  years, full analysis set**

Endpoint	Study Visit	Placebo/Ivacaftor		Ivacaftor/Ivacaftor		Overall	
		N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Absolute Change from Baseline in Percent Predicted FEV <sub>1</sub> (Percentage Points)	Week 2	26	4.7083 (7.03457)	23	2.9544 (4.55046)	49	3.8850 (6.00385)
	Week 12	26	5.4685 (7.89231)	20	4.7334 (6.38535)	46	5.1489 (7.20803)
Relative Change from Baseline in Percent Predicted FEV <sub>1</sub> (Percentage Points)	Week 2	26	8.9500 (12.80696)	23	4.5022 (7.60295)	49	6.8622 (10.81433)
	Week 12	26	10.1026 (14.21590)	20	7.5725 (9.18510)	46	9.0026 (12.22712)
Absolute Change from Baseline in Sweat Chloride (mmol/L) <sup>a</sup>	Week 2	24	-19.44 (8.711)	20	-14.75 (11.448)	44	-17.31 (10.202)
Absolute Change from Baseline in Pooled Adolescents and Adults CFQ-R Respiratory Domain	Week 2	26	2.56 (21.328)	23	7.49 (15.768)	49	4.88 (18.895)
	Week 12	26	10.26 (14.461)	22	14.65 (22.716)	48	12.27 (18.619)

CFQ-R: Cystic Fibrosis Questionnaire- Revised; FEV<sub>1</sub>: forced expiratory volume in 1 second. Baseline is defined as the most recent measurement before the first dose of study drug in Study 112. Age is the baseline age in

Study 110. a: Sweat chloride was only collected at the Baseline and the Week 2 visit. b: Pooled was defined as all questionnaire version except for the parent/caregiver version.

**Table 49: Results for efficacy endpoints: Mean (SD) changes from Study 112 Baseline, age 6 to 11 years, full analysis set**

Endpoint	Study Visit	Placebo/Ivacaftor		Ivacaftor/Ivacaftor		Overall	
		N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Absolute Change from Baseline in Percent Predicted FEV <sub>1</sub> (Percentage Points)	Week 2	8	-1.8155 (1.96264)	7	9.4107 (17.62442)	15	3.4234 (12.98678)
	Week 12	8	3.5778 (7.75808)	7	9.7781 (17.86651)	15	6.4713 (13.30981)
Relative Change from Baseline in Percent Predicted FEV <sub>1</sub> (Percentage Points)	Week 2	8	-1.8730 (2.13084)	7	20.1013 (43.63737)	15	8.3817 (30.77547)
	Week 12	8	4.1139 (9.60544)	7	20.4967 (45.07375)	15	11.7592 (31.43897)
Absolute Change from Baseline in Sweat Chloride (mmol/L) <sup>a</sup>	Week 2	8	-24.75 (9.914)	6	-25.42 (12.314)	14	-25.04 (10.553)
Absolute Change from Baseline in Pooled CFQ-R Respiratory Domain Score (points) <sup>b</sup>	Week 2	8	1.04 (12.939)	7	15.48 (14.773)	15	7.78 (15.258)
	Week 12	8	1.04 (11.302)	7	19.05 (17.817)	15	9.44 (16.923)

CFQ-R: Cystic Fibrosis Questionnaire- Revised; FEV<sub>1</sub>: forced expiratory volume in 1 second. Baseline is defined as the most recent measurement before the first dose of study drug in Study 112. Age is baseline age in Study 110. Placebo/ivacaftor = subjects who received ivacaftor in Study 110 and 112. a: Sweat chloride was only collected at the Baseline and the Week 2 visit. b: Pooled was defined as all questionnaire versions except for the parent/caregiver version.

**Comments:** Improvements in pulmonary function were observed in Study 112 for subjects in the ≥ 18 years subgroup regardless of study drug treatment in Study 110. These improvements were consistent with what was observed in Study 110. Improvements in sweat chloride and CFQ-R respiratory domain scores observed from summary statistics in Study 112 were consistent with those observed in Study 110. However, this submission only included interim analysis following 12 weeks of treatment in study 112. Hence, long term maintenance of efficacy will have to be confirmed by evaluation of the final results from study 112 which should be provided by the sponsors when the study is completed.

### 7.1.3. Analyses performed across trials (pooled analyses and meta-analyses)

Not applicable.

### 7.1.4. Evaluator's conclusions on clinical efficacy for {indication 1}

The pivotal study submitted to support use of ivacaftor for the extended indication was a well-conducted, Phase III, double-blind, placebo-controlled, parallel group study in 69 CF patients aged > 6 years with R117H-CFTR mutation. The dose of ivacaftor (150mg 12 hourly for 24 weeks) was the same as that approved for treatment of CF in patients aged > 6 years with G551D or other gating (class III) mutations. The efficacy endpoints evaluated effect of ivacaftor on lung function (change from baseline in % predicted FEV<sub>1</sub> was primary endpoint) as well as effects on growth/ nutrition (change in BMI), markers of CF such as sweat chloride, pulmonary exacerbations and inflammatory markers. The study design and endpoints complied with the EMEA guidelines on evaluation of drugs for treatment of cystic fibrosis.

Results for the primary endpoint (the absolute change in percent predicted FEV<sub>1</sub> through Week 24 in FAS) favoured ivacaftor but failed to reach statistical significance (ivacaftor-placebo

treatment difference=2.1%, 95% CI: 1.13, 5.35, p = 0.1979). Similarly, results for the secondary endpoints rate of change in BMI and time-to-first pulmonary exacerbation favoured ivacaftor, but treatment differences were not statistically significant. However, there were statistically significant and clinically relevant improvements in secondary endpoints of sweat chloride and CFQ-R respiratory domain score (Table 50).

**Table 50: efficacy endpoint results, full analysis set**

Analysis	Treatment Group	N	LS Mean	Treatment Difference (Ivacaftor vs Placebo)	P value
<b>Primary Endpoint</b>					
Percent Predicted FEV <sub>1</sub> (percentage points):	Placebo	35	0.4611	2.1114	0.1979
Absolute Change from Baseline	Ivacaftor	34	2.5724	(-1.1305, 5.3532)	
<b>Additional FEV<sub>1</sub> Endpoint</b>					
Percent Predicted FEV <sub>1</sub> (percentage points):	Placebo	35	-0.2092	5.0364	0.0611
Relative Change from Baseline	Ivacaftor	34	4.8272	(-0.2404, 10.3133)	
<b>Secondary Endpoints</b>					
Sweat Chloride (mmol/L):	Placebo	35	-2.3078	-23.9693	<0.0001
Absolute Change from Baseline	Ivacaftor	32	-26.2771	(-28.0094, -19.9293)	
BMI (kg/m <sup>2</sup> ):	Placebo	35	0.2284	0.2626	0.7780
Rate of Change from Baseline	Ivacaftor	34	0.4910	(-1.5698, 2.0950)	
Pooled CFQ R Respiratory Domain Score (points) <sup>a</sup> :	Placebo	34	-0.8289	8.3874	0.0091
Absolute Change from Baseline	Ivacaftor	33	7.5585	(2.1658, 14.6090)	
Pulmonary Exacerbations: Time-to-first	Placebo	35	NA	0.928 (hazard ratio)	0.8556
	Ivacaftor	34	NA		

NA: not applicable. a: Pooled is defined as all questionnaire versions except for the parent/caregiver version. The children ages 6 to 11 (interview format) CFQ-R instrument response option cards may not have been used.

Results favouring ivacaftor treatment were observed for event rate for pulmonary exacerbations, number of pulmonary exacerbations requiring hospitalization or IV antibiotics, duration of pulmonary exacerbations, changes from baseline in CFQ-R non-respiratory domain scores, weight, IRT, faecal elastase-1, and inflammatory mediator concentrations. The treatment effect was statistically significant for the CFQ-R emotion, social, and eating domains (Table 51). No analysis of CF-related complications was performed because no episodes of pancreatitis or DIOS occurred during the study.

**Table 51: tertiary efficacy endpoint results, full analysis set**

Endpoint and Result	P Value
<b>Event Rate Pulmonary Exacerbations</b>	
Ivacaftor group: 0.249; placebo group: 0.295	<i>P</i> = 0.6432
Rate ratio: 0.843 (95% CI: 0.409, 1.737)	
Rates for subcategories of pulmonary exacerbations (i.e., requiring hospitalization and requiring IV antibiotics) not calculated due to low event incidence, however, number of events requiring hospitalization or IV antibiotics was notably lower for the ivacaftor group.	Not done
<b>Duration of Pulmonary Exacerbations</b>	
Mean (SD) duration	<i>P</i> = 0.8472
Ivacaftor group: 5.92 (11.006) days; placebo group: 8.20 (14.371) days	
<b>Change from Baseline in CFQ-R Non-respiratory Domain Scores (Pooled Analysis)</b>	
Treatment difference (95% CI)	
Physical: 6.7224 (-1.0433, 14.4881)	<i>P</i> = 0.0885
Emotion: 5.4440 (1.7232, 9.1649)	<i>P</i> = 0.0048
Social: 7.1716 (2.1042, 12.2390)	<i>P</i> = 0.0063
Body Image: -0.4051 (-5.0262, 4.2159)	<i>P</i> = 0.8615
Eating: 4.6528 (0.1939, 9.1117)	<i>P</i> = 0.0411
Treatment Burden: -2.8084 (-8.5178, 2.9010)	<i>P</i> = 0.3289
Digestion: 2.5616 (-1.7858, 6.9089)	<i>P</i> = 0.2431
<b>Rate of Change from Baseline in Weight Through Week 24</b>	
Ivacaftor group: 1.8490 kg; placebo group: 0.9214 kg	<i>P</i> = 0.7912
Treatment difference: 0.9275 kg (95% CI: -5.9659, 7.8210)	
<b>Rate of Change from Baseline in Height Through Week 24</b>	
Ivacaftor group: 0.3699 cm; placebo group: 1.7551 cm	<i>P</i> = 0.7709
Treatment difference: -1.3851cm (95% CI: -10.8213, 8.0510)	
<b>Change from Baseline in Log-Transformed Inflammatory Mediator Concentrations</b>	
Treatment difference (95% CI)	
Leukocytes (109/L), Log Transformed Data: -0.0363 (-0.0650, -0.0076)	<i>P</i> = 0.0140
C-reactive Protein (nmol/L), Log Transformed Data: -0.1331 (-0.2633, -0.0028)	<i>P</i> = 0.0455
Immunoglobulin G (g/L), Log Transformed Data: -0.0197 (-0.0353, -0.0041)	<i>P</i> = 0.0142
Interleukin-8 (pg/mL), Log Transformed Data: -0.1013 (-0.1513, -0.0513)	<i>P</i> = 0.0001
<b>Shift from Baseline in Qualitative Microbiology Cultures</b>	
Shifts were sporadic and did not show any patterns across treatments; however, this analysis was limited by the small number of subjects and a high incidence of unknown results for sputum samples.	Not done
<b>Change from Baseline in IRT Through Week 24</b>	
Ivacaftor group: -9.2588 ng/mL; placebo group: 3.9988 ng/mL	<i>P</i> = 0.0679
Treatment difference: -13.2576 ng/mL (95% CI: -27.5323, 1.0171)	
<b>Change from Baseline in Fecal Elastase-I Through Week 24</b>	
Ivacaftor group: 0.1587 µg/g; placebo group: -15.2619 µg/g.	<i>P</i> = 0.4922
Treatment difference: 15.4206 µg/g (95% CI: -29.4148, 60.2560)	

Despite the lack of statistical significance for absolute change from baseline in the primary endpoint of percent predicted FEV<sub>1</sub>, the following results from pivotal study 110 suggested a beneficial effect of ivacaftor on lung function:

- Treatment differences for the FAS favoured ivacaftor at all treatment period time points during the 24-week study.
- The percent predicted FEV<sub>1</sub> responder analysis of showed that the number of responders favoured ivacaftor at all thresholds (3.5%, 5%, 7.5%, and 10%), with approximately twice as many responders in the ivacaftor group as the placebo group.
- Gains in percent predicted FEV<sub>1</sub> in the ivacaftor group during the Treatment Period reversed in the Follow-up Period when the subjects were no longer receiving ivacaftor.
- Analyses of additional spirometry parameters including absolute and relative change from baseline through Week 24 in FEV<sub>1</sub> (L), FVC (L), FEF<sub>25%-75%</sub> (L/sec), FEV<sub>1</sub>/FVC, percent predicted FVC, percent predicted FEF<sub>25%-75%</sub>, and percent predicted FEV<sub>1</sub>/FVC showed greater mean changes from baseline through Week 24 for the ivacaftor group than the



placebo group; other than relative change in FEF25%-75% and percent predicted FEF25%-75% these differences were not statistically significant.

In the pre-defined subgroup of subjects aged > 18 years, improvements in spirometry were statistically and clinically significant, rapid in onset, and durable through Week 24. Statistically significant treatment differences for percent predicted FEV<sub>1</sub> were observed by Week 2 (first post-baseline time point assessed) and were sustained through Week 24. There was a statistically significant difference in the responder rate between placebo and ivacaftor at the thresholds of 3.5% (P = 0.0176), 5% (P = 0.0066), and 7.5% (P = 0.0094). Results for the secondary endpoints rate of change in BMI and time-to-first pulmonary exacerbation favoured ivacaftor, but treatment relevant and consistent improvements in the secondary endpoints of absolute change from baseline in sweat chloride and the CFQ-R respiratory domain score; in fact the treatment difference for ivacaftor versus placebo in mean absolute change from baseline in the CFQ-R respiratory domain score through Week 24 for subjects aged ≥ 18 years was 12.64 points, which is more than triple the defined MCID of 4 points (Table 52). The efficacy in subjects aged 6 to 11 years was summarised in Table 53 and ivacaftor failed to show evidence of efficacy for any of the primary or secondary endpoints with exception of reduction in sweat chloride levels.

**Table 52: efficacy endpoint results, full analysis set, subjects ≥ 18 years of age**

Analysis	Treatment Group	N	LS Mean	Treatment Difference (Ivacaftor vs Placebo)	P value
<b>Primary Endpoint</b>					
Percent Predicted FEV <sub>1</sub> (percentage points):	Placebo	26	-0.4567	4.9647 (1.1497, 8.7796)	0.0119
Absolute Change from Baseline	Ivacaftor	24	4.5080		
<b>Additional FEV<sub>1</sub> Endpoint</b>					
Percent Predicted FEV <sub>1</sub> (percentage points):	Placebo	26	-1.4581	9.1339 (2.4649, 15.8029)	0.0083
Relative Change from Baseline	Ivacaftor	24	7.6758		
<b>Secondary Endpoints</b>					
Sweat Chloride (mmol/L):	Placebo	26	-4.0263	-21.8685 (-26.4556, -17.2814)	<0.0001
Absolute Change from Baseline	Ivacaftor	23	-25.8948		
BMI (kg/m <sup>2</sup> ):	Placebo	26	0.2186	0.3064 (-1.9009, 2.5136)	0.7845
Rate of Change from Baseline	Ivacaftor	24	0.5250		
Pooled CFQ R Respiratory Domain Score (points) <sup>a</sup> :	Placebo	26	-0.4596	12.6369 (5.0208, 20.2530)	0.0017
Absolute Change from Baseline	Ivacaftor	24	12.1773		

a: Pooled is defined as all questionnaire versions except for the parent/caregiver version.

**Table 53: efficacy endpoint results, full analysis set, subjects 6 to 11 years of age (inclusive)**

Analysis	Treatment Group	N	LS Mean	Treatment Difference (Ivacaftor vs Placebo)	P value
<b>Primary Endpoint</b>					
Percent Predicted FEV <sub>1</sub> (percentage points):	Placebo	8	3.5101	-6.3334	0.0301
Absolute Change from Baseline	Ivacaftor	9	-2.8233	(-11.9602, -0.7066)	
<b>Additional FEV<sub>1</sub> Endpoint</b>					
Percent Predicted FEV <sub>1</sub> (percentage points):	Placebo	8	3.8152	-6.7675	0.0405
Relative Change from Baseline	Ivacaftor	9	-2.9523	(-13.1990, -0.3360)	
<b>Secondary Endpoints</b>					
Sweat Chloride (mmol/L):	Placebo	8	1.0376	-27.6322	<0.0001
Absolute Change from Baseline	Ivacaftor	8	-26.5946	(-37.1640, -18.1005)	
BMI (kg/m <sup>3</sup> ):	Placebo	8	0.5150	-0.1813	0.8693
Rate of Change from Baseline	Ivacaftor	9	0.3336	(-2.3763, 2.0136)	
Pooled CFQ-R Respiratory Domain Score (points) <sup>a</sup> :	Placebo	7	-1.5554	-6.1327	0.1856
Absolute Change from Baseline	Ivacaftor	8	-7.6881	(-15.6774, 3.4121)	

NA: not applicable. a: Pooled is defined as all questionnaire versions except for the parent/caregiver version. The children ages 6 to 11 (interviewer format) CFQ-R instrument response option cards may not have been used.

Analysis of efficacy in subgroups based on demographics and baseline disease characteristics showed the following trends:

- absolute and relative change in percent predicted FEV<sub>1</sub> favoured ivacaftor treatment across subgroups, with the exception of the baseline percent predicted FEV<sub>1</sub> > 90% subgroup.
- sweat chloride response was consistent across all subgroups
- absolute change in the CFQ-R respiratory domain favoured ivacaftor treatment across subgroups, with the exception of the baseline percent predicted FEV<sub>1</sub> > 90% subgroup no significant BMI or BMI-for-age z-score treatments differences were found in any of the subgroups the ivacaftor treatment effect was larger for subjects with the R117H-5T variant than for subjects with the R117H-7T variant mean absolute change from baseline in percent predicted FEV<sub>1</sub> from subjects ≥ 18 years of age by R117H poly-T variant suggest evidence of a response to ivacaftor therapy in both R117H poly-T variant subgroups. The response was larger in subjects with the R117H-5T variant than in subjects with the R117H-7T variant. No evidence of a spirometry response to ivacaftor therapy was seen in subjects 6 to 11 years of age with either of the R117H poly-T variants.

The results from the subgroup analyses reflected the significant differences in spirometry and CFQ-R respiratory domain scores observed in subjects aged ≥ 18 years and those aged 6 to 11 years. Overall, subgroups including a significant number of subjects 6 to 11 years of age had smaller spirometry and CFQ-R respiratory domain treatment benefits. The demographics and baseline characteristics of subjects 6 to 11 years of age showed that these patients appeared to have more favourable features and lesser underlying lung dysfunction as follows: - 12 of 13 subjects with baseline percent predicted FEV<sub>1</sub> > 90%: were 6 to 11 years of age; 15 of 35 patients with no *P. aeruginosa* infection status at baseline were 6 to 11 years of age and 8 of 19 patients with the less severe Poly-T variant, 7T were 6 to 11 years of age.

Supportive evidence for efficacy was provided by results from an interim analysis of Study 112. After a 3- to 4-week washout period at the end of Study 110, the positive treatment effect of ivacaftor in these subjects who were previously treated with ivacaftor in Study 110 was replicated in Study 112; treatment response was also observed in ivacaftor-naïve subjects in

Study 112 (that is, subjects who were treated with placebo in Study 110). However, the interim analysis was conducted after only 12 weeks of treatment, while the study duration is 104 weeks.

Overall, there was adequate evidence to support use of ivacaftor for treatment of CF patients aged > 6 years with a R117H gene defect, especially in patients aged > 18 years with significant underlying lung disease. In patients aged 6 to 11 years, ivacaftor did not show any improvement in any of the lung function or other efficacy endpoints (with exception of improved sweat chloride levels); interpretation may have been confounded by fact that the younger patients did not have significant underlying lung disease or other symptoms as CF with R117H is a progressive disease with more symptoms as patients age.

## 8. Clinical Safety

### 8.1. Studies providing evaluable safety data

The following studies provided evaluable safety data:

- - One completed placebo-controlled, parallel-group, Phase III study 110
- - Interim analysis from an ongoing Phase III, multicentre, 2-arm, open-label study (112) in subjects with CF who participated in Studies 110, 111, or 113. The duration of Study 112 is approximately 104 weeks. Interim results (12 weeks treatment) were provided till cut-off at 07 April 2014.

#### 8.1.1. Pivotal efficacy studies

In the pivotal efficacy study 110, the following safety data were collected: Adverse events (AEs) were coded using Medical Dictionary for Regulatory Activities (MedDRA; Version 15.1). The incidence of AEs that started at, started after or increased in severity after the initial study drug dosing was summarized by treatment group. The incidence of AEs was analysed for the following Safety Set Subgroups: age at baseline ( $\geq 18$  years, 12 to 17 years [inclusive], and 6 to 11 years [inclusive]); percent predicted FEV<sub>1</sub> at baseline ( $< 70\%$ , 70% to 90% [inclusive], and  $\geq 90\%$  predicted); geographic region (North America and Europe); sex (female and male).

Descriptive statistics (raw values) were summarized for clinical laboratory values, ECG parameters, vital signs, and ophthalmologic examinations. Change from baseline and shift from baseline analyses were performed for clinical laboratory values, ECG parameters<sup>12</sup> and ophthalmologic examinations. Maximum on-treatment alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin results were categorized (for example,  $\leq 2xULN$ ,  $> 2xULN$  to  $\leq 3xULN$ ,  $> 3xULN$  to  $\leq 5xULN$ ,  $> 5xULN$  to  $\leq 8xULN$ ,  $> 8xULN$ ) and the number and percentage of subjects in each category presented by treatment group. In addition to the final analysis, an unblinded safety review was conducted by the DMC after 40 subjects had completed 8 weeks of treatment.

In the open-label study 112, AEs were not evaluated. Only SAEs were reported up to the cut-off date for interim analysis.

---

<sup>12</sup> The number and percentage of subjects with shift changes from baseline based on the overall ECG evaluation will be tabulated by treatment group and visit. In addition, the number and percentage of subjects by maximum on-treatment value of QT/QTc intervals, categorized as  $\leq 450$  msec,  $> 450$  msec and  $\leq 480$  msec,  $> 480$  msec and  $\leq 500$  msec, and  $> 500$  msec, as well as maximum on-treatment change from baseline value of QT/QTc intervals, categorized as  $\leq 30$  msec,  $> 30$  msec and  $\leq 60$  msec, and  $> 60$  msec.

**8.1.2. Pivotal studies that assessed safety as a primary outcome**

None.

**8.1.3. Dose-response and non-pivotal efficacy studies**

None.

**8.1.4. Other studies evaluable for safety only**

None.

**8.2. Patient exposure**

This submission includes safety data from 69 subjects with CF who received at least 1 dose of study drug in pivotal study 110: 34 subjects received ivacaftor, and 35 subjects received placebo. As of 07 April 2014, all 35 subjects who received placebo in Study 110 enrolled in the ongoing extension study (Study 112) and received at least 1 dose of ivacaftor.

In the pivotal study 110, the mean (SD) treatment duration was similar for placebo (155.8 [40.00] days) and ivacaftor (151.1 [46.18] days). The maximum study drug exposure was 193 days for placebo and 192 days for ivacaftor. Most subjects received at least 24 weeks of treatment; all but 3 subjects received at least 4 weeks of treatment. A total of 67 subjects (32 in the ivacaftor group and 35 in the placebo group) completed their full assigned duration of dosing (Table 54-55). Two subjects in the ivacaftor group discontinued treatment prematurely: 1 because of noncompliance with the ophthalmologic examination, and 1 because of pregnancy. Of the 67 subjects who completed the assigned duration of dosing, 59 subjects (28 in the ivacaftor group and 31 subjects in the placebo group) completed the full 24-week Treatment Period. The remaining 8 subjects had not completed 24 weeks of treatment at the time the sponsor stopped the study; however, these subjects were considered to have completed their assigned treatment duration and were eligible to enrol in Study 112.

A total of 65 subjects from Study 110 (35 subjects from the placebo arm and 30 subjects from the ivacaftor arm) enrolled in Study 112 and all 65 subjects enrolled in the ivacaftor arm.

**Table 54: study drug exposure**

Exposure Summary	Statistic/ Category	Placebo	Ivacaftor
		(N = 35) n (%)	(N = 34) n (%)
Exposure to study drug (days)	Mean (SD)	155.8 (40.00)	151.1 (46.18)
	Median (Min, Max)	168.0 (16, 193)	168.0 (16, 192)
Exposure classification (weeks)	0, <2	0	0
	2, <4	1 (2.9)	2 (5.9)
	4, <8	1 (2.9)	2 (5.9)
	8, <16	2 (5.7)	0
	16, <24	7 (20.0)	9 (26.5)
	≥24	24 (68.6)	21 (61.8)

**Table 55: Study 110- subject disposition and reasons for discontinuation**

	Placebo n (%)	Ivacaftor n (%)	Overall n (%)
All screened subjects	NA	NA	108
All randomized subjects	36	34	70
Safety set	35	34	69
FAS	35	34	69
CCS	31	30	61
PPS	33	30	63
Never dosed <sup>a</sup>	NA	NA	39
Last scheduled visit completed			
Day 1	0	0	0
Week 2	1 (2.9)	2 (5.9)	3 (4.3)
Week 4	1 (2.9)	0	1 (1.4)
Week 8	1 (2.9)	2 (5.9)	3 (4.3)
Week 16	1 (2.9)	2 (5.9)	3 (4.3)
Week 24	31 (88.6)	28 (82.4)	59 (85.5)
Completed full assigned duration of dosing	35 (100)	32 (94.1)	67 (97.1)
Failed to complete full assigned duration of dosing	0	2 (5.9)	2 (2.9)
Reason for discontinuation			
Adverse event	0	0	0
Refused further dosing (not due to AE)	0	0	0
Lost to follow-up	0	0	0
Death	0	0	0
Did not meet eligibility criteria	0	0	0
Noncompliance with study drug	0	0	0
Other noncompliance <sup>b</sup>	0	1 (2.9)	1 (1.4)
Physician decision	0	0	0
Required prohibited medication	0	0	0
Pregnancy (self or partner)	0	1 (2.9)	1 (1.4)
Study termination by sponsor	0	0	0
Other	0	0	0

Percentages are calculated relative to the number of subjects in the FAS. FAS is defined as all randomised subjects who received at least 1 dose of study drug. Safety set is defined as all subjects who received at least 1 dose of study drug. CCS is defined as all FAS subjects who had the opportunity to complete the full 24 week treatment period. PPS is defined as all FAS subjects without major protocol violations that could affect efficacy data. a: The 39 subjects counted as 'never dosed' were screen failures. In addition, 1 subject [information redacted] was randomised to the placebo group but not dosed (reason: PI decision due to high predicted FEV<sub>1</sub> value [115.318%] on Day 1). b: Subject [information redacted] was discontinued from the study due to noncompliance in completing the required ophthalmologic examination at Screening.

### 8.3. Adverse events

#### 8.3.1. All adverse events (irrespective of relationship to study treatment)

##### 8.3.1.1. Pivotal studies

The incidence of AEs was lower in the ivacaftor group compared with placebo (94.1% versus 100%). By preferred term (PT), the AEs with the highest incidence in both treatment groups were infective pulmonary exacerbation of CF (38.2% [13 subjects] in the ivacaftor group and 40.0% [14 subjects] in the placebo group) and cough (29.4% [10 subjects] in the ivacaftor group and 25.7% [9 subjects] in the placebo group). Other AEs that occurred in at least 10% of subjects in the ivacaftor group included sputum increased, nasal congestion, oropharyngeal pain, wheezing, diarrhoea, abdominal pain and headache. AEs for which the incidence was at least 5% higher with ivacaftor treatment than with placebo treatment included nasal congestion, oropharyngeal pain, abdominal pain, wheezing, upper airway cough syndrome, bacterial disease carrier, influenza-like illness and abdominal discomfort. AEs for which the incidence was at least 5% higher with placebo treatment than with ivacaftor treatment included

haemoptysis, arthralgia, pyrexia, rales, sinusitis, nasal mucosal disorder, sinus congestion, viral upper respiratory tract infection, pain, dizziness, blood potassium increased, dehydration, attention deficit/hyperactivity disorder, hypersensitivity and constipation (Table 56).

In the  $\geq 18$  years subgroup, 26 subjects received placebo treatment, and 24 subjects received ivacaftor treatment. The incidence of AEs was 95.8% (23 subjects) in the ivacaftor group and 100.0% (26 subjects) in the placebo group. AEs that occurred in at least 15% of subjects in the  $\geq 18$  years subgroup of either treatment group for which the incidence was higher ( $> 2$  subjects difference) with ivacaftor than placebo were nasal congestion, oropharyngeal pain and wheezing. AEs that occurred in at least 15% of subjects in either treatment group for which the incidence was higher ( $> 2$  subjects difference) with placebo than ivacaftor were upper respiratory tract infection and haemoptysis (Table 57).

Among subjects aged 6 to 11 years, 8 subjects received placebo treatment and 9 subjects received ivacaftor treatment. All subjects in this subgroup had at least 1 AE. There were no AEs that occurred in at least 15% of subjects in either treatment group for which the difference between treatment groups was  $> 2$  subjects (Table 57).

Consistent with the results for the overall population, infective pulmonary exacerbation of CF and cough were the most common AEs in subjects  $\geq 18$  years in both treatment groups; the incidence of both events was higher for subjects  $\geq 18$  years than for subjects 6 to 11 years. The incidence of infective pulmonary exacerbation of CF in the  $\geq 18$  years subgroup was 45.8% (11 subjects, 14 events) in the ivacaftor group and 50.0% (13 subjects, 23 events) in the placebo group. In the 6 to 11 years subgroup, the incidence of infective pulmonary exacerbation of CF was 22.2% (2 subjects, 3 events) in the ivacaftor group and 12.5% (1 subject, 1 event) in the placebo group.

The incidence of cough in the  $\geq 18$  years subgroup was 37.5% (9 subjects, 12 events) in the ivacaftor group and 26.9% (7 subjects, 8 events) in the placebo group, compared to 11.1% (1 subject, 2 events) in the ivacaftor group and 12.5% (1 subject, 2 events) in the placebo group in the 6 to 11 years subgroup.

**Table 56: Study 110- summary of adverse events, safety net**

Category	Placebo (N = 35) n (%)	Ivacaftor (N = 34) n (%)
Subjects with any AEs	35 (100.0)	32 (94.1)
Subjects with related AEs	7 (20.0)	3 (8.8)
Subjects with AEs leading to death	0	0
Subjects with SAEs	6 (17.1)	4 (11.8)
Subjects with related SAEs	0	0
Subjects with AEs leading to study drug interruption	2 (5.7)	1 (2.9)
Subjects with related AEs leading to study drug interruption	1 (2.9)	0
Subjects with AEs leading to study drug withdrawal	0	0

**Table 57: Study 110- adverse events occurring in at least 15% of subjects in either treatment group by system organ class, preferred term and age subgroups, safety set**

System Organ Class Preferred Term	Age ≥18 Years		Age 6 to 11 Years (Inclusive)	
	Placebo (N = 26) n (%)	Ivacaftor (N = 24) n (%)	Placebo (N = 8) n (%)	Ivacaftor (N = 9) n (%)
Subjects with any AEs	26 (100.0)	23 (95.8)	8 (100.0)	9 (100.0)
Subjects with any SAEs	6 (23.1)	2 (8.3)	0	2 (22.2)
<b>Infections and infestations</b>	<b>19 (73.1)</b>	<b>16 (66.7)</b>	<b>5 (62.5)</b>	<b>5 (55.6)</b>
Infective pulmonary exacerbation of CF	13 (50.0)	11 (45.8)	1 (12.5)	2 (22.2)
Bacterial disease carrier	1 (3.8)	1 (4.2)	0	2 (22.2)
Upper respiratory tract infection	5 (19.2)	2 (8.3)	0	1 (11.1)
Sinusitis	3 (11.5)	1 (4.2)	2 (25.0)	1 (11.1)
<b>Respiratory, thoracic, and mediastinal disorders</b>	<b>14 (53.8)</b>	<b>16 (66.7)</b>	<b>4 (50.0)</b>	<b>2 (22.2)</b>
Cough	7 (26.9)	9 (37.5)	1 (12.5)	1 (11.1)
Sputum increased	4 (15.4)	5 (20.8)	0	0
Haemoptysis	6 (23.1)	0	0	0
Nasal congestion	1 (3.8)	5 (20.8)	1 (12.5)	0
Oropharyngeal pain	0	4 (16.7)	2 (25.0)	1 (11.1)
Wheezing	1 (3.8)	4 (16.7)	0	0
<b>Gastrointestinal disorders</b>	<b>10 (38.5)</b>	<b>9 (37.5)</b>	<b>3 (37.5)</b>	<b>4 (44.4)</b>
Abdominal pain	0	2 (8.3)	0	2 (22.2)
Diarrhoea	3 (11.5)	4 (16.7)	1 (12.5)	1 (11.1)
Abdominal pain upper	0	1 (4.2)	2 (25.0)	1 (11.1)
<b>General disorders and administration site conditions</b>	<b>8 (30.8)</b>	<b>5 (20.8)</b>	<b>2 (25.0)</b>	<b>2 (22.2)</b>
Pyrexia	3 (11.5)	1 (4.2)	2 (25.0)	1 (11.1)
<b>Nervous system disorders</b>	<b>7 (26.9)</b>	<b>4 (16.7)</b>	<b>1 (12.5)</b>	<b>2 (22.2)</b>
Headache	3 (11.5)	4 (16.7)	1 (12.5)	2 (22.2)
<b>Psychiatric disorders</b>	<b>1 (3.8)</b>	<b>0</b>	<b>2 (25.0)</b>	<b>0</b>
Attention deficit/hyperactivity disorder	0	0	2 (25.0)	0

A subject with multiple events within an SOC or within a PT was counted only once within an SOC or PT, respectively. Adverse events were coded from MedDEA, Version 15.1

**Comments:** The higher incidence of infective pulmonary exacerbation of CF and cough in the ≥ 18 years subgroup compared to the 6 to 11 years subgroup is not unexpected because subjects in the ≥ 18 years subgroup had a worse baseline disease severity as evident by the lower mean percent predicted FEV<sub>1</sub>. Additionally, the incidence of haemoptysis was higher among subjects ≥ 18 years compared to subjects 6 to 11 years. The incidence of haemoptysis in the placebo group of subjects ≥ 18 years was 23.1% (6 subjects, 10 events), compared to no subjects in the 6 to 11 years subgroup. In the ivacaftor group, none of the subjects in the ≥ 18 years or 6 to 11 years subgroups had haemoptysis. The other AEs showed no consistent trend between the ≥ 18 years and 6 to 11 years subgroups, and interpretation of any differences were confounded by the small number of subjects in the subgroups.

In both treatment groups, the majority of subjects had AEs that were mild or moderate in severity. Compared with placebo, ivacaftor was associated with a lower incidence of moderate events (41.2% [14 subjects] in the ivacaftor group versus 57.1% [20 subjects] in the placebo group) and severe events (2.9% [1 subject] in the ivacaftor group versus 14.3% [5 subjects] in the placebo group). There were no life-threatening AEs in this study (Table 58). The most common severe AE, infective pulmonary exacerbation of CF, occurred in 3 (8.6%) subjects in the placebo group and 1 (2.9%) subject in the ivacaftor group. The other severe events were ALT increased and hypokalemia (each in 1 [2.9%] subject) in the placebo group. Consistent with their greater baseline disease severity, the incidence of severe AEs was greater for subjects in

the  $\geq 18$  years subgroup than for subjects in the  $< 18$  years subgroup. In the  $\geq 18$  years subgroup, 4 (15.4%) subjects of the placebo group and 1 (4.2%) subject in the ivacaftor group had severe AEs. In the placebo group, 3 (11.5%) subjects had severe infective pulmonary exacerbation of CF, and 1 (3.8%) subject had a severe hypokalemia. In the ivacaftor group, 1 (4.2%) subject had a severe infective pulmonary exacerbation of CF. One subject in the 12 to 17 years subgroup of the placebo group had a severe increased ALT; however, only 2 subjects were aged 12 to 17 years with no severe AE reported in the other subject who was treated with ivacaftor. No severe AEs occurred in the 6 to 11 years subgroup.

**Table 58: Study 110- severity of adverse events by treatment, safety set**

AE Severity	Placebo (N = 35) n (%)	Ivacaftor (N = 34) n (%)
Subjects with any AEs	35 (100.0)	32 (94.1)
Mild	10 (28.6)	17 (50.0)
Moderate	20 (57.1)	14 (41.2)
Severe	5 (14.3)	1 (2.9)
Life-threatening	0	0
Missing	0	0

SOC and PT within SOC were sorted in descending order of frequency in the ivacaftor column. A subject with multiple items within an SOC or within PT was counted only once within an SOC or PT, respectively. A subject with multiple severities for the same AE is counted only under the AE with the maximum severity (where the order of increasing severity is from Mild to Life Threatening). Adverse events were coded from MedDRA Version 15.1.

### 8.3.1.2. Other studies

In the open label study 112, AEs were not evaluated. Only SAEs were reported up to the cut-off date for interim analysis.

## 8.3.2. Treatment-related adverse events (adverse drug reactions)

### 8.3.2.1. Pivotal studies

The majority of AEs were considered by the investigator to be not related or unlikely related to the study drug. The incidence of AEs considered by the investigator to be related or possibly related to the study drug was lower in the ivacaftor group (8.8% [3 subjects]) than in the placebo group (20.0% [7 subjects]). One (2.9%) subject in the ivacaftor group had an AE of increased C-reactive protein (CRP) that was considered by the investigator to be related to the study drug. In both treatment groups, all related or possibly related events occurred in only 1 subject each (Table 59-60).

**Table 59: Study 110- relationship of adverse events to study drug by treatment safety set**

Relationship	Placebo (N = 35) n (%)	Ivacaftor (N = 34) n (%)
Subjects with any AEs	35 (100.0)	32 (94.1)
Related	0	1 (2.9)
Possibly related	7 (20.0)	2 (5.9)
Unlikely related	13 (37.1)	14 (41.2)
Not related	15 (42.9)	15 (44.1)
Missing	0	0

SOC and PT within SOC were sorted in descending order of frequency in the ivacaftor column. A subject with multiple events within an SOC or within a PT was counted only once within a SOC or PT, respectively. A subject with multiple severities for the same AE is counted only under the AE with the maximum severity (where the order of increasing severity is from mild to life threatening). Adverse events were coded from MedDRA, Version 15.1.



**Table 60: Study 110- related or possibly related adverse events by system organ class, preferred term, safety net**

System Organ Class Preferred Term	Placebo (N = 35) n (%)	Ivacaftor (N = 34) n (%)
<b>Subjects with any related AEs</b>	<b>7 (20.0)</b>	<b>3 (8.8)</b>
<b>Respiratory, thoracic, and mediastinal disorders</b>	<b>3 (8.6)</b>	<b>1 (2.9)</b>
Cough	1 (2.9)	1 (2.9)
Rales	1 (2.9)	0
Rhinorrhoea	1 (2.9)	0
<b>Infections and infestations</b>	<b>2 (5.7)</b>	<b>1 (2.9)</b>
Infective pulmonary exacerbation of CF	1 (2.9)	1 (2.9)
Upper respiratory tract infection	0	1 (2.9)
Viral upper respiratory tract infection	1 (2.9)	0
<b>Nervous system disorders</b>	<b>2 (5.7)</b>	<b>1 (2.9)</b>
Headache	1 (2.9)	1 (2.9)
Dizziness	1 (2.9)	0
<b>Investigations</b>	<b>2 (5.7)</b>	<b>2 (5.9)</b>
C-reactive protein increased	0	1 (2.9)
Forced expiratory volume decreased	0	1 (2.9)
Alanine aminotransferase increased	1 (2.9)	0
Hepatic enzyme increased	1 (2.9)	0
<b>Gastrointestinal disorders</b>	<b>1 (2.9)</b>	<b>0</b>
Diarrhoea	1 (2.9)	0
Vomiting	1 (2.9)	0
<b>Psychiatric disorders</b>	<b>1 (2.9)</b>	<b>0</b>
Attention deficit/hyperactivity disorder	1 (2.9)	0

SOC and PT within SOC were sorted in descending order of frequency in the ivacaftor column. A subject with multiple events within an SOC or within a PT was counted only once within a SOC or PT, respectively. A subject with multiple severities for the same AE is counted only under the AE with the maximum severity (where the order of increasing severity is from mild to life threatening). Adverse events were coded from MedDRA, Version 15.1.

### 8.3.2.2. Other studies

Not applicable.

### 8.3.3. Deaths and other serious adverse events

#### 8.3.3.1. Pivotal studies

There were no deaths reported in pivotal study 110. The incidence of SAEs was lower in the ivacaftor group (11.8% [4 subjects]) than in the placebo group (17.1% [6 subjects]). Overall, by PT, the most common SAE in both treatment groups was infective pulmonary exacerbation of CF (8.8% [3 subjects] in the ivacaftor group and 17.1% [6 subjects] in the placebo group). SAEs of cellulitis and constipation each occurred in 1 (2.9%) subject in the ivacaftor group. None of the SAEs were considered related to the study drug (Table 61).

In the ≥18 years subgroup, the incidence of subjects with at least 1 SAE in the ivacaftor group (8.3% [2 subjects]) was lower than in the placebo group (23.1% [6 subjects]). The most common SAE in both treatment groups was infective pulmonary exacerbation of CF (8.3% [2 subjects] in the ivacaftor group and 23.1% [6 subjects] in the placebo group). One (4.2%) subject in the ivacaftor group had an SAE of cellulitis. In the 6 to 11 years subgroup of the ivacaftor group, 2 (22.2%) subjects had at least 1 SAE. One (11.1%) subject had an SAE of infective pulmonary exacerbation of CF and 1 subject had an SAE of constipation. None of the subjects in the 6 to 11 years subgroup of the placebo group had an SAE.

**Table 61: Study 110- serious adverse events by system organ class, preferred term, and treatment, safety set**

System Organ Class Preferred Term	Placebo (N = 35) n (%)	Ivacaftor (N = 34) n (%)	Overall (N = 69) n (%)
Subjects with any SAEs	6 (17.1)	4 (11.8)	10 (14.5)
Infections and infestations	6 (17.1)	3 (8.8)	9 (13.0)
Infective pulmonary exacerbation of CF	6 (17.1)	3 (8.8)	9 (13.0)
Cellulitis	0	1 (2.9)	1 (1.4)
Gastrointestinal disorders	0	1 (2.9)	1 (1.4)
Constipation	0	1 (2.9)	1 (1.4)

SOC and PT within SOC were sorted in descending order of frequency in the ivacaftor column. A subject with multiple events within an SOC or within a PT was counted only once within a SOC or PT, respectively. Adverse events were coded from MedDRA, Version 15.1.

### 8.3.3.2. Other studies

A total of 65 subjects from Study 110 (35 subjects from the placebo arm and 30 subjects from the ivacaftor arm) enrolled in Study 112. All 65 subjects enrolled in the ivacaftor arm. As of 07 April 2014, 12 SAEs occurred in 8 subjects in the ivacaftor arm (Table 62). Nine of these 12 SAEs were infective pulmonary exacerbations of CF, 8 of which were considered by the investigators as not related to the study drug. One SAE of infective pulmonary exacerbation of CF was considered by the investigator as possibly related to the study drug. The remaining 3 SAEs (influenza, angioedema and urticaria) were considered by the investigators as not related to the study drug. None of the subjects in the observational arm had an SAE up to the time of the data cut-off.

**Table 62: Study 112- serious adverse events for subjects who completed assigned treatment duration in Study 110, ivacaftor arm**

Subject Age/Sex <sup>a</sup>	Treatment in Study 110/ Study 112	Case	Serious Adverse Event <sup>b</sup>	Latency From First Dose of Ivacaftor <sup>c</sup>	Causality	Action Taken	Outcome
	Ivacaftor/ Ivacaftor		Infective pulmonary exacerbation of CF	207 days	Not related	No change	Ongoing
	Ivacaftor/ Ivacaftor		Infective pulmonary exacerbation of CF	341 days	Possibly related	Withdrawn	Recovered
	Ivacaftor/ Ivacaftor		Infective pulmonary exacerbation of CF	323 days	Not related	Dose interrupted	Recovered
	Placebo/ Ivacaftor		Infective pulmonary exacerbation of CF	10 days	Not related	Dose interrupted	Recovered
	Placebo/ Ivacaftor		1) Angioedema 2) Urticaria	91 days	Not related	No change	Recovered
	Placebo/ Ivacaftor		Infective pulmonary exacerbation of CF	148 days	Not related	No change	Ongoing
	Ivacaftor/ Ivacaftor		1) Influenza 2) Infective pulmonary exacerbation of CF	347 days	Not related	No change	Recovered
	Ivacaftor/ Ivacaftor		Infective pulmonary exacerbation of CF	198 days	Not related	No change	Recovered
	Ivacaftor/ Ivacaftor		Infective pulmonary exacerbation of CF	161 days	Not related	No change	Recovered
	Ivacaftor/ Ivacaftor		Infective pulmonary exacerbation of CF	284 days	Not related	No change	Ongoing

a: subject age/sex and case identifiers have been replaced with a black boxes. b: SAEs are reported by preferred term. c: Study 110 ivacaftor treatment was included in the latency calculation.

### 8.3.4. Discontinuation due to adverse events

#### 8.3.4.1. Pivotal studies

There were no subjects in either treatment group with AEs that resulted in the discontinuation of study drug. One subject had an AE of infective pulmonary exacerbation of CF that led to

interruption of ivacaftor treatment, and 2 subjects had AEs<sup>13</sup> that led to interruption of placebo. One additional subject in the ivacaftor group missed 1 dose as a result of infective pulmonary exacerbation of CF.

#### 8.3.4.2. Other studies

Not applicable.

### 8.4. Laboratory tests

AEs associated with abnormal chemistry, haematology, and urinalysis values were infrequent and none resulted in the discontinuation of study drug. Overall, the mean results over time and the incidence in categorical shifts from baseline for the clinical laboratory parameters (serum chemistry, haematology, and coagulation studies) showed minor differences between the treatment groups that were not considered to be clinically meaningful.

#### 8.4.1. Liver function

##### 8.4.1.1. Pivotal studies

AEs associated with abnormal liver function tests (LFTs) occurred in 3 (8.6%) subjects in the placebo group and 1 (2.9%) subject in the ivacaftor group. At the majority of visits through Week 24, mean absolute changes from baseline in all LFT parameters (ALT, AFT, total bilirubin and GGT) were minimal and were generally comparable between the ivacaftor and placebo groups (Table 63). The majority of subjects had maximum on-treatment ALT, AST, and total bilirubin results > 2 × ULN, and no differences > 5% were noted between the placebo and ivacaftor treatments for any category (Table 64). No subjects in either group had a maximum ALT or AST value that was > 5 × ULN or a maximum total bilirubin value that was > 2 × ULN. In the placebo group, 1 (2.9%) subject had at least 1 maximum ALT value > 2 xULN to > 3x ULN, and 1 (2.9%) subject had at least 1 maximum ALT value > 3 xULN to > 5x ULN. In the ivacaftor group, 2 (5.9%) subjects had at least 1 maximum ALT value > 2x ULN to > 3x ULN, and 1 (2.9%) subject had at least 1 maximum ALT value > 3 x ULN to > 5 x ULN; this subject also had at least 1 maximum AST value > 2 x ULN to > 3 x ULN.

**Table 63: Study 11- liver function test parameter absolute changes from Baseline to Week 24, safety set**

Parameter	n	Placebo N = 35			n	Ivacaftor N = 34		
		Mean Change (SD)	Median Change	Min/Max		Mean Change (SD)	Median Change	Min/Max
Alanine aminotransferase (U/L)	29	2.0 (7.31)	1.0	-13/26	27	2.7 (13.04)	2.0	-37/34
Alkaline phosphatase (U/L)	29	-5.5 (23.53)	-2.0	-95/32	27	-10.0 (18.23)	-8.0	-68/21
Aspartate aminotransferase (U/L)	29	1.10 (6.548)	1.00	-8.0/20.0	27	1.59 (8.523)	0.00	-22.0/27.0
Gamma-glutamyl transferase (U/L)	29	-0.66 (4.220)	0.00	-12.0/6.0	27	-2.37 (10.248)	1.00	-42.0/8.0
Total bilirubin (umol/L)	29	-1.4 (4.06)	-1.0	-10/13	27	0.0 (2.69)	0.0	-6/5

Baseline is defined as the most recent measurement before intake of the first dose of study drug.

<sup>13</sup> 2 subjects had AEs that led to interruption of placebo: dehydration, gastroenteritis, and hypokalemia in 1 subject; diarrhoea, and vomiting in the other subject.

**Table 64: Study 11- maximum on-treatment liver function test results, safety set**

Maximum On-Treatment Result	Liver Function Test	Placebo N = 35 n (%)	Ivacaftor N = 34 n (%)
≤2 × ULN	ALT (U/L)	33 (94.3)	31 (91.2)
	AST (U/L)	35 (100.0)	33 (97.1)
	Total bilirubin (µmol/L)	35 (100.0)	34 (100.0)
>2 × ULN to ≤3 × ULN	ALT (U/L)	1 (2.9)	2 (5.9)
	AST (U/L)	0	1 (2.9)
	Total bilirubin (µmol/L)	0	0
>3 × ULN to ≤5 × ULN <sup>a</sup>	ALT (U/L)	1 (2.9)	1 (2.9)
	AST (U/L)	0	0
	Total bilirubin (µmol/L)	0	0
>5 × ULN	ALT (U/L)	0	0
	AST (U/L)	0	0
	Total bilirubin (µmol/L)	0	0

**8.4.1.2. Other studies**

No data available for study 112.

**8.4.2. Kidney function****8.4.2.1. Pivotal studies**

No significant changes were reported in kidney function laboratory parameters in study 110.

**8.4.2.2. Other studies**

No data available for study 112.

**8.4.3. Other clinical chemistry****8.4.3.1. Pivotal studies**

No other significant changes were reported in other clinical chemistry parameters in study 110.

**8.4.3.2. Other studies**

No data available for study 112.

**8.4.4. Haematology****8.4.4.1. Pivotal studies**

No significant changes were reported in haematology laboratory parameters in study 110.

**8.4.4.2. Other studies**

No data available for study 112.

**8.4.5. Electrocardiograph****8.4.5.1. Pivotal studies**

In the ivacaftor group, maximum increases into the category of > 450 to ≤ 480 msec in QTcB<sup>14</sup> were observed for 2 (5.9%) subjects. No subject had a QTc value greater than 500 msec. No subject had a maximum on-treatment increase from baseline in QTc interval > 60 msec. Maximum increases of > 30 to ≤ 60 msec in QTcB were observed in 1 (2.9%) subject in the placebo group and 4 (11.8%) subjects in the ivacaftor group. No subjects in the placebo group

<sup>14</sup> QT interval corrected for heart rate according to Bazzet's formula (a commonly accepted method to correct QT interval for heart rate): QTcB = QT/√RR (Bazzet HC: Heart, 1920)

and 2 (5.9%) subjects in the ivacaftor group had maximum increases of  $> 30$  to  $\leq 60$  msec in QTcF<sup>15</sup>. There were no AEs associated with ECG abnormalities in Study 110.

#### **8.4.5.2. Other studies**

No data available for study 112.

#### **8.4.6. Vital signs**

##### **8.4.6.1. Pivotal studies**

No clinically meaningful trends were observed over time in heart rate, blood pressure, body temperature, and respiratory rate. One subject in the placebo group had an AE of increased blood pressure. No other AEs associated with abnormal vital signs occurred, and none of the subjects discontinued study drug as a result of abnormal vital signs. There were no clinically meaningful changes in physical findings.

##### **8.4.6.2. Other studies**

None.

#### **8.4.7. Ophthalmological examination**

##### **8.4.7.1. Pivotal studies**

Due to the finding of a dose-related increase in cataracts in juvenile rats in a nonclinical study, the protocol for Study 110 was amended to add an ophthalmologic examination at Screening for all subjects. Subjects aged 6 to 11 years also had a follow-up ophthalmologic examination at Week 24. Visual acuity of the left and right eyes was measured at baseline for all subjects and at follow-up for subjects who had a follow-up examination. Changes from baseline to follow-up were minimal in both treatment groups and no clinically important trends attributable to ivacaftor treatment were observed. There were no shifts to abnormal in slit lamp examination of lens for either treatment group and no subjects developed lens opacities during the study.

##### **8.4.7.2. Other studies**

No data available for study 112.

## **8.5. Post-marketing experience**

A cumulative and interval summary tabulation of serious and non-serious adverse reactions was provided in Module 5.3.5.3. A total of 1954 subjects (747970 person-days) received at least 1 dose of ivacaftor during the time period from the International Birth Date of ivacaftor (31 January 2012) to 23 January 2014. The post-marketing data are consistent with those from clinical studies and the established safety profile of ivacaftor and no new safety concerns identified.

## **8.6. Safety issues with the potential for major regulatory impact**

### **8.6.1. Liver toxicity**

In the pivotal study 110, AEs associated with abnormal liver function tests (LFTs) occurred in 3 (8.6%) subjects in the placebo group and 1 (2.9%) subject in the ivacaftor group. At the majority of visits through Week 24, mean absolute changes from baseline in all LFT parameters (ALT, AST, total bilirubin and GGT) were minimal and were generally comparable between the ivacaftor and placebo groups. No subjects in either ivacaftor or placebo group had a maximum ALT or AST value that was  $> 5 \times$  ULN or a maximum total bilirubin value that was  $> 2 \times$  ULN.

---

<sup>15</sup> QT interval corrected for heart rate according to Fridericia's formula (a commonly accepted method to correct QT interval for heart rate)  $QTcF = QT / \sqrt[3]{RR}$  (Fridericia LS: Acta Medica Scandinavica, 1920)

**8.6.2. Haematological toxicity**

None.

**8.6.3. Serious skin reactions**

None.

**8.6.4. Cardiovascular safety**

None.

**8.6.5. Unwanted immunological events**

None.

**8.7. Other safety issues****8.7.1. Safety in special populations**

In Study 110, the incidence of AEs was summarized for subgroups based on age at baseline (6 to 11 years, 12 to 17 years and  $\geq 18$  years at baseline), sex (female and male), percent predicted FEV<sub>1</sub> severity at baseline (< 70%,  $\geq 70\%$  to  $\leq 90\%$  and > 90% predicted), and geographic region (North America and Europe).

**8.7.1.1. Age:**

Results of the analyses of AEs by age subgroups are discussed in sections 8.4.1.1. Safety results in the subgroups > 18 years were similar to those in the overall FAS population and also similar to those aged 6 to 11 years. There were only 2 subjects aged 11 to 17 years.

**8.7.1.2. Gender:**

The incidence of AEs was lower for female subjects than for male subjects in the ivacaftor group (89.5% [17 subjects, 75 events] versus 100.0% [15 subjects, 81 events], respectively) and was the same for female and male subjects in the placebo group. The incidence of infective pulmonary exacerbation of CF was higher in male subjects than in female subjects in the ivacaftor group (53.3% [8 subjects, 11 events] versus 26.3% [5 subjects, 6 events]); however, in the placebo group, the incidence of infective pulmonary exacerbation of CF was lower in male subjects than in female subjects (26.7% [4 subjects, 4 events] versus 50.0% [10 subjects, 20 events]). The other AEs showed no consistent trend between the male and female subgroups, and any differences were likely caused by the small number of subjects in the subgroups (Table 65).

**Table 65: Study 11- adverse events occurring in at least 15% of subjects in either treatment group by system organ class, preferred term, and sex, safety set**

System Organ Class Preferred Term	Male		Female	
	Placebo N = 15 n (%)	Ivacaftor N = 15 n (%)	Placebo N = 20 n (%)	Ivacaftor N = 19 n (%)
<b>Subjects with any AEs</b>	<b>15 (100.0)</b>	<b>15 (100.0)</b>	<b>20 (100.0)</b>	<b>17 (89.5)</b>
<b>Infections and infestations</b>	<b>9 (60.0)</b>	<b>11 (73.3)</b>	<b>15 (75.0)</b>	<b>10 (52.6)</b>
Infective pulmonary exacerbation of CF	4 (26.7)	8 (53.3)	10 (50.0)	5 (26.3)
Upper respiratory tract infection	1 (6.7)	1 (6.7)	4 (20.0)	2 (10.5)
Sinusitis	1 (6.7)	0	4 (20.0)	2 (10.5)
<b>Respiratory, thoracic, and mediastinal disorders</b>	<b>8 (53.3)</b>	<b>10 (66.7)</b>	<b>11 (55.0)</b>	<b>8 (42.1)</b>
Cough	4 (26.7)	6 (40.0)	5 (25.0)	4 (21.1)
Oropharyngeal pain	0	1 (6.7)	2 (10.0)	4 (21.1)
Nasal congestion	1 (6.7)	2 (13.3)	1 (5.0)	3 (15.8)
Sputum increased	2 (13.3)	3 (20.0)	2 (10.0)	2 (10.5)
Rhinorrhoea	3 (20.0)	3 (20.0)	0	0
Haemoptysis	3 (20.0)	0	3 (15.0)	0
Rales	0	0	3 (15.0)	0
<b>Gastrointestinal disorders</b>	<b>5 (33.3)</b>	<b>6 (40.0)</b>	<b>8 (40.0)</b>	<b>7 (36.8)</b>
Diarrhoea	2 (13.3)	4 (26.7)	2 (10.0)	1 (5.3)
Abdominal pain	0	0	0	4 (21.1)
Vomiting	1 (6.7)	3 (20.0)	3 (15.0)	0
<b>General disorders and administration site conditions</b>	<b>4 (26.7)</b>	<b>3 (20.0)</b>	<b>7 (35.0)</b>	<b>4 (21.1)</b>
Pyrexia	3 (20.0)	1 (6.7)	3 (15.0)	1 (5.3)
<b>Nervous system disorders</b>	<b>4 (26.7)</b>	<b>3 (20.0)</b>	<b>5 (25.0)</b>	<b>3 (15.8)</b>
Headache	3 (20.0)	3 (20.0)	2 (10.0)	3 (15.8)

**8.7.1.3. Baseline percent predicted FEV<sub>1</sub>:**

The overall incidence of AEs in the ivacaftor group was lower in the FEV<sub>1</sub> ≥ 70% to ≤ 90% predicted subgroup compared to the FEV<sub>1</sub> < 70% and FEV<sub>1</sub> > 90% predicted subgroups. All subjects in the FEV<sub>1</sub> < 70% and FEV<sub>1</sub> > 90% predicted subgroups of the ivacaftor and placebo groups had AEs. The overall incidence of AEs in the FEV<sub>1</sub> ≥ 70% to ≤ 90% predicted subgroup was lower in the ivacaftor group (85.7% [12 subjects, 53 events]) than in the placebo group (100.0% [14 subjects, 75 events]). Consistent with disease severity, the incidence of infective pulmonary exacerbation of CF and cough were higher in the FEV<sub>1</sub> < 70% predicted subgroup compared to the FEV<sub>1</sub> ≥ 70% to ≤ 90% and FEV<sub>1</sub> > 90% predicted subgroups. Within the FEV<sub>1</sub> < 70% predicted subgroup, the incidence of pulmonary exacerbation of CF was similar in both treatment groups, while the incidence of cough was slightly higher in the ivacaftor group. Additionally, the incidence of haemoptysis was higher among subjects treated with placebo in the FEV<sub>1</sub> < 70% predicted subgroup as compared to the ≥ 70% to ≤ 90% and > 90% predicted subgroups. None of the subjects in the ivacaftor group had haemoptysis. The other AEs showed no consistent trend in the FEV<sub>1</sub> < 70%, FEV<sub>1</sub> ≥ 70% to ≤ 90%, and FEV<sub>1</sub> > 90% predicted subgroups, and any differences were likely caused by the small number of subjects in the subgroups (Table 66).

**Table 66: Study 11- adverse event occurring in at least 15% of subjects in either treatment group by system organ class, preferred term, and baseline percent predicted FEV<sub>1</sub>, safety set**

System Organ Class Preferred Term	Baseline FEV <sub>1</sub> <70% Predicted		Baseline FEV <sub>1</sub> ≥70% to ≤90% Predicted		Baseline FEV <sub>1</sub> >90% Predicted	
	Placebo N = 15 n (%)	Ivacaftor N = 13 n (%)	Placebo N = 14 n (%)	Ivacaftor N = 14 n (%)	Placebo N = 6 n (%)	Ivacaftor N = 7 n (%)
Subjects with any AEs	15 (100.0)	13 (100.0)	14 (100.0)	12 (85.7)	6 (100.0)	7 (100.0)
Infections and infestations	10 (66.7)	10 (76.9)	10 (71.4)	8 (57.1)	4 (66.7)	3 (42.9)
Infective pulmonary exacerbation of CF	8 (53.3)	7 (53.8)	5 (35.7)	5 (35.7)	1 (16.7)	1 (14.3)
Upper respiratory tract infection	2 (13.3)	1 (7.7)	3 (21.4)	0	0	2 (28.6)
Sinusitis	2 (13.3)	1 (7.7)	1 (7.1)	1 (7.1)	2 (33.3)	0
Respiratory, thoracic, and mediastinal disorders	8 (53.3)	10 (76.9)	8 (57.1)	5 (35.7)	3 (50.0)	3 (42.9)
Cough	5 (33.3)	6 (46.2)	3 (21.4)	3 (21.4)	1 (16.7)	1 (14.3)
Nasal congestion	1 (6.7)	5 (38.5)	1 (7.1)	0	0	0
Oropharyngeal pain	0	4 (30.8)	0	0	2 (33.3)	1 (14.3)
Wheezing	1 (6.7)	3 (23.1)	0	0	0	1 (14.3)
Sputum increased	2 (13.3)	2 (15.4)	2 (14.3)	3 (21.4)	0	0
Upper-airway cough syndrome	0	2 (15.4)	0	1 (7.1)	0	0
Rhinorrhoea	0	1 (7.7)	3 (21.4)	1 (7.1)	0	1 (14.3)
Haemoptysis	5 (33.3)	0	1 (7.1)	0	0	0
Gastrointestinal disorders	7 (46.7)	3 (23.1)	4 (28.6)	6 (42.9)	2 (33.3)	4 (57.1)
Diarrhoea	3 (20.0)	1 (7.7)	1 (7.1)	3 (21.4)	0	1 (14.3)
Abdominal pain upper	0	0	0	0	2 (33.3)	2 (28.6)
Vomiting	3 (20.0)	1 (7.7)	1 (7.1)	1 (7.1)	0	1 (14.3)
Constipation	0	0	2 (14.3)	1 (7.1)	1 (16.7)	0
General disorders and administration site conditions	6 (40.0)	3 (23.1)	4 (28.6)	2 (14.3)	1 (16.7)	2 (28.6)
Pyrexia	2 (13.3)	1 (7.7)	3 (21.4)	1 (7.1)	1 (16.7)	0
Nervous system disorders	4 (26.7)	1 (7.7)	5 (35.7)	2 (14.3)	0	3 (42.9)
Headache	2 (13.3)	1 (7.7)	3 (21.4)	2 (14.3)	0	3 (42.9)
Skin and subcutaneous tissue disorders	2 (13.3)	1 (7.7)	1 (7.1)	0	2 (33.3)	0
Eczema	0	0	0	0	1 (16.7)	0
Ingrowing nail	0	0	0	0	1 (16.7)	0

A subject with multiple events within an SOC or within a PT was counted only once within a SOC or PT, respectively. Adverse events were coded from MedDRA, Version 15.1.

#### 8.7.1.4. Geographical regions:

The overall incidence of AEs in North America and Europe was lower in the ivacaftor group (North America: 95.8% [23 subjects, 119 events]; Europe: 90.0% [9 subjects, 37 events]) than in the placebo group (North America: 100.0% [30 subjects, 173 events]; Europe: 100.0% [5 subjects, 31 events]). In the ivacaftor group, there was no meaningful difference between North America and Europe in the incidence of any AEs, including infective pulmonary exacerbation of CF, cough, or haemoptysis. However, in the placebo group the incidence of infective pulmonary exacerbation of CF, cough, and haemoptysis was higher in Europe compared to North America. In the placebo group, the incidence of infective pulmonary exacerbation of CF group was 80.0% (4 subjects, 11 events) in Europe and 33.3% (10 subjects, 13 events) in North America. The incidence of cough was 60.0% (3 subjects, 3 events) in Europe and 20.0% (6 subjects, 9 events) in North America. The incidence of haemoptysis was 40.0%



(2 subjects, 2 events) in Europe and 13.3% (4 subjects, 8 events) in North America. The higher incidence of infective pulmonary exacerbation of CF, cough, and haemoptysis in Europe in the placebo group is likely a function of the small number of subjects in this subgroup and the fact that all 5 subjects in the Europe placebo subgroup were  $\geq 18$  years of age. Subjects  $\geq 18$  years of age had a higher baseline disease severity as evidenced by a lower mean percent predicted FEV<sub>1</sub> at baseline (64.53%) compared to subjects 6 to 11 years of age (95.84%). By comparison, the North America placebo subgroup included subjects 6 to 11 years of age (8 subjects), 12 to 17 years of age (1 subject), and  $\geq 18$  years of age (21 subjects). The other AEs showed no consistent trend between North America and Europe and any differences were likely caused by the small number of subjects in the subgroups (Table 67).

**Table 67: Study 110- adverse events occurring in at least 15% of subjects in either treatment group by preferred term and geographic region, safety set**

System Organ Class Preferred Term	North America		Europe	
	Placebo N = 30 n (%)	Ivacaftor N = 24 n (%)	Placebo N = 5 n (%)	Ivacaftor N = 10 n (%)
<b>Subjects with any AEs</b>	<b>30 (100.0)</b>	<b>23 (95.8)</b>	<b>5 (100.0)</b>	<b>9 (90.0)</b>
<b>Infections and infestations</b>	<b>20 (66.7)</b>	<b>14 (58.3)</b>	<b>4 (80.0)</b>	<b>7 (70.0)</b>
Infective pulmonary exacerbation of CF	10 (33.3)	8 (33.3)	4 (80.0)	5 (50.0)
Upper respiratory tract infection	5 (16.7)	3 (12.5)	0	0
Sinusitis	5 (16.7)	2 (8.3)	0	0
Bacterial disease carrier	1 (3.3)	0	0	3 (30.0)
<b>Respiratory, thoracic, and mediastinal disorders</b>	<b>15 (50.0)</b>	<b>16 (66.7)</b>	<b>4 (80.0)</b>	<b>2 (20.0)</b>
Cough	6 (20.0)	8 (33.3)	3 (60.0)	2 (20.0)
Nasal congestion	2 (6.7)	5 (20.8)	0	0
Sputum increased	3 (10.0)	4 (16.7)	1 (20.0)	1 (10.0)
Oropharyngeal pain	2 (6.7)	4 (16.7)	0	1 (10.0)
Wheezing	1 (3.3)	4 (16.7)	0	0
Haemoptysis	4 (13.3)	0	2 (40.0)	0
Pleuritic pain	0	0	1 (20.0)	0
Sinus congestion	1 (3.3)	0	1 (20.0)	0
<b>Gastrointestinal disorders</b>	<b>10 (33.3)</b>	<b>9 (37.5)</b>	<b>3 (60.0)</b>	<b>4 (40.0)</b>
Abdominal pain	0	2 (8.3)	0	2 (20.0)
Vomiting	2 (6.7)	1 (4.2)	2 (40.0)	2 (20.0)
Diarrhoea	4 (13.3)	4 (16.7)	0	1 (10.0)
Constipation	2 (6.7)	1 (4.2)	1 (20.0)	0
<b>Investigations</b>	<b>8 (26.7)</b>	<b>4 (16.7)</b>	<b>3 (60.0)</b>	<b>3 (30.0)</b>
Blood potassium increased	0	0	2 (40.0)	0
Blood calcium increased	0	0	1 (20.0)	0
C-reactive protein increased	0	1 (4.2)	1 (20.0)	0
<b>General disorders and administration site conditions</b>	<b>10 (33.3)</b>	<b>6 (25.0)</b>	<b>1 (20.0)</b>	<b>1 (10.0)</b>
Pyrexia	6 (20.0)	2 (8.3)	0	0
Non-cardiac chest pain	0	0	1 (20.0)	0
<b>Nervous system disorders</b>	<b>8 (26.7)</b>	<b>5 (20.8)</b>	<b>1 (20.0)</b>	<b>1 (10.0)</b>
Headache	4 (13.3)	5 (20.8)	1 (20.0)	1 (10.0)
<b>Injury, poisoning, and procedural complications</b>	<b>3 (10.0)</b>	<b>4 (16.7)</b>	<b>1 (20.0)</b>	<b>1 (10.0)</b>
Laceration	0	0	1 (20.0)	1 (10.0)
<b>Skin and subcutaneous tissue disorders</b>	<b>4 (13.3)</b>	<b>0</b>	<b>1 (20.0)</b>	<b>1 (10.0)</b>
Pruritus generalised	0	0	1 (20.0)	0
<b>Musculoskeletal and connective tissue disorders</b>	<b>7 (23.3)</b>	<b>2 (8.3)</b>	<b>1 (20.0)</b>	<b>0</b>
Musculoskeletal pain	0	1 (4.2)	1 (20.0)	0

### 8.7.2. Safety related to drug-drug interactions and other interactions

No new data was provided.

### 8.7.3. Adverse drug reaction assessment and analysis

The safety data from Study 110 were reviewed for potential adverse drug reactions (ADRs). Among the AEs for which the incidence was at least 5% higher in ivacaftor-treated subjects than placebo, nasal congestion, oropharyngeal pain, abdominal pain, and wheezing (USPI only) are established ADRs. The difference for the other AEs of abdominal discomfort, bacterial disease carrier, influenza-like illness, and upper-airway cough syndrome was no more than 3 subjects between the ivacaftor and placebo groups. In the significantly larger (213 subjects) and longer (48 weeks) placebo-controlled Phase III studies in subjects with the G551D-CFTR gating mutation (Study 102 and Study 103), abdominal discomfort, bacterial disease carrier, influenza-like illness, and upper-airway cough syndrome all occurred in a small (< 3%) and generally comparable proportion of ivacaftor- and placebo-treated subjects. As Study 110 enrolled a relatively small number (N = 69) of subjects treated for 24 weeks, the ability to identify true ADRs is rather limited, unless a very significant difference in the incidence of AEs is noted. Therefore, the incidence of these 4 AEs was further evaluated by pooling with AEs reported from Studies 102 and 103. The pooled data showed that the incidence of abdominal discomfort, bacterial disease carrier, influenza-like illness, and upper-airway cough syndrome were all lower than 5% and generally comparable between the ivacaftor- and placebo-treated subjects (Table 68).

**Table 68: the incidence of abdominal discomfort, bacterial disease carrier, influenza-like illness and upper-airway cough syndrome in the pooled Study 102 and 103**

Preferred term	Placebo	Ivacaftor
	(N = 104)	(N = 109)
	n (%)	n (%)
Abdominal discomfort	2 (1.9)	2 (1.8)
Bacterial disease carrier	0	3 (2.8)
Influenza-like illness	0	1 (0.9)
Upper-airway cough syndrome <sup>a</sup>	2 (1.9)	1 (0.9)

a: PT 'Postnasal drip' in MedDRA Version 12.0 in the Module 5.3.5.3/VX-770 ISS/Table 2.3.3.1 was demoted to lowest level term (LLT) in MedDRA Version 15.1, in which the correspondent PT is upper-airway cough syndrome.

**Comments:** Overall, the safety profile in subjects with the R117H mutation in CFTR protein who participated in Study 110 was similar to that of the prior Phase III studies in G551D gating subjects (Study 102 and Study 103) and no new ADRs were identified.

### 8.7.4. Use in pregnancy/ lactation

There was 1 pregnancy in Study 110 who received her first dose of ivacaftor on 28 September 2012 and her last dose on 31 January 2013 (Study Week 16); no doses were missed. On 01 February 2013, the subject informed the investigator that she was pregnant and was discontinued from study on 13 Feb, 2013<sup>16</sup>. The subject delivered a healthy baby at 28 weeks gestation via caesarean section due to premature rupture of membranes.

<sup>16</sup> At the Early Termination Visit on 13 February 2013, the subject had a positive urine pregnancy test and a low value (< 0.1 mIU/mL) for follicle stimulating hormone (normal range 1.2 to 153 mIU/mL). Based on the subject's history of premature rupture of membranes, she had a cervical cerclage procedure performed at 14 weeks and 2 days of gestation. She was admitted for cervical insufficiency at 15 weeks gestation and developed gestational diabetes mellitus at 25 weeks and 5 days. The investigator confirmed that cervical insufficiency and gestational diabetes were not AEs.

### **8.7.5. Overdose, drug abuse, withdrawal/ rebound, effects on ability to drive or operate machinery**

No new information was provided.

## **8.8. Evaluator's overall conclusions on clinical safety**

Ivacaftor was well tolerated when administered at 150 mg q12h for 24 weeks to 69 subjects in the target patient population of subjects with the R117H-CFTR mutation. The overall incidence of AEs was 94.1% in the ivacaftor group and 100% in the placebo group. The most commonly occurring AEs were consistent with those expected for patients with CF including infective pulmonary exacerbation of CF (ivacaftor versus placebo 38.2% versus 40.0%) and cough (29.4% versus 25.7%).

The number of subjects evaluated for safety of ivacaftor for the proposed indication was adequate considering the low prevalence of this specific form of CF (~90 CF patients with R117H mutation in Australia); however, the duration of exposure was not adequate (only 24 weeks) and only limited interim results (up to 12 more weeks) was available to evaluate long term safety of ivacaftor for proposed indication. However, the open label study 112 is still ongoing with expected duration of up to 104 weeks and should provide additional data on long term safety which should be submitted by the sponsors when available.

The favourable safety profile of ivacaftor was evident by the lower incidence of AEs, severe AEs and SAEs in the ivacaftor group as compared to the placebo group and was also supported by the fact that there were no deaths and no subjects discontinued study drug or withdrew from the study for a safety-related reason. Most AEs were of mild or moderate severity in both treatment groups and were considered by the investigator to be unlikely related or not related to the study drug. The incidence of SAEs was lower in the ivacaftor group (11.8%) than in the placebo group (17.1%). The most common SAE in both treatment groups was infective pulmonary exacerbation of CF (8.8% [3 subjects] in the ivacaftor group and 17.1% [6 subjects] in the placebo group). All SAEs of infective pulmonary exacerbation of CF resolved without study drug discontinuation and none were considered to be related to the study drug.

In study 110, subgroup analyses did not suggest any notable treatment-related differences in safety based on age, sex, baseline FEV<sub>1</sub> severity, or geographic region.

The safety profile of the ≥ 18 years subgroup was consistent with expectations for patients with CF and with the safety profile established in previous clinical studies. Similar to the overall population, the incidence of AEs and SAEs was lower in the ivacaftor group than in the placebo group. In the ≥ 18 years subgroup, the most common AEs in the ivacaftor group were infective pulmonary exacerbation of CF and cough.

The safety profile of the 6 to 11 years subgroup was also consistent with the safety profile established in previous clinical studies. All subjects in the 6 to 11 years subgroup had at least 1 AE; none of the AEs occurred in more than 2 subjects in either the ivacaftor or placebo treatment group. The incidence of infective pulmonary exacerbation of CF and cough was lower in the 6 to 11 years subgroup than in the ≥ 18 years subgroup, which is not unexpected given the greater baseline disease severity for subjects ≥ 18 years.

As expected, the incidence of infective pulmonary exacerbation of CF and cough was higher in the FEV<sub>1</sub> < 70% predicted subgroup than in the FEV<sub>1</sub> ≥ 70% to ≤ 90% predicted subgroup and the FEV<sub>1</sub> > 90% predicted subgroup. The incidence of haemoptysis was higher among subjects treated with placebo in the FEV<sub>1</sub> < 70% predicted subgroup than in the ≥ 70 subgroup and an interpretation of these differences in AEs were confounded by the small number of subjects.

The incidence of LFT elevations was low and similar in both treatment groups. The majority of subjects had maximum on-treatment ALT and AST results > 2 × ULN. There were no total

bilirubin values  $> 2 \times$  ULN. Results of the other laboratory assessments, vital signs, and ECGs were generally similar in the ivacaftor and placebo groups, were consistent with the results of other clinical trials, and did not raise any safety concerns.

A total of 1954 subjects (747970 person-days) received at least 1 dose of ivacaftor during the time period from the International Birth Date of ivacaftor (31 January 2012) to 23 January 2014. The postmarketing safety data are consistent with those from clinical studies and the established safety profile of ivacaftor with no new safety concerns.

As expected based on ivacaftor's mechanism of action, the safety profile of ivacaftor in subjects with the R117H-CFTR mutation was similar to the safety profile of ivacaftor in subjects with the G551D-CFTR mutation and other mutations that cause severe defects in channel gating.

## 9. First round benefit-risk assessment

### 9.1. First round assessment of benefits

The benefits of ivacaftor in the proposed usage are:

- Ivacaftor produced clinically relevant and statistically significant improvements in percent predicted FEV<sub>1</sub>, CFQ-R respiratory domain and sweat chloride in subjects with sufficient disease severity (in subjects  $\geq 18$  years of age). The lack of benefit in subjects 6 to 11 years of age may be due to lack of significant lung disease at baseline in this age group due to progressive nature of a milder disease profile in this subgroup.
- Treatment differences for the FAS favoured ivacaftor at all treatment period time points during the 24-week pivotal study and there were twice as many responders (with  $> 3.5\%$ ,  $5\%$ ,  $7.5\%$ , and  $10\%$  improvement in percent predicted FEV<sub>1</sub> over placebo) in the ivacaftor group as the placebo group.
- Gains in percent predicted FEV<sub>1</sub> in the ivacaftor group during the Treatment Period reversed in the Follow-up Period when the subjects were no longer receiving ivacaftor.
- Supportive evidence for efficacy was provided by results from an interim analysis of Study 112. However, the interim analysis was conducted after only 12 weeks of treatment, while the study duration was 104 weeks.
- No new safety concerns or ADRs were identified following 24 weeks treatment with ivacaftor 150 mg q12h to 69 subjects with CF who have at least 1 allele of an R117H-CFTR mutation. Compared with placebo treatment, treatment with ivacaftor led to lower incidences of serious and non-serious AEs. The observed AEs were consistent with the known safety profile of ivacaftor and of patients with CF. The safety profile was consistent and comparable across the age subgroups.

### 9.2. First round assessment of risks

The risks of ivacaftor in the proposed usage are:

- Common AEs include nasopharyngitis, URTI, headache, nasal congestion, oropharyngeal pain, rash, abdominal pain and diarrhoea. Most of these are mild to moderate in severity, did not result in ivacaftor discontinuation, and resolved spontaneously without treatment.
- Other potential risks include elevated transaminases and drug-drug interactions. Therefore, the product labelling specifically recommends close monitoring of unexplained elevations in transaminase levels until resolution and proper dose adjustments when ivacaftor is used concomitantly with moderate or strong cytochrome P450 (CYP) 3A inhibitors.

- Study 110 failed to meet the primary outcome measure (a statistically significant absolute change from baseline through 24 weeks of treatment in percent predicted FEV<sub>1</sub>).
- There was no evidence of efficacy in CF patients aged 6 to 11 years and only 2 subjects aged 12 to 17 years were evaluated in the submitted clinical studies.
- Lack of evidence for long term efficacy and safety of ivacaftor when used for treatment of CF patients with R117H mutation. The pivotal study 110 had only 24 week treatment period compared to 48-week studies submitted for ivacaftor in CF patients with G551D and other gating mutations. There is an ongoing long term (104 weeks) open label study 112, but this submission only included results of the 12-week interim analysis.

### 9.3. First round assessment of benefit-risk balance

CF is an autosomal recessive disease with serious, chronically debilitating morbidities and high premature mortality and there is no available cure for CF at present. Although the R117H mutation is in the less severe spectrum of CF, it is associated with severe disease when compared to a normal population and there remains a clear and substantial unmet need in this population. These patients demonstrate progression of disease with advancing age and have a decreased life expectancy.

The pivotal study 110 evaluated efficacy and safety of ivacaftor 150mg bid for 24 weeks in 69 subjects (50 were aged > 18 years and 19 were 6 to 17 years old) with CF with a R117H mutation in the CFTR gene. Results of the primary endpoint (change in % predicted FEV<sub>1</sub>) favoured ivacaftor compared with placebo but treatment difference was not statistically significant for the FAS. However, responder analysis revealed that the proportion of patients showing > 5% and 7.5% and 10% improvement in % predicted FEV<sub>1</sub> following 24 weeks treatment with ivacaftor was almost double that observed with placebo. Statistically, clinically relevant and consistent treatment effects were observed in the secondary endpoints of absolute change from baseline in sweat chloride and CFQ-R respiratory domain score. However, there were no statistically significant improvements in BMI, pulmonary exacerbations or other endpoints.

In the pre-defined subgroup analysis in subjects aged ≥ 18 years, ivacaftor resulted in a robust, positive, clinically relevant, and statistically significant improvements in pulmonary function (% predicted FEV<sub>1</sub>) compared to placebo through 24 weeks of treatment. Treatment with ivacaftor also resulted in substantial and statistically significant improvements in CFTR activity as measured by sweat chloride, and in respiratory symptoms as measured by the CFQ-R respiratory domain score, compared to placebo through 24 weeks of treatment.

Although the subgroup of subjects 6 to 11 years of age showed a comparable sweat chloride response to the ≥ 18 year subgroup, this age group did not show any other meaningful response to ivacaftor treatment. Results for the 6 to 11-year-old subjects did not show any safety signal but it is not known if CFTR default correction actually translates into a long-lasting clinical benefit in these younger patients with well-preserved lung function.

Overall, results from the subgroup analyses indicated that ivacaftor was able to show a positive clinical benefit in subjects who have sufficient underlying disease that can be modulated by ivacaftor treatment.

Improvement in pulmonary function was observed in the open-label, long-term, rollover study 112 for subjects in the ≥ 18 years subgroup regardless of study drug treatment in Study 110. These improvements were consistent with what was observed in Study 110. Improvements in sweat chloride and CFQ-R respiratory domain scores observed from summary statistics in Study 112 were consistent with those observed in Study 110. However, this submission only included interim analysis following 12 weeks of treatment in study 112. Hence, long term maintenance of efficacy will have to be confirmed by evaluation of the final results from study 112 (with

proposed duration of 104 weeks) which should be provided by the sponsors when the study is completed.

Results from Study 110 and Study 112 did not reveal any new ADRs or any additional risks associated with ivacaftor treatment. Compared with placebo treatment, treatment with ivacaftor led to lower incidences of serious and non-serious AEs. The common AEs associated with ivacaftor treatment were URTI, headache, nasal congestion, oropharyngeal pain, rash, abdominal pain and diarrhoea. Most of these are mild to moderate in severity and did not result in ivacaftor discontinuation, and resolved spontaneously without treatment. No treatment-limiting toxicities were identified, although the size of the safety database may have precluded detection of rare or uncommon events. No age-specific risks were identified. Other potential risks include elevated transaminases and drug-drug interactions. Therefore, the product labelling specifically recommends close monitoring of unexplained elevations in transaminase levels until resolution and proper dose adjustments when ivacaftor is used concomitantly with moderate or strong cytochrome P450 (CYP) 3A inhibitors. The ADRs and potential risks are readily identified clinically or with routine laboratory monitoring. The safety profile of ivacaftor has been well characterized. The observed AEs were consistent with the known safety profile of ivacaftor and of patients with CF.

Treatment with ivacaftor targets the underlying pathophysiology of CF and has systemic benefit including substantial improvements in pulmonary measures with corresponding improvements in CFTR function (indicated by significant reduction in sweat chloride levels). Although ivacaftor did not produce statistically significant improvements in primary efficacy endpoint in the pivotal study, there was enough evidence to suggest it could provide clinical benefits in subjects who have sufficient underlying disease as shown by subgroup analysis in patients aged > 18 years who had significantly greater disease manifestations compared to the younger patients (6 to 17years).

CF patients with an R117H-CFTR mutation demonstrate progression of disease with advancing age and have a decreased life expectancy. Many individuals with an R117H-CFTR mutation were not diagnosed with CF until the late childhood or adult years, when the disease had progressed and symptoms became much more evident although this has changed recently due to advances in newborn screening for CFTR mutations. However, there is no drug currently approved to treat the underlying cause of CF in this population and ivacaftor would provide a useful option to improve the treatment and outlook for CF patients with this CFTR mutation.

Overall, the benefit-risk profile of ivacaftor is favourable for proposed use in CF patients aged 6 years or older with a R117H-CFTR mutation.

## **10. First round recommendation regarding authorisation**

It is recommended that application for marketing of ivacaftor for proposed indication 'for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have an R117H mutation in the CFTR gene' be approved. However, approval should be conditional to the following:

- incorporation of the suggested changes to the proposed PI,
- adequate response to questions in section 12.2 of this evaluation report, and
- sponsors agree to provide final results of long-term (104 weeks) open label study 112 for evaluation when the study is completed.

## 11. Clinical questions

### 11.1. Pharmacokinetics

#### 11.1.1. Question1

Can the sponsor please provide the estimates of ivacaftor  $C_{min}$  and AUC for Studies 007 and 010, which were undertaken in healthy subjects, as they have done for the studies in patients with CF in Tables 4 and 5.

#### 11.1.2. Question2

As it is difficult to judge whether ivacaftor PKs are consistent across both CF populations (that is reference CF subjects and subjects with the R117H mutation) a full non-compartmental PK analysis of the results of Study 110, which includes typical PK parameters such  $T_{max}$ ,  $C_{max}$ , AUC,  $t_{1/2}$  etc may help answer this question. Therefore, can the sponsor please provide a full non-compartmental analysis of the ivacaftor PK parameters for Study 110?

### 11.2. Pharmacodynamics

Not applicable.

### 11.3. Efficacy

#### 11.3.1. Question1

In the pivotal study 110, the baseline characteristics seem to indicate that patients in the ivacaftor group had a slightly better profile with less severe disease manifestations at baseline (higher percent predicted FEV<sub>1</sub>, BMI, lower sweat chloride and *P. aeruginosa* infection and lower prevalence of the more severe R117H-5T variant) (Table 9). Could the sponsors clarify if this slight imbalance had any effect on the efficacy results?

#### 11.3.2. Question2

The efficacy and safety data from ongoing, long-term, 104 week, open-label study 112 must be provided for evaluation when the study is completed.

### 11.4. Safety

None.

### 11.5. PI and CMI

Kindly address the issues mentioned in section 11.1.

## 12. Second round evaluation of clinical data submitted in response to questions

### 12.1. Pharmacokinetics

#### 12.1.1. Question1

Can the sponsor please provide the estimates of ivacaftor  $C_{\min}$  and AUC for Studies 007 and 010, which were undertaken in healthy subjects, as they have done for the studies in patients with CF in Tables 4 and 5?

##### 12.1.1.1. Sponsor's Response:

Simulations to estimate ivacaftor  $C_{\min}$  and AUC using the population-PK model were performed only for studies in CF patients and did not include subjects from Phase I studies (including Studies 007 and 010). However, the following PK parameters are provided from the non-compartmental analysis for these studies (Table 69). The results indicate similar exposure of ivacaftor in these studies relative to that observed in CF patients, which aligns with the population-PK model finding of similar ivacaftor CL/F in healthy subjects and CF patients.

**Table 69: mean (SD) ivacaftor AUC and  $C_{\min}$  in healthy subjects following ivacaftor 150 mg single-dose (Study 007) and 150 mg q12h at steady-state (Study 010)**

	Study 007	Study 010 (Day 10)
N	16	21
AUC (ng·h/mL)	6649 (1853)	9544 (4603)
$C_{\min}$ (ng/mL)	NA	523 (303)

AUC: area under the concentration versus time curve; AUC from time of dosing to infinity ( $AUC_{0-\infty}$ ) for Study 007 and AUC from the time of dosing to 12 hours after dosing ( $AUC_{0-12}$ ) for Study 010;  $C_{\min}$ : minimum concentration within a dose interval; N: number of observations; NA: not applicable

##### 12.1.1.2. Evaluator's response:

The evaluator is satisfied with the Sponsor's response.

#### 12.1.2. Question2

As it is difficult to judge whether ivacaftor PKs are consistent across both CF populations (that is reference CF subjects and subjects with the R117H mutation) a full non-compartmental PK analysis of the results of Study 110, which includes typical PK parameters such  $T_{\max}$ ,  $C_{\max}$ , AUC,  $t_{1/2}$  and so on may help answer this question. Therefore, can the sponsor please provide a full non-compartmental analysis of the ivacaftor PK parameters for Study 110?

##### 12.1.2.1. Sponsor's response:

As described in Report J178, the approximately 20% difference in ivacaftor Cl/F in CF patients with R117H versus a gating mutation may be due to the fact all R117H data comes from a separate study and therefore reflects differences in study design and inherent inter-study variability.

PK sampling in Study 110 and other Phase III studies was not designed for the purposes of performing non-compartmental analysis (NCA). However, sparse PK samples obtained at the Week 2 Visit in Study 110 were analysed using NCA to provide approximate PK values (Table 70), which are compared to that of Studies 102, 103, and 111 conducted in patient with G551D or other gating mutation (Table 71). Given the scarcity of the PK sample collection, parameters such as  $T_{\max}$  and  $t_{1/2}$  could not be accurately estimated using NCA. Ivacaftor



exposure in patients with the R117H-CFTR mutation is similar to that observed in patients with a gating mutation when compared by age group.

**Table 70: Study 11: mean (SD) steady-state ivacaftor PK parameters in CF patients with the R117H-CFTR mutation following ivacaftor 150 mg q12h**

Population	R117H		
Study	110		
Age (years)	≥18	12 to <18	6 to <12
N	23	1 <sup>a</sup>	9
C <sub>max</sub> (ng/mL)	1290 (560)	1210	1810 (989)
AUC <sub>0-12</sub> (ng·h/mL)	11900 (5430)	11700	16100 (10800)
C <sub>trough</sub> (ng/mL)	779 (412)	790	1090 (1110)
CL <sub>ss</sub> /F (L/h)	16.8 (12.2)	12.8	12.7 (7.20)

AUC<sub>0-12</sub>: area under the concentration versus time curve from the time of dosing to 12 hours after dosing; C<sub>max</sub>: maximum observed concentration; C<sub>trough</sub>: trough concentration; CL<sub>ss</sub>/F: oral clearance; N: number of observations. PK sampling in Study 110 was conducted at Week 2 and includes predose, 1, 2, 3, 4, and 6 to 8 hours postdose samples. The predose sample was recycled and used for C<sub>12</sub> for the estimation of AUC<sub>0-12</sub>; as such, AUC<sub>0-12</sub> values are considered approximate. a: Individual values are reported; no summary statistics.

**Table 71: Studies 102, 103, and 111- mean (SD) steady-state ivacaftor PK parameters in CF patients with a gating mutation following ivacaftor 150 mg q12h**

Population	G551D			Non-G551D Gating		
Study	102	103		111		
Age (years)	≥18	12 to <18	6 to <12	≥18	12 to <18	6 to <12
N	60 <sup>a</sup>	14 <sup>b</sup>	26	19	11	8
C <sub>max</sub> (ng/mL)	1310 (658)	1010 (530)	2030 (1030)	1450 (720)	1370 (741)	2350 (1500)
AUC <sub>0-12</sub> (ng·h/mL)	11800 (6570)	8220 (5820)	17400 (10900)	13500 (7350)	12200 (6750)	21300 (13700)
C <sub>trough</sub> (ng/mL)	773 (544)	545 (492)	1040 (874)	962 (587)	853 (542)	1400 (934)
CL <sub>ss</sub> /F (L/h)	17.3 (11.6)	30.8 (26.4)	12.4 (7.63)	14.3 (7.27)	16.9 (9.78)	10.9 (9.01)

AUC<sub>0-12</sub>: area under the concentration versus time curve from the time of dosing to 12 hours after dosing; C<sub>max</sub>: maximum observed concentration; C<sub>trough</sub>: trough concentration; CL<sub>ss</sub>/F: oral clearance; N: number of observations. PK sampling in Study 110 was conducted at Week 2 or Week 14 and includes predose, 1, 2, 3, 4, and 6 to 8 hours postdose samples. The predose sample was recycled and used for C<sub>12</sub> for the estimation of AUC<sub>0-12</sub>; as such, AUC<sub>0-12</sub> values are considered approximate. a: N=63 for C<sub>max</sub> b: N=17 for C<sub>max</sub>

#### 12.1.2.2. Evaluator's response:

The evaluator is satisfied with the Sponsor's response.

## 12.2. Efficacy

### 12.2.1. Question 1

In the pivotal study 110, the baseline characteristics seem to indicate that patients in the ivacaftor group had a slightly better profile with less severe disease manifestations at baseline (higher percent predicted FEV<sub>1</sub>, BMI, lower sweat chloride and *P. aeruginosa* infection and lower prevalence of the more severe R117H-5T variant) (Table 9). Could the sponsors clarify if this slight imbalance had any effect on the efficacy results?

#### 12.2.1.1. Sponsor response:

Although there was a slight imbalance in baseline characteristics in Study 110 as described, the analysis model incorporated continuous baseline value of age and the dependent variable being

analysed to adjust for such differences. Because of this, this slight imbalance is not considered to have a substantial effect on the overall efficacy results.

**12.2.1.2. Evaluator's response:**

The response is acceptable.

**12.2.2. Question 2**

The efficacy and safety data from ongoing, long-term, 104 week, open-label study 112 must be provided for evaluation when the study is completed.

**12.2.2.1. Sponsor's response:**

Vertex agrees to provide the CSR from Study 112 when it is complete.

**12.2.2.2. Evaluator's response:**

The response is acceptable.

**12.2.2.3. PI and CMI**

The sponsor has provided satisfactory response to all the queries, comments in section 11.1 of the first round report and has also incorporated all suggested changes in the modified draft of PI (dated 26 Oct 2015).

## **13. Second round benefit-risk assessment**

### **13.1. Second round assessment of benefits**

After consideration of the responses to clinical questions, the benefits of ivacaftor in the proposed usage are unchanged from those identified in Section 9.1.

### **13.2. Second round assessment of risks**

After consideration of the responses to clinical questions, the risks of Ivacaftor in the proposed usage are unchanged from those identified in Section 9.2.

### **13.3. Second round assessment of benefit-risk balance**

The benefit-risk balance of ivacaftor in the proposed usage is favourable.

## **14. Second round recommendation regarding authorisation**

It is recommended that application for marketing of ivacaftor be approved for proposed indication *'for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have an R117H mutation in the CFTR gene'*.

## **15. References**

Chu C-S, Trapnell BC, Curristin S, Cutting GR, Crystal RG. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. *Nat Genet.* 1993;3:151-6.

Comer DM, Ennis M, McDowell C, Beattie D, Rendall J, Hall V, et al. Clinical phenotype of cystic fibrosis patients with the G551D mutation. *Q J Med.* 2009;102:793-98.

Kiesewetter S, Macek Jr. M, Davis C, Curristin SM, Chu C-S, Graham C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. *Nat Genet.* 1993;5:274-8.

Massie RJH, Poplawski N, Wilcken B, Goldblatt J, Byrnes C, Robertson C. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. *Eur Respir J.* 2001;17:1195-200.

McCloskey M, Redmond AO, Elborn JS. Clinical features associated with a delayed diagnosis of cystic fibrosis. *Respiration.* 2000;67:402-7

McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. *Chest.* 2006;130:1441-7.

## **Therapeutic Goods Administration**

PO Box 100 Woden ACT 2606 Australia

Email: [info@tga.gov.au](mailto:info@tga.gov.au) Phone: 1800 020 653 Fax: 02 6232 8605

<https://www.tga.gov.au>